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Abstract 
Compact myelin is an innovative acquisition in jawed vertebrates that is formed by the wrapping 
of glial cell membranes around neuronal axons in the central and peripheral nervous systems. 
The major functions of compact myelin include providing trophic support to axons and 
increasing the propagation of nerve impulses, which has facilitated the escape and predatory 
behaviors of vertebrates. Schwann cells are neural crest derived glia that form compact myelin in 
the peripheral nervous system (PNS). The SRY-related HMG box 10 (SOX10) transcription 
factor is essential for all stages of Schwann cell development. Specifically, SOX10 activates the 
expression of key myelin genes in the PNS and has therefore been reported as a pro-myelination 
transcription factor. Previously identified SOX10 target genes have been shown to be critical for 
Schwann cell function. Thus, the identification of additional genes regulated by SOX10 will 
improve our understanding of myelination in the PNS. We developed a stringent, computational 
method for genome-wide identification of SOX10 response elements. Experimental validation of 
a set of predicted SOX10 response elements revealed SOX5, SOX6, and NFIB as novel SOX10 
target genes. To further explore the utility of our computational data we compared our 
predictions to published SOX10 ChIP-seq data from rat sciatic nerve and our own DNase-seq 
data generated from cultured Schwann cells. This analysis—along with subsequent functional 
studies—revealed SOX10 response elements that map to HES1, MYCN, ID2, and ID4. 
Remarkably, SOX5, SOX6, HES1, MYCN, ID2, and ID4 all encode proteins that inhibit 
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myelination. Thus, our computationally anchored strategy revealed a putative novel function for 
SOX10 in Schwann cells, which suggests a model where SOX10 activates the expression of 
genes that inhibit myelination during non-myelinating stages of Schwann cell development. We 
then deeply characterized the SOX10 response element at SOX6, which revealed that this 
element resides at a previously unreported alternative promoter that directs the expression of a 
specific mRNA isoform. SOX6 was previously reported to inhibit glial cell differentiation in the 
central nervous system; however, the role of SOX6 in Schwann cells has not yet been 
characterized. To explore the role of SOX6 in Schwann cells, we set out to identify SOX6 target 
loci via overexpression of SOX6 in culture Schwann cells followed by RNA-seq analysis. Gene 
ontology analysis of up-regulated genes revealed a putative role for SOX6 in Schwann cell 
proliferation and regeneration following nerve injury, which should be explored using further 
computational and functional studies. Importantly, the computational and functional datasets we 
present here will be valuable for the study of transcriptional regulation, SOX protein function, 
and glial cell biology. 
 
1	  	  
Chapter 1 
An Overview of Schwann Cell Biology 
 
1.1 Introduction 
Compact myelin is a lipid-rich layer formed by Schwann cells and oligodendrocytes along the 
axons of both the peripheral and central nervous systems respectively. The myelin sheath in 
jawed vertebrate organisms allows rapid conduction of action potentials along the nerves, which 
has contributed to fast responses to stimuli and offered the advantages of both predation and 
escape behaviors. The SRY-related HMG box 10 (SOX10) transcription factor is essential for all 
stages of peripheral nerve myelination. Indeed, mutations in SOX10 and in SOX10 target genes 
cause several forms of demyelinating peripheral neuropathy. The main focus of my dissertation 
is to elucidate the transcriptional regulatory pathways important for peripheral nerve myelination 
by identifying novel SOX10 target loci. In this chapter, I provide an overview of how Schwann 
cells form myelin in the peripheral nervous system. Next, I present the evolution of myelin and 
discuss key differences between vertebrate myelin and invertebrate glial cell membranes. 
Finally, I discuss the transcriptional mechanisms important for vertebrate myelination and the 
role of SOX10 in this process.
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1.2 An Introduction to the nervous systems 
A typical vertebrate nerve consists of two cell types: neurons and glia. A neuron consists of a cell 
body, several branched projections called dendrites, and an axon (Fig. 1.1). Glial cells: (i) form 
the myelin sheath; (ii) provide trophic support to axons; and (iii) play a crucial role in nerve 
repair following injury. Schwann cells and oligodendrocytes are the glial cells that form compact 
myelin in the peripheral nervous system (PNS) and central nervous system (CNS), respectively 
(del Rio, 1921; Geren, 1954; Pérez-Cerdá et al., 2015). These cells form myelin in axon 
segments, thus generating periodic gaps called the nodes of Ranvier. The nodes of Ranvier 
contain high concentrations of sodium ion channels, which facilitate propagation of action 
potentials along the nerve; a process called saltatory (derived from the Latin word saltare, which 
means ‘to jump’) conduction (D'Este et al., 2017; Duflocq et al., 2008). 
 
Compact myelin is specific to jawed vertebrates and is formed by the wrapping of glial cell 
membranes around the axons. Myelin was first observed in the eighteenth century by Antonie 
van Leeuwenhoek and his reports were based on observations using a peripheral nerve isolated 
from a cow (Rosenbluth, 1999; Tomassy et al., 2016). Several years later, in 1838, as part of his 
thesis, Robert Remak observed rabbit peripheral nerves during different stages of development. 
He noted that some nerves were surrounded by a sheath but that other nerves lacked this 
structure (Boullerne, 2016; Sakuta, 2010). He called the latter nerve bundles ‘organic fibers’, 
which are now referred to as Remak bundles. Remak bundles contain multiple axons surrounded 
by Schwann cells that are not myelinated. In the same year, Matthias Schleiden and Theodor 
Schwann were working on the ‘cell theory’, which proposed that all living things were composed 
of cells. 
3 	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Structure of a neuron. The cell body and dendrites are depicted in blue and Schwann 
cells that form the myelin sheath are shown in yellow. The nuclei of the neuron and Schwann 
cells are shown in green and orange, respectively. 
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Schwann studied various animal tissues including peripheral nerves and noticed that the nerve 
bundles were composed of two types of fibers: white fibers and organic (or Remak) fibers. 
Schwann noted that the membrane of the white fibers was granulated and that the nuclei 
remained on the nerve fiber during various developmental stages. He proposed that the cells 
formed a continuous layer that came together to form the nerve fiber such that the nuclei always 
remained on the nerve fiber; these cells were later named Schwann cells (Boullerne, 2016; del 
Rio, 1921; Geren, 1954; Pérez-Cerdá et al., 2015). In 1854, the German pathologist Rudolf 
Virchow coined the term ‘myelin’, which is derived from the Greek word myelos (marrow) 
analogous to bone marrow; in the following years, the fatty substance surrounding the axon was 
referred to as myelin (Boullerne, 2016; Duflocq et al., 2008; Virchow, 1854). 
 
1.3 Peripheral nerve myelination 
Schwann cells are derived from neural crest cells (NCCs) (D'Este et al., 2017; Douarin et al., 
1991), which are a transient multipotent population of cells that arise from the border as the 
neural plate folds to form the neural tube. NCCs separate themselves from the neural tube by a 
process called delamination (LaBonne and Bronner-Fraser, 1999; Rosenbluth, 1999; Tomassy et 
al., 2016) and undergo an epithelial to mesenchymal transition (EMT), a process by which the 
cells lose their epithelial properties to become mesenchymal cells. Following EMT, NCCs 
migrate to different locations within the embryo and—depending on the local environment—
become restricted to generate distinct cell types. NCCs give rise to myriad cell types including 
melanocytes, Schwann cells, enteric nervous system neurons, and craniofacial cartilage 
(Anderson, 1993; Boullerne, 2016; Sakuta, 2010; Sauka-Spengler and Bronner-Fraser, 2008). 
Peripheral nerve myelination involves two developmental stages: (i) the transition of NCCs into 
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Schwann cell precursors (SCP); and (ii) the differentiation of SCPs into myelinating or non-
myelinating Schwann cells (Jessen et al., 1994). SCP migrate along axonal tracts in the 
developing peripheral nerve (Zorick and Lemke, 1996). Communication between axons and 
Schwann cells is essential for myelination, axonal maintenance, and repair. Schwann cell 
development and myelination depend on mitogenic signals from the axons of the peripheral 
nerves. Conversion of SCP to immature Schwann cells entails gene expression changes, cell 
survival, and response to mitogens. Neuregulin-1 (NRG1) is a signaling molecule produced by 
axons that is essential for SCP survival in embryonic nerves; loss of Nrg1 in mice is embryonic 
lethal and the embryos die by E11.5. Analysis of these mutant embryos revealed significantly 
reduced number of Schwann cell precursors suggesting that NRG1 is important for early stages 
of Schwann cell development (Meyer and Birchmeier, 1995). NRG1 is one of the longest genes 
~1.4MB long and undergoes alternative splicing to produce at least 15 different isoforms (Falls, 
2003). Based on biological properties they are grouped into different types I-VI (Steinthorsdottir 
et al., 2004). Type III, in particular, is critical for the survival and proliferation of the SCP 
(Taveggia et al., 2005; Wolpowitz et al., 2000). NRG1 type III binds to receptor tyrosine kinases 
(Erbb2/3) that are expressed in Schwann cells (Levi et al., 1995) and this interaction elicits a 
cascade of regulatory pathways important for Schwann cell development (Britsch et al., 1998). 
ERBB2/3 form heterodimers and ERBB2 contains the catalytically active kinase domain and 
ERBB3 contains the NRG1 binding domain (Limpert and Carter, 2010). Early stages of 
Schwann cell development rely on NRG1/ErbB signaling and loss of Nrg1, ErbB2, or ErbB3 in 
mice leads to absence of SCP (Meyer and Birchmeier, 1995; Riethmacher and Sonnenberg-
Riethmacher, 1997; Woldeyesus et al., 1999). The NRG1/ErbB signaling pathway is critical for 
SCP survival and later for Schwann cell differentiation (Britsch et al., 1998; Leimeroth et al., 
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2002a). Immature Schwann cells that associate with single large axons (>1 μm diameter) form 
the myelin sheath and those that associate with several small caliber axons (<1μm diameter) 
form the non-myelinating Remak bundles (Sherman and Brophy, 2005). Schwann cells possess 
remarkable plasticity and can dedifferentiate to an immature state resulting in demyelination. 
Demyelination of peripheral axons can occur in two ways: first, myelinating Schwann cells can 
lose axonal contact and dedifferentiate into the immature state following nerve injury to facilitate 
the recovery process; second, in patients with inherited demyelinating peripheral neuropathies 
the dedifferentiation pathway can be activated inappropriately due to the altered function of 
mutated genes. Once immature Schwann cells have associated with single axons, they exit the 
cell cycle to become pro-myelinating cells and initiate the myelination program (Fig. 1.2) (Jessen 
and Mirsky, 2005) 
 
1.4 The developmental timeline of vertebrate myelination 
Myelination is a dynamic process and occurs in a conserved temporal manner where axons in the 
PNS are myelinated before the CNS axons (Cravioto, 1965; Laurence, 2017). In 1965, Humberto 
Cravioto observed myelination in humans by isolating the sciatic nerves from 12-,14-,16-, and 
22-weeks old fetuses. He made the following observations: (i) migrating Schwann cells were 
observed at 12-weeks; (ii) Schwann cells were mostly in the immature state at 14-weeks with the 
presence of occasional myelinated axons; (iii) myelinated axons were more frequent by 16- 
weeks; and (iv) a large number of axons were myelinated by 22-weeks (Cravioto, 1965; Jessen 
and Mirsky, 2005). In contrast, onset of PNS myelination is a postnatal event in rodents. 
Schwann cell migration occurs around embryonic (E) day 12-13 mice nerves (E14-15 in rat  
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Figure 1.2 Stages of Schwann cell development. Neural crest cells give rise to Schwann cell 
precursors, which migrate along axons and differentiate to form immature Schwann cells. 
Immature Schwann cells have two fates: (i) those that are associated with single axonal segments 
become promyelinating Schwann cells and eventually form the myelin sheath; and (ii) those that 
are associated with multiple axons form non-myelinating Schwann cells. Dashed arrows indicate 
that these cells types can revert back to the immature stage. Adapted from Jessen and Mirsky, 
2005. 
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nerves), immature Schwann cells are observed in E13-E15 mice nerves (E15-17 in rat nerves), 
and myelination begins after birth. Gestation time is about 19-21 days, 21-23 days for mice and 
rats, respectively (Jessen and Mirsky, 2005; Zalc et al., 2008). 
 
1.5 The evolution of myelination 
The myelin sheath has three major functions: (i) increase the conduction velocities along the 
axons; (ii) maintain axon integrity; and (iii) provide trophic factors to axons. The myelin sheath 
increases nerve conduction velocities by several magnitudes compared to an unmyelinated nerve 
and this enables a faster response to stimulus. The conduction velocity of an unmyelinated axon 
is about 0.5-10 meter per second (m/s) and that for a myelinated axon can be as high as 150 m/s. 
From an evolutionary standpoint, the two ways to improve conduction velocities are to either 
increase the axonal diameter or insulate the axons with myelin. The propagation speed of an 
action potential is directly proportional to the axon diameter in unmyelinated axons and this 
mechanism works well for invertebrates considering their smaller body sizes (Schweigreiter et 
al., 2006; Zalc et al., 2008). However, most vertebrates have larger bodies and myelin offers a 
more efficient way of improving the conduction velocity compared to increasing axonal diameter 
(Schweigreiter et al., 2006; Zalc et al., 2008). Thus, ecological conditions, the need for rapid 
escape, and large body sizes may have selected for the emergence of myelin in jawed vertebrates 
(Schweigreiter et al., 2006; Zalc et al., 2008).  
 
Myelin was first observed in placoderms about 425 million years ago (Zalc et al., 2008). By 
comparing the length and the diameter of oculomotor nerves from fossilized placoderms skulls 
and their similarly-sized immediate ancestors (osteostraci), it was noted that the nerve in 
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placoderms was ten times longer compared to osteostraci, with the diameter in both species 
remaining constant. It was thus proposed that the only plausible way for placoderms to increase 
the length of the nerve while maintaining a constant diameter was a layer of myelin along the 
placoderm axons. Placoderms were active predators with hinged jaws. Since the structures that 
form the jaw are derived from the neural crest cells, it was proposed that the appearance of 
Schwann cells—also a neural crest derived cell type—may be coupled to the evolution of PNS 
myelin to facilitate predatory and escape behaviors (Zalc, 2016; Zalc et al., 2008). Myelination 
has not been observed in invertebrates, however, annelids and anthropods possess myelin-like 
layers surrounding their axons (Bullock et al., 1984; Davis et al., 1999; Pereyra and Roots, 1988; 
Roots et al., 1991) (Fig. 1.3). 
 
All vertebrate species except agnathostomes (the jawless hagfish and lamprey) have myelinated 
axons (Bullock et al., 1984; Smith et al., 2013). Although lampreys lack myelin sheaths they do 
have glial cells and, interestingly, sequencing the lamprey genome revealed the presence of 
myelin-associated proteins (Smith et al., 2013). Peripheral myelin protein (PMP22), myelin 
protein zero (MPZ), and myelin proteolipid protein (PLP) are components important for the 
formation of myelin in the peripheral and central nervous systems and these genes were 
identified in the lamprey genome. Combined with the high conservation of the protein-coding 
sequences of these loci between lamprey and jawed vertebrates, these data suggest that the 
evolution of regulatory pathways (e.g., transcription factors and cis-acting regulatory sequences) 
in gnathostomes led to their recruitment for the formation of myelin (Bullock et al., 1984; Smith 
et al., 2013).  
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Figure 1.3 Myelin Evolution. A simplified phylogenetic tree showing the presence of myelin 
across the animal kingdom. Species labeled in green contain myelin-like layers around axons, 
those shown in red do not contain myelin and Gnathostomes have compact myelin. Figure 
adapted from Knowles 2017 
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1.6 A Comparison of invertebrate and vertebrate myelin  
The axons in all chordates with the exception of jawless fish are surrounded by a compact, multi-
layered myelin sheath (Bullock et al., 1984; Davis et al., 1999; Pereyra and Roots, 1988; Roots et 
al., 1991). In contrast, invertebrate axons associate with a loosely wound myelin-like 
ensheathment (Davis et al., 1999; Friede and Bischhausen, 1982; Michailov et al., 2004; Pereyra 
and Roots, 1988; Roots et al., 1991). The key differences of invertebrate and vertebrate myelin 
with respect to morphology, conduction velocity, and lipid and protein content are discussed 
below.  
 
1.6.1.Morphology 
Glial cells in vertebrates form compact myelin and the morphology of myelin is conserved across 
species. The cell membrane of Schwann cells and oligodendrocytes are wrapped around axons to 
form compact myelin in the peripheral and central nervous systems respectively. The thickness 
of the myelin sheath depends on the axonal diameter (Friede and Bischhausen, 1982; Michailov 
et al., 2004) and this process is controlled by Neuregulin-1 signaling in the peripheral nerve 
(Michailov et al., 2004; Schweigreiter et al., 2006). The myelin-like layer in invertebrates has 
variable morphology (Roots and Lane, 1983; Schreiner et al., 2007; Schweigreiter et al., 2006). 
In the earthworm Lumbricus terrestris, the glial cells wrap around giant axons to form a compact 
structure similar to what is observed in vertebrates (Cardone and Roots, 1991; Pusch et al., 1998; 
Roots and Lane, 1983; Schreiner et al., 2007); where as in the crayfish Procambrus clarkii it is 
loosely wound and number of layers can vary (Cardone and Roots, 1991; Heuser and 
Doggenweiler, 1966; Pusch et al., 1998).  
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Another striking difference between vertebrate and invertebrate myelin is the position of the glial 
cell nuclei. The location of the nuclei can vary in invertebrates and can be found in any location 
within the myelin-like layer (Bunge et al., 1989; Heuser and Doggenweiler, 1966; Schweigreiter 
et al., 2006). In contrast, vertebrate glial cell nuclei consistently reside within the outermost layer 
of compact myelin (Bunge et al., 1989; Günther, 1976; Schweigreiter et al., 2006). 
 
1.6.2 Conduction velocity 
The conduction velocity of action potentials along the axons is higher in vertebrates compared to 
invertebrates. For example, the conduction velocity of the myelinated giant axon (diameter 
~90μm) of the earthworm Lumbricus terrestris is about 30 m/s (Günther, 1976; Lee et al., 1999; 
Schweigreiter et al., 2006) and that of a rat axon (diameter ~4.5μm) is about 59 m/s (Garbay et 
al., 2000; Lee et al., 1999; Schweigreiter et al., 2006). Faster conduction velocities enable rapid 
response to changes in the environment and offer a selective advantage. 
 
1.6.3 Lipid and protein content 
A key feature that distinguishes myelin from other cell membranes is a high lipid-to-protein ratio 
(Bürgisser et al., 1986; Garbay et al., 2000; Waehneldt et al., 1986). Myelin in vertebrates is 
mainly composed of phopholipids, cholesterol, galactocerebroside, sulphatide, and small 
amounts of protein (Bürgisser et al., 1986; Jeserich et al., 1990; Roots, 2008; Waehneldt et al., 
1986). Myelin-like layers in annelids and crustaceans are also composed of phospholipids and 
cholesterol; however, this layer in these species lack galactocerebroside and sulphatide (Roots, 
2008; Ryu et al., 2007). Crustaceans have a higher lipid to protein ratio (15:1) compared to 
vertebrate and annelids (2:1) (Laurence, 2017; Roots, 2008; Ryu et al., 2007).  
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Both compact myelin in vertebrates and myelin-like structures in invertebrates contain low 
molecular weight proteins. The protein components of the invertebrate myelin-like sheath is 
unclear and have not been fully catalogued (Cardone and Roots, 1996; Laurence, 2017; Monuki 
et al., 1993; Ryu et al., 2007). Immunoblot analysis of the ventral nerve cord of the earthworm 
Lumbricus terrestris suggested a simple protein expression pattern with 80, 42, and 30 kDa sized 
proteins (Campagnoni, 1988; Cardone and Roots, 1996; Saavedra et al., 1989).  
 
Protein composition within the myelin sheath differs across different vertebrate species and 
between the CNS and the PNS. Myelin basic protein (MBP) is one of the main components of 
both CNS and PNS myelin in vertebrate species. MBP is a cell adhesion molecule which 
facilitates myelin compaction (Campagnoni, 1988; Givogri et al., 2001; Nawaz et al., 2013; 
Saavedra et al., 1989; Zorick et al., 1999). The GOLLI gene contains 10 exons in humans and 
undergoes alternative splicing to produce different MBP isoforms (Givogri et al., 2001; Roach et 
al., 1985). Mbp null mutant mice, called shiverer, arose spontaneously and display severe CNS 
hypomyelination. Interestingly, the PNS was only moderately affected (Greenfield et al., 1973; 
Roach et al., 1985; Topilko et al., 1994) likely due to the fact that PNS myelin contains about 
half the amount of MBP detected in CNS myelin. The most abundant protein in the PNS is 
Myelin Protein Zero (MPZ or P0), a transmembrane glycoprotein (Greenfield et al., 1973; Lemke 
and Axel, 1985; Topilko et al., 1994). The cytoplasmic domains of MBP and MPZ share 
sequence homologies (Bai et al., 2011; Jones et al., 2011; Lemke and Axel, 1985; Saavedra et 
al., 1989; Tai and Smith, 1984; Waehneldt and Jeserich, 1984) so, the absence of Mbp may be 
compensated by Mpz in the peripheral nerves of the shiverer mutant mice. 
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MPZ encodes a highly conserved cell adhesion molecule that is the major component of 
peripheral myelin in all vertebrates; interestingly, MPZ is also expressed in the CNS myelin 
sheath of aquatic vertebrates (Bai et al., 2011; Jones et al., 2011; Lanwert and Jeserich, 2001; 
Saavedra et al., 1989; Tai and Smith, 1984; Waehneldt and Jeserich, 1984). Mammals express a 
single isoform of MPZ but several alternative isoforms have been detected in teleost and 
cartilaginous fish (Giese et al., 1992; Lanwert and Jeserich, 2001; Tai and Smith, 1984; 
Waehneldt and Jeserich, 1984). Heterozygous null Mpz mice display normal myelinated axons, 
which could be due to the presence of Mbp. However, homozygous null mice exhibit tremors, 
motor coordination abnormalities, and severe hypomyelination (Giese et al., 1992; Martini et al., 
1995). Mice deficient of both Mbp and Mpz display severe PNS demyelination and die at about 
5-6 weeks of age (FOLCH and LEES, 1951; Martini et al., 1995). In terrestrial vertebrates, 
proteolipid protein (PLP) is the major component of the CNS myelin (FOLCH and LEES, 1951; 
Puckett et al., 1987) and in mammals, PLP is expressed in Schwann cells but it is excluded from 
the myelin sheath (Puckett et al., 1987; Snipes et al., 1992). In addition to MBP, MPZ, and PLP, 
other proteins such as peripheral myelin protein (PMP22) (Mikol and Stefansson, 1988; Snipes et 
al., 1992), myelin-associated glycoprotein (MAG) (Mikol and Stefansson, 1988) are associated 
with the process of myelination in vertebrates. 
 
Protein composition of myelin-like layer in invertebrates remains obscure and the presence of 
cell adhesion proteins such as MBP, MPZ, PLP, and PMP22 may have led to the formation of 
compact myelin in vertebrates. Sequencing the lamprey genome, a jawless vertebrate, has 
provided interesting evidence of the presence of myelin proteins such as PLP, MPZ, and PMP22 
in spite of not having myelinated axons (Smith et al., 2013). SOX genes have been identified 
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throughout the animal kingdom and are transcriptional regulators that are important for many 
developmental processes. In particular SOXE proteins (SOX8, SOX9, and SOX10) are critical 
for neural crest specification and differentiation and SOX10 is critical for myelination (discussed 
in detail later) (Guth and Wegner, 2008). Interestingly, SoxE (SoxE1, SoxE2, and SoxE3) genes 
have been identified in lampreys and SoxE3 displays limited sequence homology to SOX9 
(Lakiza et al., 2011). Whereas, SoxE1 and SoxE2 do not share any sequence similarity with 
either SOX8 or SOX10 and are not orthologous (Guth and Wegner, 2008; Lakiza et al., 2011). 
Owing to the importance of SOX10 in myelination, vertebrate-specific neofunctionalization of 
SOXE proteins and altered transcriptional regulation of genes important for myelination may 
have contributed to formation of compact myelin in gnathostomes. Additionally, evolution of 
cis-regulatory sequences required for the expression of these myelin genes may have evolved in 
vertebrates, which could explain the differences we observe between compact myelin and 
myelin-like layer in invertebrates. Thus, a thorough understanding of the regulatory pathways 
important for myelination will provide unique insights into the evolution of myelin in jawed 
vertebrates. The aim of my Ph.D. thesis research is to investigate the transcriptional regulation of 
genes important for vertebrate myelination. 
 
1.7 Transcriptional regulation of peripheral nerve myelination  
1.7.1 An overview of transcription 
According to the central dogma of molecular biology: (i) DNA is transcribed into RNA, and this 
is a reversible process where RNA can be reverse transcribed to DNA; and (ii) RNA is translated 
into proteins. Transcription is a process catalyzed by the enzyme RNA polymerase in which 
information from DNA molecules is transcribed to a single-stranded messenger RNA (mRNA) 
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molecule. Bacteria contain a single RNA polymerase enzyme, in contrast to eukaryotes, which 
contain three RNA polymerases: RNA polymerase I, II, and III. RNA polymerase II (Pol II) 
transcribes all protein-coding genes and RNA polymerase I and III transcribe genes that code for 
transfer RNA, ribosomal RNA, and other small RNAs (Chambon, 1975).  
 
A transcriptional unit is the region of DNA that contains appropriate signals (such as initiation 
and termination) which results in the generation of a nascent transcript. The main steps of 
transcription are: (i) formation of the preinitiation complex; (ii) promoter clearance; (iii) 
elongation; and (iv) termination. RNA polymerase initiates transcription by binding to a DNA 
segment called the promoter (Nevins, 1983). Pol II along with the general transcription factors 
forms a preinitiation complex (PIC) that binds to a core promoter sequence to initiate 
transcription. Promoters often contain an AT-rich sequence called the TATA box or Goldberg 
Hogness box, which is located 25-30 bases upstream from the transcription start site (TSS) 
(Corden et al., 1980). 
 
A general transcription factor, TFIID, binds to the TATA-box and recruits other transcription 
factors and Pol II resulting in the formation of the PIC (Roeder, 1996). Binding of the PIC to the 
promoter is sufficient to drive low levels of transcription, a process referred to as basal 
transcription. Promoter sequences are usually asymmetric so the RNA polymerase can bind only 
in one direction and the template strand is chosen based on the location and orientation of the 
promoter (Roeder, 1996). Following the assembly of the PIC, TFIIH unwinds the DNA strands 
that reside roughly 12-14 base pairs around the TSS to create a transcription bubble (Roeder, 
1996). Pol II facilitates the polymerization of the first nucleotide and RNA synthesis occurs in 
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the 5’ to 3’ direction. Within this transcription bubble, Pol II releases short transcripts called 
abortive transcripts (Munson and Reznikoff, 1981). Pol II contains a highly conserved domain 
called the C-terminal repeat domain (CTD), which is essential for Pol II function. It consists of 
25-52 tandem repeats of the heptad sequence Y1S2P3T4S5P6S7, with serine 2 and serine 5 capable 
of undergoing phosphorylation (Corden, 1990). The phosphorylation patterns change as 
transcription proceeds and each phosphorylation pattern recruits different proteins which serve 
different functions (Phatnani and Greenleaf, 2006). Phosphorylation of the CTD disrupts Pol II 
interactions with the basal transcription machinery and Pol II enters the elongation phase of 
transcription (Jiang et al., 1996). As the nascent RNA is being produced, the eukaryotic pre-
mRNA undergoes processing to form the mature mRNA and the phosphorylation status of the 
CTD recruits the factors needed for producing the mature mRNA. The pre-mRNA undergoes 5’-
capping, splicing, and 3’-end processing and these events occur co-transcriptionally to ultimately 
form the mature RNA (Proudfoot et al., 2002).  
 
1.7.2 The function of cis-regulatory elements in transcriptional regulation  
Cis-acting regulatory elements (CREs) are DNA sequences (typically, but not exclusively, non-
coding sequences) associated with transcriptional regulation that play an important role in the 
spatial and temporal expression of a given locus; CREs have been shown to be critical for 
specifying gene expression patterns required for establishing diverse cell types. CREs usually 
contain consensus motifs (specific DNA sequences) for transcription factors and binding of TFs 
to these motifs elicits a transcriptional response. Promoters, enhancers, repressors, and insulators 
are well-characterized classes of CREs (Noonan and McCallion, 2010) (Fig. 1.4). CREs can 
drive basal levels of transcription (promoters), increase transcription (enhancers), inhibit  
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Figure 1.4 Schematic of the function of cis-acting regulatory elements. (i) The transcriptional 
machinery binds to the promoter (P) and leads to basal levels of gene expression. (ii) Enhancer 
(E) acts on the promoter in a position- and orientation-independent manner to activate gene 
expression. (iii) Repressor (R) acts on the promoter to decrease gene expression. (iv) Enhancer 
(E) activates the expression of gene X and the insulator (I) element prevents ectopic expression 
of gene Y. PX and PY are the promoters of Gene X and Y respectively. Adapted from Noonan 
and McCallion, 2010. 
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transcription (repressors), or prevent ectopic gene transcription (insulators) (Fig. 1.4). The core 
promoter element consists of a TATA box, an initiator element, and the transcription start site 
(TSS), which defines the direction of transcription. Only about 24% of human genes contain a 
TATA-box and most human promoters are GC-rich (Yang et al., 2007). CpG islands are regions 
of DNA that contain multiple cytosine-guanine repeats and ~70% of human promoters reside 
within these sequence elements (Saxonov et al., 2006). CpG islands play a critical role in 
regulating transcription by influencing the local chromatin environment. The cytosine in the CpG 
dinucleotide can undergo methylation to form 5-methylcytosine and about 80% of CpG islands 
in the human genome are methylated (Bird, 1999). Importantly, methylation of the CpG islands 
is inversely related to transcriptional activity and, as such, this process is an important 
mechanism for regulating gene expression (Razin and Riggs, 1980; Vardimon et al., 1982).  
 
Most eukaryotic genes have a single promoter; however, certain genes in the human genome 
have multiple promoters with about three putative alternative promoters residing at each locus 
with more than one such element (Kimura et al., 2006). Use of alternative promoters—and 
alternative first exons—significantly contributes to the diversity of protein products expressed 
from a single gene. For example, a series of sequential, internal promoters can lead to a series of 
N-terminally truncated proteins that may have different cellular functions (Fogarty et al., 2016). 
In contrast, alternative promoters can produce transcripts with identical open reading frames 
(ORFs); 60-80% of alternative promoters produce protein with identical ORFs (Landry et al., 
2003). Here, differential 5’ untranslated regions may alter gene function, for example by altering 
the cellular location of a transcript or the rate of protein translation (Phelps et al., 1998). In 
addition to promoters, distal cis-acting regulatory elements such as enhancers, repressors, and 
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insulators can affect the expression levels of a given locus. Enhancers are DNA sequences that 
stimulate or enhance gene expression by exerting an effect on gene promoters. Enhancers are 
enriched with short DNA motifs that serve as binding sites for transcription factors. Binding of 
transcription factors to enhancers results in the recruitment of co-activators and chromatin 
remodeling proteins and that results in an open chromatin configuration that allows increased 
transcription. The first enhancer was identified in the animal virus SV40 in 1981 (Banerji et al., 
1981). The authors transiently transfected HeLa cells with a plasmid containing the rabbit 
hemoglobin β1 gene and did not detect transcription. However, when they co-transfected a 
plasmid that contains a fragment from the Simian Virus 40 (SV40), it resulted in a 200-fold 
increase in hemoglobin β1 transcript levels (Banerji et al., 1981). To narrow down the region that 
caused enhanced hemoglobin β1 levels, the authors created several deletion mutants of the SV40 
DNA fragment and tested their ability to increase transcription. This revealed a 72-bp fragment 
of the SV40 DNA that caused increased expression of the hemoglobin β1 transcript (Banerji et 
al., 1981). The DNA fragment within the mouse immunoglobulin heavy chain locus was the first 
eukaryotic enhancer discovered (Banerji et al., 1983). The authors cloned this enhancer fragment 
in a plasmid that expresses β-globin gene reporter. They cloned the enhancer at different 
locations (upstream and downstream) relative to the reporter gene and performed transient 
transfection as described above to measure the activity of the enhancer. This fragment was able 
to stimulate the transcription of β-globin gene in a distance- and orientation-independent manner 
(Banerji et al., 1983).  
 
DNA is wrapped around nucleosomes, with each core nucleosome being an octamer with two 
copies each of the histone proteins H2A, H2B, H3, and H4. The amino termini of these histone 
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proteins can undergo post-translational modifications such as methylation and acetylation, and 
these modifications alter chromatin structure and affect gene transcription. DNase I is an enzyme 
that digests nucleosome depleted regions of DNA (open chromatin) and regulatory regions such 
as promoters, enhancers are located in such regions (Boyle et al., 2008a).  
 
Enhancers can be classified as inactive, poised, primed, or active and can be distinguished by the 
chromatin accessibility and the type of histone modifications they are associated with (Heinz et 
al., 2015; Shlyueva et al., 2014). Chromatin associated with inactive enhancers is highly 
compacted and lacks chromatin modifications (Heinz et al., 2015). Enhancers are considered to 
be poised if they contain histone H3 lysine 27 trimethylation (H3K27me3), a Polycomb protein-
associated repressive mark (Heinz et al., 2015; Zentner et al., 2011). Poised enhancers may 
exhibit some basal activity and signal dependent binding of transcription factors can cause them 
to become active (Heinz et al., 2015; Samstein et al., 2012). Primed enhancers, which represent 
an intermediate class of enhancers, are associated with H3K4 monomethylation (Zentner et al., 
2011). Lineage specific factors recognize these chromatin marks and bind primed enhancers and 
regulates genes in a cell-specific manner (Heinz et al., 2015). H3K27 acetylation distinguishes 
active from poised or primed enhancers (Creyghton et al., 2010). Some of the prominent features 
of enhancers are: (i) they can act on gene promoters in a distance- and orientation-independent 
manner; (ii) they are sensitive to DNase I treatment; (iii) they contain sequence motifs for 
transcription factors; and (iv) the histones within the vicinity of enhancers can be modified as 
follows: poised (H3K27me3+, H3K27ac-); primed (H3K4me1+, H3K27ac-); and active 
(H3K4me1+, H3K27ac+).  
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With recent advances in sequencing technologies several genome-wide studies have identified 
enhancers based on the above properties. DNase-seq experiment was developed to identify the 
regions of open chromatin within the entire genome (Boyle et al., 2008a; Crawford et al., 2006). 
In addition to DNase-seq other techniques such as MNase-seq (Schones et al., 2008), FAIRE-seq 
(Giresi et al., 2007) and ATAC-seq (Buenrostro et al., 2013) have been developed to identify 
genome-wide distributions of open chromatin regions. Chromatin immunoprecipitation 
combined with massive parallel sequencing (ChIP-seq) involves crosslinking proteins to DNA, 
using an antibody against the protein of interest to isolate the protein-DNA complex, recovering 
the DNA fragments, and performing high-throughput DNA sequencing to identify DNA 
sequences bound to specific proteins (e.g., transcription factors or histones). Various studies—
including the encyclopedia of DNA elements (ENCODE) consortium—have used the above 
techniques to identify thousands of enhancer elements in various species. The aim of the 
ENCODE project is to identify and catalogue all functional elements within the human genome 
(ENCODE Project Consortium et al., 2007). The ENCODE project has generated several ChIP-
seq data sets across multiple cell types using antibodies against various histone marks, co-
activator p300, and specific transcription factors. These techniques—and the associated, freely 
available resources—have proven invaluable for characterizing transcriptional hierarchies 
important for specific cell populations, and in this thesis I employ them for studies on Schwann 
cell biology. 
 
1.8 The transcription factor SOX10 is essential for peripheral nerve myelination 
There are two opposing transcriptional programs that control myelination in the peripheral 
nervous system: transcription factors that inhibit myelination and transcription factors that 
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promote myelination. Negative regulators of myelination are important during early Schwann 
cell development to inhibit ectopic myelination as precursors divide and migrate along peripheral 
nerve axons. As Schwann cell development progresses toward radial sorting and membrane 
extension, positive regulators increase the expression of genes important for the process of 
myelination. The transcription factors c-Jun and SOX2 (Jessen and Mirsky, 2008; Parkinson et 
al., 2008; Roberts et al., 2017a) are negative regulators of myelination and are expressed early 
during Schwann cell development. In contrast, SOX10, OCT6, and EGR2 are well known for 
their role in promoting myelination (Jessen and Mirsky, 2005). Interestingly, OCT6 and EGR2 
expression begin at the point of myelin formation while SOX10 is expressed throughout the 
Schwann cell (and neural crest) lineage. This observation raises the question of how myelination 
is inhibited in the context of a pro-myelination factor such as SOX10.  
 
1.8.1 The SRY-related HMG-box 10 (SOX10) transcription factor 
The SRY-related HMG-box (SOX) family of transcription factors plays an important role in 
regulating genes during embryonic development. The sex-determining region Y (SRY) gene 
encodes a protein, which contains a 75 amino acid protein domain called the high mobility group 
(HMG) box. The HMG box recognizes specific DNA sequences and facilitates binding of SRY 
to DNA (Harley et al., 1992). There are two types of HMG-box proteins: (i) those containing 
multiple HMG boxes, which bind DNA independent of the sequence; and (ii) those containing a 
single HMG box, which bind DNA in a sequence-dependent manner (Prior and Walter, 1996). 
Proteins in the SOX family of transcription factors have been a single HMG domain and all bind 
DNA in a sequence-dependent manner (Gubbay et al., 1990; Travis et al., 1991; Waterman and 
Jones, 1990). SOX proteins recognize the sequence 5’-(A/T)(A/T)CAA(A/T)G-3’ within the 
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minor groove of DNA (Harley et al., 1994; Laudet et al., 1993). Based on the presence of an 
HMG domain and amino acid sequence similarities, 20 SOX proteins have been classified into 
eight groups: SOXA-H (Bowles et al., 2000). In spite of recognizing the same DNA sequence, 
SOX proteins from different groups have acquired distinct biological functions and spatio-
temporal expression patterns (Kamachi and Kondoh, 2013; Kondoh and Kamachi, 2010).  
In vertebrate species, the SOXE group includes SOX8, SOX9, and SOX10 (Guth and Wegner, 
2008). The transcripts encoding SOX8, SOX9, and SOX10 were identified using RT-PCR on 
total RNA isolated from 11.5 days post coitum (dpc) mouse embryos (Wright et al., 1993). 
SOXE genes are expressed in the early neural crest cells (NCCs) and are involved in multiple 
stages of neural crest development (Cheung and Briscoe, 2003; Reiprich et al., 2008). SOX9 
expression precedes SOX8 and SOX10 and there is evidence that SOX9 induces the expression 
of SOX10 (Cheung and Briscoe, 2003). SOX10 expression begins in late, pre-migratory NCCs 
and plays a crucial role in the development and specification of PNS neurons and glial cells 
(Kuhlbrodt et al., 1998; Stolt and Wegner, 2010). In the PNS, most neurons and glial cells 
(Schwann cells) are derived from the NCCs and expression of SOX8 and SOX9 are down 
regulated before the cells commit to a neuronal or glial fate (Weider and Wegner, 2017). As the 
neurons mature SOX10 expression is repressed, whereas Schwann cells continue to express 
SOX10 (Kuhlbrodt et al., 1998). Melanocytes are the other neural crest derived cell type that 
continue to express SOX10 (Mollaaghababa and Pavan, 2003). In addition to NCC derived cell 
lineages, SOX10 is important for oligodendrocyte development and myelination in the central 
nervous system (Li et al., 2007) 
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Although these three SOX proteins share >90% amino acid identity, they are not entirely 
functionally redundant. Replacing the Sox10 locus with Sox8 in mice was not sufficient to fully 
rescue the phenotype of Sox10 null mice. Sox8 was able to fully rescue the loss of Sox10 in the 
PNS, however Sox8 was unable to rescue the defects observed in melanocytes, oligodendrocytes, 
and the enteric nervous system (Kellerer et al., 2006). Recent data reveal that Sox8 was able to 
rescue the loss of Sox10 during later stages of oligodendrocyte differentiation. Specifically, 
deleting Sox8 along with Sox10 in differentiating oligodendrocytes in mice caused severe 
myelination defects suggesting that both Sox8 and Sox10 are required for maintaining 
myelination in the central nervous system (Turnescu et al., 2017). SOX10 is essential for all 
stages of Schwann cell development. Mice homozygous for a conditional null allele of Sox10 
lack Schwann cells leading to impaired development of the PNS (Britsch et al., 2001). 
Furthermore, ablation of Sox10 expression at various stages of Schwann cell development 
(through the use of a conditional null allele and stage-specific CRE recombinase transgenes) 
results in defective PNS myelination. Specifically, deleting Sox10 at the immature Schwann cell 
stage in mice causes absence of myelinating and non-myelinating Schwann cells (Finzsch et al., 
2010). The peripheral nerves of these mice are translucent (due to the lack of myelin) compared 
to the opaque nerves from wild-type littermates and the mutant mice die by five-seven weeks 
after birth (Finzsch et al., 2010). Additionally, conditional deletion of Sox10 in myelinating 
Schwann cells in mice leads to severe hypomyelination and impairs Schwann cell homeostasis 
(Fröb et al., 2012). Thus, SOX10 is indispensable for Schwann cell development, maintenance, 
and myelination. 
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1.8.2 Structure of the SOX10 protein 
SOX10 encodes a 466 amino-acid protein that contains four major domains: a dimerization 
domain, an HMG domain, a K2 domain, and a transactivation domain (Fig. 1.5). The 
dimerization (DIM) domain is unique to the SOXE group and facilitates homodimerization and 
heterodimerization with other SOX proteins (Huang et al., 2015; Peirano and Wegner, 2000). 
SOX10 can function as a monomer or a dimer through binding a single (e.g., 5’-ACAAA-3’) or a 
head-to-head (e.g., 5’-ACAAAnnnnnnTTTGT-3’) consensus sequence, respectively (Peirano 
and Wegner, 2000). The length of the intervening spacer sequence between the monomeric sites 
can vary; however, a six-base pair spacer is most frequently observed (Schlierf et al., 2002). The 
HMG domain enables binding of SOX10 to DNA in a sequence-specific manner. Binding of 
SOX10 to the minor groove of DNA induces a bend in the DNA helix facilitating recruitment of 
several co-factors and thus, SOX10 acts as an architectural protein. The bending angle is 75-80° 
for a monomeric site and 103.5-122° for a dimeric site (Peirano and Wegner, 2000; Schlierf et 
al., 2002). The function of the K2 domain is poorly defined but there is evidence that this domain 
possess transactivation potential (Schepers et al., 2000). The K2 domain has also been called a 
“cell-specific transactivation domain” based on evidence from transgenic mice where the 
endogenous Sox10 locus was replaced with a SOX10 construct lacking the K2 domain (Schreiner 
et al., 2007). Development of neural crest cells and oligodendrocytes were unaffected in mice 
lacking the K2 domain. However, loss of the K2 domain affected Schwann cell myelination, 
melanocytes, and the enteric nervous system. Schwann cells from the above mice were restricted 
in the promyelinating stage and did not express myelin genes such as Mbp and Mpz (Schreiner et 
al., 2007) suggesting that the K2 domain is important for Schwann cell myelination. The 
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Figure 1.5 Structure of the SOX10 protein. The major domains of SOX10 are displayed from    
N- to C-terminus: dimerization (DIM; orange) domain, high mobility group (HMG; green) 
domain, K2 domain (yellow), and transactivation (TA; blue) domain. Numbers indicate amino 
acid positions along the protein. 
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transactivation (TA) domain is within the C-terminus of the SOX10 protein which is important 
for its regulatory function (Pusch et al., 1998). In addition, the TA domain physically interacts 
with positive transcription elongation factor b (P-TEFb) suggesting that SOX10 plays a role in 
transcription elongation (Arter and Wegner, 2015). 
 
1.8.3 The function of SOX10 in Schwann cells 
Each stage of Schwann cell development is tightly regulated by transcription factors and, not 
surprisingly, SOX10 plays a central role in this process. Our current understanding is that 
SOX10 directs a promyelinating program in Schwann cells by activating the expression of 
several key genes. NRG1/ErbB signaling is critical for early stages of Schwann cell 
development. While SOX10 is not known to regulate NRG1, SOX10 is known to regulate its 
receptor ErbB3 (Prasad et al., 2011) (Fig. 1.6A). Binding of axonally derived ligand NRG1 to 
ERBB3 elicits a signaling cascade, which promotes Schwann cell differentiation(Leimeroth et 
al., 2002b).  At the immature Schwann cell stage, SOX10 activates the expression of OCT6, a 
POU domain transcription factor. SOX10 binds to the Schwann cell-specific enhancer (SCE) 
located 10kb downstream of OCT6 to activate gene expression (Jagalur et al., 2011; 
Mandemakers et al., 2000). Although OCT6 is expressed in other cell types in the central 
nervous system and the skin, deleting the 4.3kb long SCE in mice resulted in Schwann cell 
specific ablation of Oct6 expression (Ghazvini et al., 2002). SOX10 physically interacts with and 
recruits the chromatin remodeling protein called BRG1 to SCE (Weider et al., 2012) (Fig. 1.6B). 
Conditional deletion of Brg1 in mouse Schwann cells leads to stalled Schwann cell 
differentiation and reduced Oct6 expression, and these mice suffer from severe peripheral 
neuropathy (Ryu et al., 2007; Weider et al., 2012). The activation of OCT6 also depends on 
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axonal signals that increase intracellular cyclic AMP (cAMP) levels. cAMP activates Protein 
Kinase A, an enzyme that phosphorylates CREB, and phosphorylated CREB activates the 
expression of target genes (Lee et al., 1999). Additionally, the SCE contains a consensus motif 
for the CREB transcription factor (Jagalur et al., 2011), suggesting that SOX10 and CREB 
regulate OCT6. After the induction of OCT6, the immature Schwann cells transition into the 
promyelinating stage. In this stage, SOX10, OCT6, and BRN2 activate expression of the 
transcription factor locus Early Growth Response 2 (EGR2/KROX20). The three proteins bind to 
the myelinating Schwann cell element (MSE) located 35kb downstream of EGR2 (Ghislain and 
Charnay, 2006). Activation of EGR2 also depends on the Mediator complex. The Med12 subunit 
interacts with SOX10 and binds to the MSE (Vogl et al., 2013) (Fig. 1.6C). Importantly, the 
myelination program is arrested in the promyelination stage in Egr2 null mice (Topilko et al., 
1994). Once EGR2 is expressed, SOX10 and EGR2 synergistically activate the expression of 
genes important for myelination; indeed, SOX10 and EGR2 are critical for the formation and 
maintenance of the myelin sheath (Bremer et al., 2011; Decker et al., 2006; Fröb et al., 2012; 
Topilko et al., 1994). Genome-wide studies have been performed that reveal co-occupancy of 
SOX10 and EGR2 at several loci (Srinivasan et al., 2012). These and other studies have revealed 
that SOX10 and ERG2 synergistically regulate the expression of Peripheral Myelin Protein 22 
(PMP22) (Jones et al., 2011),(Jones et al., 2012), Myelin Basic Protein (MBP) (Denarier et al., 
2005), Myelin Protein Zero (MPZ) (LeBlanc et al., 2006) and Connexin32 (GJB1) (Bondurand et 
al., 2001; Jang et al., 2010) (Fig. 1.6D). Taken together, these have added to our current 
understanding that SOX10 regulates a promyelination program in Schwann cells by activating 
key genes at different developmental stages of Schwann cell development. 
 
30 	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 A transcriptional hierarchy for Schwann cell development. (A) SOX10 activates the 
expression of ERBB3 in Schwann cell precursors. (B) SOX10, along with the chromatin 
remodeler BRG1, activates the expression of OCT6 via a Schwann cell specific enhancer (SCE) 
in immature Schwann cells.(C) In the promyelinating stage, SOX10 activates the expression of 
EGR2 via the myelinating Schwann cell enhancer (MSE). Other factors such as OCT6, BRN2, 
BRG1, and histone deacetylase (HDAC) bind to the MSE. (D) SOX10 and EGR2 act 
synergistically to activate expression of myelin genes. Loci are not drawn to scale. 
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1.8.4 The function of SOX10 in other cell types  
SOX10 expression begins as the neural crest cells start to migrate and neural crest cells give rise 
to many distinct cell types including melanocytes, enteric nervous system, sensory neurons, and 
Schwann cells (Cheung and Briscoe, 2003; Erickson and Reedy, 1998) consistent with SOX10 
being important for the development of other neural crest derivatives. Furthermore, SOX10 is  
expressed in developing and differentiated oligodendrocytes—cells that do not arise from the 
neural crest—indicating that SOX10 is critical for myelination in general. In melanocytes, 
SOX10 regulates the expression of microphthalmia-associated transcription factor (MITF) (Lee 
et al., 2000). During the later stages of melanocyte development, SOX10 and MITF 
synergistically activate the expression of dopachrome tautomerase (DCT), which functions in 
melanin synthesis (Jiao et al., 2004). In the enteric nervous system, SOX10 and PAX3 activate 
the expression of the tyrosine kinase receptor locus c-RET, which is important for the 
development of these cells (Lang et al., 2000). Finally, SOX10 is expressed in the 
oligodendrocyte progenitors in the central nervous system (CNS) and plays a crucial role in 
oligodendrocyte myelination (Stolt et al., 2002). In oligodendrocyte precursor cells, OLIG2 
regulates the expression of SOX10 by binding to a distal enhancer U2 or MCS4 (Antonellis et al., 
2008; Küspert et al., 2011). Once induced, SOX10 and OLIG2 regulate the myelination program 
in the CNS by activating the expression of myelin genes such as proteolipid protein (PLP), 
myelin-associated glycoprotein (MAG), and MBP (Stolt et al., 2002). SOX10 is well known as an 
activator of gene expression; however, SOX10 has been shown to repress gene expression in 
Bergmann glial cells in chick brain. Specifically, SOX10 represses the expression of chick 
kainate binding protein, which is a member of the ionotropic glutamate receptor family (Cruz-
Solis et al., 2009).  
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One of the earliest studies on the function of SOX10 were performed in a spontaneous mutation 
that arouse in mice termed Dominant megacolon (Dom). These mice contain a frame shift 
mutation in the Sox10 coding region that abolishes the transactivation domain (Herbarth et al., 
1998; Lane and Liu, 1984; Southard-Smith et al., 1998). Dom-/- mice are embryonic lethal and 
heterozygous animals display defects in neural crest derived cell lineages. Loss of Sox10 in 
heterozygous Dom mice causes pigmentation defects (due to loss of melanocytes), loss of enteric 
ganglia, and loss of glial cells and neurons in the PNS (Herbarth et al., 1998; Southard-Smith et 
al., 1998). Similar defects were observed in the zebrafish mutant colorless (cls) (Dutton et al., 
2001; Kelsh and Eisen, 2000). Another spontaneous mouse mutant of Sox10 called Sox10Hry is 
characterized by pigmentation defects and reduced number of enteric neurons (Antonellis et al., 
2006). This phenotype is associated with reduced Sox10 expression caused by a ~16kb deletion 
of non-coding sequences located ~40kb upstream of Sox10 TSS. It was then shown that the 
deletion contains non-coding sequences important for Sox10 expression (Antonellis et al., 2006). 
Detailed characterization of the ~16kb deletion revealed three cis-acting regulatory elements that 
contribute to the phenotype observed in Sox10Hry mice (Antonellis et al., 2008).  
 
1.8.5 Mutations in SOX10 and in SOX10 target genes cause demyelinating peripheral 
neuropathy 
Mutations in the human SOX10 gene cause several neurocristopathies and, interestingly, 
different SOX10 mutations correlate strongly with disease severity and expressivity. SOX10 
mutations can cause Waardenburg-Hirschsprung or Waardenburg-Shah disease (WS4) (Pingault 
et al., 1998) or a more severe syndrome called peripheral demyelinating neuropathy, central 
dysmyelinating leukodystophy, Waardenburg, and Hirschsprung disease (PCWH) (Inoue et al., 
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2002). WS4 is a combination of Waardenburg syndrome and Hirschsprung disease; individuals 
with WS4 display pigmentation defects, hearing loss, heterochromia, and aganglionic megacolon 
(Omenn and McKusick, 1979). PCWH is characterized by defects in Schwann cells, 
oligodendrocytes, melanocytes, and enteric neurons (Inoue et al., 2002). The distinct phenotypes 
observed depends on the type of SOX10 mutation. Disease-associated SOX10 mutations that 
result in a premature stop codon early in the transcript undergo nonsense-mediated decay (NMD) 
resulting in haploinsufficiency and causing WS4. Mutations in SOX10 that result in premature 
stop codons later in the transcript escape NMD and result in PCWH. In the latter situation, the 
mutant protein acts in a dominant-negative manner on the remaining wild-type SOX10 protein 
and resulting in a greater than 50% reduction in SOX10 function, thus giving rise to a more 
severe phenotype (Inoue et al., 2004). The peripheral neuropathy phenotype observed in 
individuals with PCWH is similar to Charcot-Marie-Tooth (CMT) disease. CMT, also referred to 
as hereditary motor and sensory neuropathy, has a prevalence of one in 2,500 individuals 
worldwide. It is divided into two major subclasses based on electrophysiological studies: CMT 
type 1 and CMT type 2. (Warner et al., 1999). CMT1 primarily affects the Schwann cells and 
CMT2 affects the axons of the peripheral nerves. Demyelinating CMT can be divided into two 
major forms based on the inheritance pattern: autosomal dominant (CMT1) and autosomal 
recessive (CMT4) (Brennan et al., 2015). 
 
CMT1 is an early onset disorder and patients typically present with symptoms during the first 
two decades of life. Symptoms include foot deformity, distal muscle weakness, sensory loss, and 
muscle atrophy (Saporta et al., 2011). As noted above, the myelin sheath acts as an electrical 
insulator and allows rapid propagation of electrical impulses. The speed at which the electric 
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impulses are conducted along the nerve is called the motor nerve conduction velocity (MNCV). 
The MNCV of patients suffering from CMT1 is <40 meters per second (m/s); normal ranges are 
50-60m/s (Saporta et al., 2011). The most common cause of CMT1 is a 1.4MB duplication on 
chromosome 17p11.2, which accounts for 60-70% of CMT cases (Lupski et al., 1991; Saporta et 
al., 2011). Interestingly, many forms of demyelinating CMT are caused by mutations in SOX10 
target genes that are critical for myelination such as PMP22 (Lupski et al., 1991), MPZ 
(Hayasaka et al., 1993), EGR2/KROX20 (Warner et al., 1998) and GJB1/CX32 (Bergoffen et al., 
1993). Indeed, mutations within regulatory regions at many of these loci have been identified in 
patients with CMT. For example, duplications of distal regulatory elements at PMP22, not 
including the transcriptional unit, are observed in patients with a mild form of CMT (Weterman 
et al., 2010). Similarly, pathogenic variants have been identified in the promoter region of GJB1; 
and functional studies have revealed that the mutations reside within SOX10 binding sites and 
that they reduce SOX10 binding (Kabzińska et al., 2011). Recently, deletion of this promoter has 
been identified in patients with CMT and the deletion segregated with disease (Kulshrestha et al., 
2017).  It has long been noted that patients with CMT disease display severe variability in age of 
onset and disease severity, even among patients with an identical pathogenic variant. This 
phenotypic variability suggests that there are other genetic factors that could modify disease 
severity. Thus, identifying additional SOX10-responsive regulatory sequences will improve our 
understanding of myelination and novel sequences to screen for mutations and modifiers of 
peripheral neuropathy.  
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1.9 Negative regulators of myelination  
Positive and negative signaling pathways in Schwann cells ensure that myelination occurs at the 
correct developmental stage and similar pathways regulate remyelination following peripheral 
nerve injury. One of the notable features of myelinating Schwann cells is their plasticity, that is, 
the ability to dedifferentiate to form immature Schwann cells following injury (Fig 1.2). Damage 
to the peripheral nerve can be due to physical injury or to genetic mutations as observed in 
patients with CMT1. Following nerve injury, peripheral axons degenerate and myelinating 
Schwann cells lose axonal contact leading to demyelination (Jessen and Mirsky, 2008). 
Subsequently, macrophages are activated and recruited to the site of injury and phagocytize 
myelin and axonal debris (Martini et al., 2008). In the event that an axon begins to regenerate, 
Schwann cells reinitiate the myelination program.  
 
Negative regulators of myelination are often highly expressed during early stages of Schwann 
cell development, and then down regulated as myelination occurs. Furthermore, a subset of these 
regulators may be induced after nerve injury to facilitate the dedifferentiation process (Jessen 
and Mirsky, 2008). To date, a number of transcription factors have been characterized as myelin 
inhibitors including c- JUN, SOX2, and EGR1/3 (Jessen and Mirsky, 2008). c-JUN is a 
ubiquitously expressed transcription factor that is a component of the AP-1 complex. c- JUN is 
expressed during early stages of Schwann cell development and blocks myelination by 
repressing EGR2 expression (Parkinson et al., 2008). Additionally, c- JUN expression is induced 
post nerve injury (and in the nerves of patients with CMT1) and mediates the Schwann cell 
dedifferentiation process (Hutton et al., 2011; Klein et al., 2014; Parkinson et al., 2008). 
Recently, genome-wide analyses of gene expression changes were assessed in mature rat 
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peripheral nerves pre- and post-nerve injury. The authors performed ChIP-seq for H3K27ac 
marks using sham and injured rat sciatic nerves, which revealed an enrichment of c-JUN motifs 
in injury-induced enhancers at genes known to be upregulated post injury (Hung et al., 2015). 
Other transcription factors such as NOTCH1, Inhibitor of DNA-binding 2 (ID2) are also known 
to repress myelination (Quintes and Brinkmann, 2017; Woodhoo et al., 2009). Thus, a balance 
between positive and negative regulators is essential for proper myelination during development 
and to facilitate recovery after injury. However, little is known about how these negative 
regulators are activated during development and how the balance between the two opposing 
myelination programs is achieved.   
 
1.10 Summary 
Myelin is a multi-layered sheath formed by glial cells that wrap a membrane around axons in the 
peripheral and central nervous system. This sheath is unique to vertebrates and seems to have co-
evolved with jaws and certain sections of the brain. The myelinating glia of the peripheral and 
central nervous system are Schwann cells and oligodendrocytes, respectively. Myelination is a 
dynamic process orchestrated by transcriptional regulators. One gene that is essential for 
Schwann cells encodes the SRY-related HMG box 10 (SOX10) transcription factor. SOX10 is 
expressed during all stages of Schwann cell development and directs a transcriptional hierarchy 
that promotes PNS myelination. Importantly, mutations in SOX10 and in SOX10 target genes 
result in demyelinating neuropathy. Thus, identifying and characterizing the full panel of SOX10 
target loci will provide novel insights into SOX10 function, Schwann cell biology, and the 
pathogenesis of demyelinating neuropathy. My dissertation focuses on defining regulatory 
pathways important for Schwann cells by identifying SOX10 target genes.  
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In chapter 2, I will discuss the computational pipeline we developed to identify conserved 
SOX10 consensus sequences. I performed in vitro assays to validate a handful of putative 
SOX10 response elements and these data revealed a novel, and rather surprising, role for SOX10 
in Schwann cells. Specifically, that SOX10 activates the expression of negative regulators of 
myelination including SOX5, SOX6, NOTCH1, ID2, ID2, MYCN, and HES5. In chapter 3, I 
provide evidence for SOX10 regulating the expression of SOX6 via an alternative promoter. To 
further study the role of SOX6 in Schwann cells, I performed expression studies to identify direct 
and indirect SOX6 target genes. Finally, in chapter 4, I will discuss the impact of my thesis work 
and present outstanding questions that can be pursued for future investigation. 
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Chapter 2 
Stringent Comparative Sequence Analysis Reveals  
SOX10 as a Putative Inhibitor of Glial Cell Differentiation 
 
2.1 Introduction 
Schwann cells produce the myelin sheath in the peripheral nervous system (PNS), which allows 
rapid saltatory conduction and long-range communication between the central nervous system 
and innervated muscles and sensory organs. Schwann cell development is directed by a 
transcriptional hierarchy that promotes the expression of proteins important for migration along 
peripheral nerves, radial sorting of axons, and the initiation of myelination (Jessen and Mirsky, 
2005; Stolt and Wegner, 2016). Atop this hierarchy sits the transcription factor SOX10, which is 
critical for the development and long-term function of Schwann cells (Kuhlbrodt et al., 1998)and 
is expressed during all stages of Schwann cell development (Britsch et al., 2001; Kuhlbrodt et 
al., 1998). 
 
Three major lines of evidence underscore the importance of SOX10 for the function of Schwann 
cells. First, ablation of Sox10 expression in mouse models causes: (i) a lack of Schwann cells 
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when performed during early development (Britsch et al., 2001); (ii) lethality due to peripheral 
neuropathy when performed in immature Schwann cells (Finzsch et al., 2010); and (iii) 
demyelination of peripheral nerves when performed in terminally differentiated Schwann cells 
(Bremer et al., 2011). Second, dominant-negative SOX10 mutations cause an autosomal 
dominant disease characterized by peripheral demyelinating neuropathy, central dysmyelinating 
leukodystrophy, Waardenburg-Shah syndrome, and Hirschsprung disease (Inoue et al., 1999; 
2004); the non-PNS phenotypes reflect the role of SOX10 in other neural crest derivatives (i.e., 
melanocytes and enteric neurons) and in oligodendrocytes. Finally, mutations in SOX10 target 
genes including those encoding peripheral myelin protein 22 (PMP22), myelin protein zero 
(MPZ), and gap junction beta 1 (GJB1) cause demyelinating peripheral neuropathy (Bondurand 
et al., 2001; Jones et al., 2011; 2007; LeBlanc et al., 2006; Peirano et al., 2000). 
 
The identification of additional SOX10 response elements and target loci will provide important 
information on the process of myelination in the peripheral nerve as well as novel target 
sequences to scrutinize for mutations and modifiers of peripheral neuropathy. Indeed, genome-
wide analyses have been essential for characterizing SOX10 biology in Schwann cells (Lopez-
Anido et al., 2015; Srinivasan et al., 2012); however, these efforts have primarily focused on 
identifying positive regulators of myelination by examining tissues or cells in a myelinating 
state. Thus, less-biased approaches are needed to complement the above studies and to identify 
functions of SOX10 outside of the regulation of promyelinating loci. 
 
In this chapter, I describe a stringent computational strategy to rapidly predict SOX10 response 
elements in the human genome. Combined with molecular functional studies, this strategy 
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revealed that SOX10 positively regulates the expression of SOX5, SOX6, NOTCH1, HMGA2, 
HES1, MYCN, ID4, and ID2. Interestingly, each of these genes has a known or predicted role in 
the negative regulation of glial cell differentiation. As such, we identified a putative novel role 
for SOX10 in Schwann cells and present a model where SOX10 activates the expression of 
negative regulators of myelination to temper the pro-myelinating program during non-
myelinating stages of Schwann cell development. 
 
The author did all of the work presented in this chapter except the computational pipeline, which 
was generated by Drs. Law, Antonellis, and Prasad. The Svaren laboratory at the University of 
Wisconsin performed the qRT-PCR analyses. The DNase hypersensitivity assay was performed 
by Dr. Crawford’s laboratory at Duke University.  
 
2.2 Methods 
2.2.1 Computational identification and prioritization of SOX10 consensus sequences 
To identify all SOX10 consensus sequences in the human genome we downloaded individual 
text files for each human chromosome (hg18) from the UCSC Human Genome Browser (Kent et 
al., 2002) and wrote a Perl script that examines each file for the consensus sequences (using a 
regular expression analysis) ‘ACACA’ or ‘ACAAD’; where ‘D’ is a G, T, or A nucleotide. To 
identify two SOX10 consensus sequence monomers that are oriented in a head-to-head manner 
(and that may represent a dimeric SOX10 binding site) we wrote a second Perl script that 
examines the human chromosome text files and reports each ‘ACACA’ or ‘ACAAD’ consensus 
sequence that is five to 10 base pairs 5’ to the reverse complement of this consensus sequence: 
‘TGTGT’ or ‘HTTGT’, where ‘H’ represents an A, C, or T nucleotide.  
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To identify genomic sequences that are identical between human, mouse, and chicken we 
downloaded the vertebrate (44 species) multiz alignment (maf) files from the UCSC Human 
Genome Browser (hg18) and extracted the alignments for human, mouse, and chicken. Next, we 
utilized the program ExactPlus (Antonellis et al., 2006) to identify all human sequences that are 
at least 5 base pairs long and identical between all three species. All subsequent computational 
analyses that assess for overlap between these and other datasets were performed using the 
UCSC Table Browser (Karolchik et al., 2004) and the ‘intersection’ tool. For these analyses we 
employed UCSC Genome custom tracks containing each: (1) human RefSeq (hg18) protein-
coding sequence to exclude coding sequences; (2) human RefSeq entry (hg18) plus 2.5 kb 
upstream and 2.5 kb downstream of the transcriptional unit to identify regions that map to known 
genes; (3) SOX10 ChIP-seq peak in the rat genome (rn5) using HOMER analysis (Heinz et al., 
2010) of previously described P15 sciatic nerve data sets; and (4) DNase-seq peak in the rat 
genome (rn5) that has an F-Seq (Boyle et al., 2008b) score of at least 0.08. 
 
To identify the 57 loci with a known or predicted role in peripheral nerve myelination we 
performed the following PubMed searches in September 2014: (1) each gene name plus 
‘Schwann’; and (2) each gene name plus ‘Myelin’. We also searched for each gene name plus 
‘Schwannoma’ in the GEO Profiles database at NCBI to determine if gene expression is depleted 
upon treatment with SOX10 siRNA (Lee et al., 2008).  
 
2.2.2 Luciferase reporter gene expression constructs 
Primers containing attB1 and attB2 Gateway cloning (Thermo Fisher Scientific) sequences were 
designed for each region identified by our computational pipeline and were synthesized by IDT. 
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The primers were resuspended using ultrapure water (Thermo Fisher Scientific cat # 10977023) 
to make 200μM stock solutions and diluted 1:10 prior to PCR. Regions were PCR-amplified 
using human or rat genomic DNA and subsequently cloned into pDONR221 using BP clonase 
(Thermo Fisher Scientific cat # 11789020). Protocol used for each BP reaction: 2μL PCR 
amplified product, 0.5μL pDONR221, 1.5μL TE buffer, and 1μL BP clonase. The reaction was 
incubated at room temperature for one hour.  To stop the reaction, 1μL Proteinase K was added 
and the reaction was incubated at 37°C for ten minutes. 3μL of above reaction was mixed with 
12.5μL Top10 One shot E.coli cells (Thermo Fisher Scientific cat # C404003) and incubated on 
ice for 15 minutes. The bacteria were heat shocked at 42°C for 45 seconds and were recovered 
by adding 62.5μL SOC growth media (Thermo Fisher Scientific cat # C404003) and incubating 
at 37°C with shaking. The transformation reaction was plated on 50mg/mL kanamycin selective 
plates. The plates were incubated overnight at 37°C.  Individual colonies were picked and grown 
in 7mL of kanamycin selective media. Plasmid DNA was isolated using the Qiagen miniprep kit 
(Qiagen cat # 27104) and was subjected to BsrG1 (NEB cat # R0575S) digestion to ensure 
presence of the insert. The following protocol was used for BsrG1 reactions: 6.75μL ultrapure 
water, 1μL (150ng) plasmid DNA, 1μL bovine serum albumin (BSA), 1μL NEB buffer 2, and 
0.25μL BsrG1. The reaction was incubated at 37°C for one hour. The reaction products were run 
on a 1% agarose tris-EDTA-borate (TBE) gel to identify pDONR221 plasmids that contained our 
insert. These pDONR221 constructs were sequence verified using Sanger sequencing and cloned 
upstream of an E1B minimal promoter (Antonellis et al., 2006) directing luciferase expression in 
the forward (pE1B Forward) or reverse (pE1B Reverse) orientation using LR clonase (Thermo 
Fisher Scientific cat # 11791100). Mutagenic primers to delete SOX10 consensus sequences 
were designed using an online tool called QuikChange primer design 
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(http://www.genomics.agilent.com/primerDesignProgram.jsp) and were synthesized by IDT. The 
primers were re-constituted to 1250ng/μL and subsequently diluted 1:10 prior to the reaction. 
Site directed mutagenesis performed using the QuikChange II Mutagenesis Kit (QuikChange II 
cat # 200521) using the following protocol: 5μL 10X buffer, 1μL pDONR construct (50ng/μL), 
1μL forward primer, 1μL reverse primer, 1μL dNTPs, 3μL Quik solution, 38μL ultrapure water 
and 1μL Pfu tag polymerase. After amplification, 1μL Dpn1 enzyme was added to the reaction 
and incubated at 37°C for two hours. Following Dpn1 digestion, ethanol precipitation was 
performed using the following protocol: Quikchange reaction, 150μL 100% ethanol, and 5μL 
3M sodium acetate. The reaction was incubated at -80°C for two hours and then centrifuged at 
13200 rpm for 30 minutes at 4°C. After centrifugation, the supernatant was discarded and the 
pellet was dried using vacuum centrifuge for five minutes. The dried pellet was re-suspended in 
15μL ultrapure water and transformed into Top10 one shot E.coli cells as described above.  The 
resulting mutant constructs were sequence verified to ensure that the SOX10 consensus site was 
deleted and that no other mutations were generated. Subsequently, the constructs were 
recombined into the pE1B luciferase vector as described above. 
 
2.2.3 Cell culture and luciferase assays 
Cultured rat Schwann cells (S16)(Goda et al., 1991; Toda et al., 1994) and mouse motor neuron 
derived cells (MN1) (Salazar-Grueso et al., 1991) were maintained in Dulbecco’s modified 
Eagle’s medium (Thermo Fisher Scientific cat # ILT12430054) supplemented with 10% fetal 
bovine serum (Thermo Fisher Scientific cat # 26140-079),  2mM L-glutamine (Thermo Fisher 
Scientific cat # ILT25030081), and 1X Penicillin-Streptomycin (Thermo Fisher Scientific cat # 
ILT15070063). For luciferase assays, 1x104 cells were plated in each well of a 96-well culture 
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plate (Corning Life Sciences cat # 07-200-565) and incubated overnight at 37°C in 5% CO2.  
Cells were transfected using Lipofectamine 2000 (Thermo Fisher Scientific 11668-019). 
Transfections were performed using the following protocol for each well: 25μL Opti-MEM 
(Thermo Fisher Scientific cat # 31985062) was mixed with 0. 25μL Lipofectamine 2000 and this 
mixture was incubated for 10 minutes at room temperature (Mix 1). 200ng of the pE1B construct 
(Antonellis et al., 2006) was mixed with 2ng of pCMV-Renilla in 25μL of Opti-MEM (Mix 2). 
Prior to transfection, pE1B plasmid for each region was diluted to 200ng/μL and pCMV-Renilla 
was diluted to 2ng/μL. After the 10-minute incubation 25μL of Mix 1 was added to Mix 2, 
mixed well, and incubated at room temperature for 20 minutes. The cells were washed with 
60μL 1XPBS and 50μL of transfection mixture was added to each well.  Cells were incubated at 
37°C for 4 hours and then grown in 75μL standard growth media for 48 hours. For 
overexpression studies, 100ng of a construct to express wild-type or E189X SOX10 (Inoue et al., 
2004), wild-type SOX8, SOX9, or EGR2 was included in the transfection reaction. 48 hours after 
transfection the cells were washed with 60μL 1XPBS and subsequently lysed in 20μL of 1X 
passive lysis buffer [4μL of 5X Passive Lysis Buffer (Promega cat # E1980) and 16μL ultrapure 
water]. The plate was shaken for one hour at room temperature. 10μL of the lysate was 
transferred to a 96-well white assay plate (Corning Life Sciences cat # CLS3789) and a Dual 
Luciferase Assay (Promega cat # E1980) was performed using a luminometer to determine the 
activities of luciferase and renilla. Luciferase activity was normalized to renilla activity and the 
fold increase in luciferase activity was calculated relative to the empty control vector (set to 1), 
which does not contain a genomic insert. For each genomic segment, three independently 
isolated reporter gene constructs were studied in eight technical replicates for a total of 24 
reactions per segment.  
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2.2.4 Standard and quantitative RT-PCR 
Total RNA was isolated from S16 and MN1 cells. 1x105 cells were plated in a 6-well plate (USA 
Scientific cat # CC7682-7506) and incubated overnight at 37°C in 5% CO2. Transfections were 
performed using the following protocol for each well: 1mL Opti-MEM (Thermo Fisher Scientific 
cat # 31985062) was mixed with 10μL Lipofectamine 2000 and this mixture was incubated for 
10 minutes at room temperature (Mix 1). 4μg of wild-type or E189X SOX10 (Inoue et al., 2004) 
1mL of Opti-MEM (Mix 2). After the 10-minute incubation 1mL of Mix 1 was added to Mix 2, 
mixed well, and incubated at room temperature for 20 minutes. The cells were washed with 2mL 
1XPBS and 2mL of transfection mixture was added to each well. Mock transfections were 
performed in the absence of DNA. Cells were incubated at 37°C for 4 hours and then grown in 
3mL standard growth media. After 72 hours, total RNA was isolated from the transfected cells 
using the RNeasy kit (Qiagen cat # 74104). Subsequently, cDNA was synthesized using 1μg of 
total RNA and the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific 
4368814). The following protocol was used for cDNA synthesis: 3.2μL ultrapure water, 2μL 
10X random primers, 2μL 10X RT buffer, 0.8μL 25X dNTPs, 1μL RNase inhibitor, 1μL reverse 
transcriptase, and 1μg RNA in 10μL ultrapure water. The cycler conditions are as follows: 25°C 
for 10 minutes, 37°C for two hours, and 85°C for five minutes. For standard RT-PCR was 
performed on isolated cDNA using gene specific primers. A PCR for β-actin served as a positive 
control. All PCR products were subjected to DNA sequencing to confirm specificity. For 
quantitative RT-PCR, RNA was purified from three independent rat sciatic nerves at the P1, P15, 
and adult time points using the RNeasy Lipid kit (Qiagen cat # 74804), and quantitative RT-PCR 
was performed as described (Gokey et al., 2012).  
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2.2.5 siRNA-mediated depletion of SOX10  
Control siRNA (siControl 1, Ambion catalog number AM4611) or Sox10 siRNA (siSox10 1, 
Life Technologies catalog number s131239) were transfected into S16 cells as described using 
the Amaxa Nucleofection system following the manufacturer’s instructions. At 48 hours post-
transfection, RNA was isolated using Tri-Reagent (Ambion) and analyzed by quantitative RT-
PCR as described (Gokey et al., 2012). The Svaren laboratory performed this experiment.   
 
2.2.6 DNase hypersensitivity site identification 
DNase-seq was performed with three biological replicates of rat Schwann (S16) cells at passage 
numbers five, eight, and 14. Each replicate contained ~20 million cells frozen into 1 mL of 
freezing media. Cells were thawed and DNase-seq libraries generated as previously described 
(Song and Crawford, 2010) with the exception of adding a 5’ phosphate to linker 1 to increase 
the ligation efficiency. DNase-seq libraries from three replicates were pooled into one lane of an 
Illumina Hi-Seq 2000. Raw reads were aligned to the rat (rn5) genome using Bowtie (Langmead, 
2010) and unique mapping with up to two mismatches allowed in an alignment. For the three 
samples, 69.2% (36,295,401), 70.8% (43,564,606), and 67.9% (39,579,719) of the reads mapped 
to rn5. Peaks were called using F-Seq and the default settings(Boyle et al., 2008b). For the three 
samples: 502,787 (sample 1), 438,254 (sample 2), and 412,267 (sample 3) peaks were identified. 
149,342 were shared among all three samples. We next used sample 2 as a representative 
experiment and extracted all DNase-seq peaks with an F-Seq score [52] of at least 0.08. This 
revealed a set of 31,845 peaks (7.3%) that were used to prioritize SOX10 response elements (see 
section ‘Computational identification and prioritization of SOX10 consensus sequences’ above). 
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Data from the three samples have been submitted to GEO (GSM2166058, GSM2166059 and 
GSM2166060). The Crawford laboratory performed this experiment.   
 
2.3 Results 
2.3.1 Genome-wide prediction of SOX10-responsive transcriptional regulatory elements 
SOX10 binds to a well-defined consensus sequence (‘ACACA’ or ‘ACAAD’; where ‘D’ is a G, 
T, or A nucleotide) as a monomer or as a dimer when two consensus sequences are oriented in a 
head-to-head fashion (Peirano and Wegner, 2000; Srinivasan et al., 2012). To identify putative 
SOX10 binding sites in the human genome, we wrote a Perl script to scan each human 
chromosome and report all occurrences of the above SOX10 consensus sequence. This revealed 
over 33 million monomeric consensus sequences and ~549,000 dimeric consensus sequences 
with an intervening sequence of five to 10 base pairs. 
 
Multiple-species conservation analysis is an effective approach for predicting non-coding DNA 
sequences with a role in transcriptional regulation (Antonellis and Green, 2008). Importantly, 
functionally validated SOX10 binding sites have been identified in non-coding genomic 
sequences that are conserved between human and chicken (Antonellis et al., 2008; Gokey et al., 
2012; Hodonsky et al., 2012). To prioritize the large dataset of SOX10 consensus sequences, we 
aligned the human, mouse, and chicken genomes and identified all genomic sequences that are 
five base pairs or longer (the length of the monomeric SOX10 consensus sequence) and that are 
identical between these three species.  
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Figure 2.1. Computational pipeline to predict SOX10-responsive genomic regions. (A) Each of 
the 33,453,484 monomeric (depicted as a red box) and 549,081 dimeric SOX10 consensus site 
identified in the human genome (HG18). (B) Multi-species conservation analysis identified 
2,009,829 conserved genomic segments (longer than five base pairs, shown in green) among 
human, mouse, and chicken. (C) Compared data sets generated in (A) and (B) and identified 
110,561 monomeric and 10,112 dimeric SOX10 conserved consensus sequences (SOX10-CCS) 
that are conserved in human, mouse, and chicken. (D) Prioritized dimeric conserved SOX10 sites 
within introns and proximal promoter elements of RefSeq genes. The arrowhead indicates 
annotated transcription start site. 
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This revealed over two million conserved coding and non-coding genomic segments. To develop 
a panel of prioritized SOX10 consensus sequences for functional studies, we used the rationale 
that: (1) focusing on conserved dimeric SOX10 consensus sequences will enrich for bona fide 
SOX10 binding sites; (2) focusing on non-coding sequences will deprioritize sequences that are 
conserved due to the function of the gene product; and (3) focusing on proximal promoter and 
intronic sequences will provide a candidate target gene for further studies. Thus, we compared 
the above datasets to identify dimeric SOX10 consensus sequences that are conserved between 
human, mouse, and chicken (including the intervening sequence), reside in non-coding 
sequences, and map to an intron or 2.5 kb upstream or downstream of a known (RefSeq) human 
gene. This revealed 238 genomic sequences at 160 loci for further study. To determine the 
efficacy of our approach, we further prioritized the above 238 genomic segments by identifying 
the subset that map to loci with a known or predicted role in myelination. This revealed 57 
genomic sequences at 32 loci with a conserved, dimeric SOX10 consensus sequence that resides 
within an intron or directly upstream of a myelin-related transcriptional unit; we named these 
elements SOX10 Conserved Consensus Sequences (Fig. 2.1).  
 
2.3.2 Seven conserved SOX10 consensus sequences display regulatory activity in Schwann 
cells 
Using our computational pipeline, we identified 57 regions that harbor conserved head-to-head 
SOX10 consensus sequences at loci with a known or predicted role in myelination. To test if 
these sequences are active in Schwann cells in vitro, a region surrounding each consensus 
sequence was amplified from human genomic DNA and cloned upstream of a minimal promoter 
directing the expression of a luciferase reporter gene. The regulatory activity of each genomic 
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segment was tested in cultured rat Schwann (S16) cells (Goda et al., 1991; Toda et al., 1994), 
which express endogenous SOX10 (Hodonsky et al., 2012). The luciferase expression directed 
by each genomic segment was determined in luciferase activity assays compared to a control 
vector with no genomic insert (‘Empty’). Seven of the 57 genomic segments demonstrated a 
greater than 2.5-fold increase in luciferase activity compared to the empty vector in S16 cells 
(Fig. 2.2): SOX10-CCS-01 (3.7-fold increase; maps to PAX7), SOX10-CCS-13 (54-fold 
increase; maps to SOX6), SOX10-CCS-18 (82-fold increase; maps to SOX5), SOX10-CCS-19 
(49-fold increase; maps to SOX5), SOX10-CCS-39 (5.9-fold increase; maps to TCF7L2), 
SOX10-CCS-43 (25-fold increase; maps to BCAS3), and SOX10-CCS-51 (2.6-fold increase; 
maps to NFIB). These data suggest that these seven genomic sequences (Table 1) are potential 
SOX10 response elements. 
 
2.3.3 The SOX10 consensus sequence is required for the orientation-independent activity of 
three regulatory elements at SOX5, SOX6, and NFIB 
To determine if the regulatory activity of the seven genomic segments is dependent on the 
orientation of the DNA sequence, we retested the activity of each segment in both the ‘forward’ 
and ‘reverse’ orientation relative to a construct with no genomic insert (‘Empty’) within our 
reporter gene construct in S16 cells. This revealed three genomic segments that enact a greater 
than 2.5-fold increase in luciferase activity in both orientations (Fig. 2.3): SOX10-CCS-13 (72- 
fold forward and 9-fold reverse), SOX10-CCS-19 (70-fold forward and 33-fold reverse), and 
SOX10-CCS-51 (4-fold forward and 9-fold reverse). To assess the specificity of these results to 
Schwann cells, we tested each of the seven genomic segments in both orientations in cultured  
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Figure 2.2. Seven regions demonstrate regulatory activity in Schwann cells. Each of the 57 
genomic segments containing prioritized SOX10 consensus sequences was cloned upstream of a 
luciferase reporter gene and tested for enhancer activity in cultured Schwann (S16) cells. 
Luciferase data are expressed relative to a control vector that does not harbor a genomic insert 
(‘Empty’). Regions that display a greater than 2.5-fold increase (red line) in luciferase activity 
are indicated in red text and by an arrow. Error bars indicate standard deviations. 
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Element ID Locus UCSC Coordinates1 SOX10 Consensus Sequence2 
SOX10-CCS-01 PAX7 chr1:18,854,300-
18,855,055 
ACAAACTCATTAAACTTGT 
SOX10-CCS-13 SOX6 chr11:16,334,301-
16,335,278 
ACAATCAAGCATTGT 
SOX10-CCS-18 SOX5 chr12:24,058,988-
24,059,872 
ACAAAAATGTATTGT 
SOX10-CCS-19 SOX5 chr12:24,059,397-
24,060,164 
ACACAGAACATTATTGT 
SOX10-CCS-39 TCF7
L2 
chr10:114,894,980-
114,895,808 
ACAATCCCCAAGATTTTTGT 
SOX10-CCS-43 BCAS
3 
chr17:56,683,905-
56,684,657 
ACACATTAATAACGTTTTGT 
SOX10-CCS-51 NFIB chr9:14,299,332-
14,299,796 
ACAATCTGTTCTTTGTGT 
 
Table 2.1. Seven genomic segments with regulatory activity in Schwann cells 
1Coordinates refer to the March 2006 UCSC Genome Browser Human assembly (hg18). 
2SOX10 consensus sequences are indicated in bold, underlined text. 
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Figure 2.3. Four genomic segments are active in Schwann cells. (A) The seven active regions 
from Figure 2.2 were tested in forward and reverse orientation in rat Schwann (S16) cells (A) 
and mouse motor neuron cells (B). Luciferase data are expressed relative to a control vector 
without a genomic segment (‘Empty’). Error bars indicate standard deviations and arrows and 
lines indicate genomic segments that are active in both orientations. 
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mouse motor neurons (MN1 cells)(Salazar-Grueso et al., 1991), which do not express 
endogenous SOX10 (Hodonsky et al., 2012). None of the genomic segments enact a greater than 
2.5-fold increase in luciferase activity in both orientations in MN1 cells suggesting that our data 
in S16 cells is Schwann-cell specific; however, three had low levels of activity in only the 
forward orientation in MN1 cells: SOX10-CCS-39 (5.5-fold), SOX10-CCS-43 (6.7-fold), and 
SOX10-CCS-51 (4-fold) (Fig. 2.3). 
 
To test the necessity of the conserved SOX10 consensus sequence for the observed activity 
associated with the seven genomic segments described above, we deleted the dimeric SOX10 site 
along with the intervening sequence in each construct (ΔSOX10) and compared the activity to 
the wild-type genomic segment using the more active orientation. This revealed three genomic 
segments that display at least a 50% reduction in activity upon deleting the SOX10 consensus 
sequence (Fig. 2.4): SOX10-CCS-13, SOX10-CCS-19, and SOX10-CCS-51. Combined, our data 
are consistent with these three genomic segments—at the SOX6, SOX5, and NFIB loci, 
respectively—representing Schwann cell enhancers that harbor functional SOX10 binding sites. 
 
2.3.4 SOX10 is required for the activity of the three regulatory elements at SOX5, SOX6, 
and NFIB  
To test if SOX10 induces the activity of SOX10-CCS-13, SOX10-CCS-19, and SOX10-CCS-51, 
we co-transfected each reporter gene construct with or without a construct to express wild-type 
SOX10 in MN1 cells, which do not express endogenous SOX10 (Hodonsky et al., 2012; Inoue et 
al., 2004). Subsequently, we compared the activity of each construct in the presence or absence 
of SOX10 expression. 
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Figure 2.4. Three genomic regions require the SOX10 consensus sequence for their luciferase 
activity. Luciferase reporter gene constructs containing either the wild-type sequence (WT) or 
the sequence lacking the SOX10 consensus sequence(s) (ΔSOX10) were transfected into S16 
cells and tested in luciferase assays. The luciferase activity associated with each ΔSOX10 
construct is expressed relative to the respective wild-type construct. Error bars indicate standard 
deviations and arrows and lines indicate genomic segments with a required SOX10 consensus 
sequence. P-value calculated using two-tailed student t-test. 
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There was a ~1,000-fold increase in the activity of SOX10-CCS-13 and a ~200-fold increase in 
the activities of SOX10-CCS-19 and SOX10-CCS-51 in the presence of SOX10 (Fig. 2.5). 
SOX8, SOX9, and SOX10 belong to the SOXE family of transcription factors, which bind to 
nearly identical sequence motifs (Stolt and Wegner, 2010).To test if SOX10 specifically 
regulates SOX10-CCS-13, SOX10-CCS-19, and SOX10-CCS-51, we co-transfected each 
reporter construct with or without a construct to express SOX8 or SOX9 in MN1 cells (Fogarty 
et al., 2016; Hodonsky et al., 2012)and compared the effect on regulatory activity with that 
induced by SOX10 . In the presence of SOX8 we observed a ~140-fold, ~75-fold, and ~50 fold 
increase in the activity of SOX10-CCS-13, SOX10-CCS-19, and SOX10-CCS-51, respectively. 
In the presence of SOX9 we observed a ~350-fold, ~150-fold, and ~80-fold increase in the 
activity of SOX10-CCS-13, SOX10-CCS-19, and SOX10-CCS-51, respectively. Importantly, 
SOX8 and SOX9 did not increase the luciferase activity of these regions to the same level as 
SOX10, suggesting that SOX10 has a higher affinity for the sequences within SOX10-CCS-13, 
SOX10-CCS-19, and SOX10-CCS-51 (Fig 2.6).  
 
SOX10 is known to synergistically interact with other transcription factors to enact gene 
expression [OCT6, BRN2, and EGR2 in Schwann cells, OLIG2 and MYRF in oligodendrocytes 
(Emery, 2013), and PAX3 and MITF in melanocytes (Harris et al., 2010)]. Thus, we wanted to 
determine if the well-characterized co-factor in Schwann cells (EGR2) works synergistically to 
activate these elements. EGR2, a master regulator of Schwann cell myelination, is regulated by 
SOX10, OCT6, and BRN2 (Ghislain and Charnay, 2006). SOX10 and EGR2 synergistically 
regulate key myelin genes such as PMP22 (Jones et al., 2011), MPZ (Jones et al., 2007), and 
GJB1 (Bondurand et al., 2001). 
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Figure 2.5. SOX10 is sufficient for the regulatory activities of SOX10-CCS-13, SOX10-CCS-19 
and SOX10-CCS-51. Luciferase reporter gene constructs harboring SOX10-CCS-13, SOX10-
CCS-19 or SOX10-CCS-51 were transfected into mouse motor neurons (MN1) with or without a 
construct to express wild-type SOX10. The luciferase activity associated with each construct in 
the presence of SOX10 is expressed relative to that of the construct in the absence of SOX10. P-
value calculated using two-tailed student t-test. 
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Figure 2.6. SOX8 and SOX9 also increase the regulatory activity of SOX10-CCS-13, SOX10-
CCS-19, and SOX10-CCS-51. Luciferase reporter gene constructs harboring SOX10-CCS-13, 
SOX10-CCS-19, or SOX10-CCS-51 were transfected into mouse motor neurons (MN1) with 
constructs to express SOX8 or SOX9. The luciferase activity associated with each construct in 
the presence of SOX8 or SOX9 is expressed relative to that of the same construct in the absence 
of these transcription factors. Error bars indicate standard deviations. Please note that the SOX10 
data are identical to those in Figure 2.5 and are included to facilitate a comparison. P-value 
calculated using two-tailed student t-test. 
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We co-transfected SOX10-CCS-13, SOX10-CCS-19, and SOX10-CCS-51 reporter constructs 
with a construct to express EGR2 and SOX10 in MN1 cells and compared the effect on 
regulatory activity with that induced by SOX10 alone. In the presence of EGR2 we observed a 
moderate increase in luciferase activity of SOX10-CCS-13 (~2.2-fold), SOX10-CCS-19 (~12-
fold) and SOX10-CCS-51 (~10-fold) (Fig 2.7). However, in the presence of both EGR2 and 
SOX10 we did not see an increase in activity above that induced by SOX10 alone (even though 
an equivalent amount of SOX10 expression vector was transfected in each experiment). These 
data suggest that the three regions are primarily regulated by SOX10 and that EGR2 and SOX10 
do not act synergistically upon them. 
 
To determine if SOX10 is necessary for the activity of SOX10-CCS-13, SOX10-CCS-19, and 
SOX10-CCS-51 in Schwann cells, S16 cells were transfected with each SOX10-CCS luciferase 
reporter gene construct along with a construct to express a dominant-negative mutant form of 
SOX10 (E189X), which interferes with the function of endogenous SOX10 (Inoue et al., 2004). 
Importantly, E189X SOX10 has been shown to specifically reduce the activity of genomic 
elements. While the strategies presented here also are unable to fully capture all SOX10 binding 
sites, the combination of multiple datasets and methodologies generally yields a stronger  
segments harboring SOX10 binding sites in luciferase assays (Brewer et al., 2014). We observed 
a greater than 85% reduction in the activity of all three genomic segments upon co-transfection 
with E189X SOX10 (Fig. 2.8). Combined, our data indicate that SOX10 is required for the in 
vitro enhancer activity of SOX10-CCS-13, SOX10-CCS-19, and SOX10-CCS-51. 
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Figure 2.7. EGR2 does not act synergistically with SOX10 to activate SOX10-CCS-13,    
SOX10-CCS-19, or SOX10-CCS-51 in vitro. Luciferase reporter gene constructs harboring 
SOX10-CCS-13, SOX10-CCS-19, or SOX10-CCS-51 were transfected into mouse motor 
neurons (MN1) with constructs to express EGR2 and/or SOX10. The luciferase activity      
associated with each construct in the presence of the transcription factor(s) is expressed relative 
to that of the untreated reporter construct. Error bars indicate standard deviations. Please note 
that the SOX10 data are identical to those in Figure 2.5 and are included to facilitate a 
comparison. P-value calculated using two-tailed student t-test 
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2.3.5 SOX10 regulates the expression of genes that inhibit myelination 
Our stringent computational and functional analyses rapidly identified a previously unreported 
SOX10-responsive promoter at the SOX6 locus. Importantly, this finding was facilitated by the 
knowledge of a well-defined SOX10 consensus sequence and reports that SOX10 binding sites  
can be conserved among vertebrate species including human and chicken (Antonellis et al., 
2008; Gokey et al., 2012; Hodonsky et al., 2012). To determine if our conservation analysis 
combined with whole genome datasets can reveal a set of high-confidence SOX10 response 
elements for further study we: (1) utilized available SOX10 ChIP-seq data generated from rat 
Schwann cell nuclei in vivo (Srinivasan et al., 2012); (2) performed DNase-seq on cultured rat 
Schwann (S16) cell nuclei; and (3) identified 67,482 non-coding SOX10 monomeric consensus 
sequences conserved between human, mouse, and chicken (data not shown), and converted them 
to the rat genome [rn5; 61,133 (90.5%) were successfully converted]. Intersecting these three 
data sets revealed 214 rat genomic segments that harbor conserved SOX10 consensus sequences 
and that map to SOX10 ChIP-seq and DNase-seq peaks (these genomic segments were 
computationally extracted as SOX10 ChIP-seq peaks). To determine if this approach identified 
specific biological pathways, we extracted the name of the rat RefSeq gene closest to each 
region—the 214 genomic segments map to 191 known genes —and performed a gene ontology 
search using the overrepresentation test for biological processes (geneontology.org). This 
analysis revealed 183 biological processes with a p-value less than 0.05 and 37 biological 
processes that showed a greater than five-fold enrichment compared to the human genome. Ten 
of the identified biological processes directly relate to myelinating glia, which all resided in the 
top 14 enriched terms (Table 2.2). 
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Figure 2.8. SOX10 is necessary for the luciferase activity of the three genomic regions.          
Luciferase reporter gene constructs harboring SOX10-CCS-13, SOX10-CCS-19 or               
SOX10-CCS-51 were transfected into rat Schwann (S16) cells with or without a construct to 
express dominant-negative (E189X) SOX10. The luciferase activity associated with each      
construct in the presence of E189X SOX10 is expressed relative to that of the construct in the 
absence of E189X SOX10. Error bars indicate standard deviations in both panels. P-value 
calculated using two-tailed student t-test. 
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Therefore, this combined strategy provided a highly confident set of 214 SOX10-response 
elements at 191 loci for future functional studies aimed at better understanding the biological 
process of myelination. 
 
Interestingly, three of the 10 gene ontology biological processes that relate to myelination 
specifically relate to negative regulation of gliogenesis, which was due to the presence of six 
genes: NOTCH1, HMGA2, HES1, MYCN, ID4, and ID2 (Table 2). Computational analyses 
revealed eight SOX10 consensus sequences within DNase-seq and SOX10 ChIP-seq peaks at 
these six loci (Table 2.3). To determine if NOTCH1, HMGA2, HES1, MYCN, ID4, and ID2 
harbor bona fide SOX10 response elements, we amplified genomic regions surrounding the 
SOX10 consensus sequences using rat genomic DNA and cloned each genomic segment (in both 
the ‘forward’ and ‘reverse’ orientation) upstream of a minimal promoter directing luciferase 
expression. The regulatory activity of each genomic segment was tested in S16 cells as described 
above. This revealed five genomic segments (‘regions’ or ‘R’) that directed reporter gene activity 
at least 2.5-fold higher than the empty control vector in both orientations: Notch1-R1 (4.7-fold 
forward and 56-fold reverse), Hmga2-R2 (93.7-fold forward and 87-fold reverse), Hes1-R1 (22- 
fold forward and 7.6-fold reverse), Mycn-R1 (28-fold forward and 16-fold reverse) and Id2-R1 
(8.9-fold forward and 4.1-fold reverse) (Fig. 2.9A). Regions Notch1-R2 (7.6-fold) and Id4-R1 
(8.6-fold) directed reporter gene activity at least 2.5-fold higher than the empty control vector 
only in the forward orientation (Fig. 2.9A).   
 
 
 
64	  	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2. Gene Ontology annotations for loci. Number in columns labeled Human, Our list, 
Expected refer to number of genes in the human genome associated with the GO term, number of 
genes from our list associated with the GO term, and number of genes expected by chance. The 
gene name in the column labeled ‘Loci ‘are those from our list 
 
 
 
 
 
 
 
 
 
GO biological process  
Homo 
Sapiens 
Our 
List Expected P-value 
Negative regulation of 
oligodendrocyte differentiation 12 4 0.1 2.74E-02 
Negative regulation of glial cell 
differentiation 25 6 0.21 6.34E-04 
Regulation of astrocyte 
differentiation 25 6 0.21 6.34E-04 
Regulation of oligodendrocyte 
differentiation 28 5 0.23 3.29E-02 
Negative regulation of 
gliogenesis 34 6 0.28 3.77E-03 
Oligodendrocyte differentiation 60 10 0.5 9.43E-07 
Regulation of gliogenesis 74 10 0.61 6.96E-06 
Regulation of glial cell 
differentiation 54 7 0.45 3.23E-03 
Glial cell differentiation 135 13 1.12 1.22E-06 
Gliogenesis 168 13 1.39 1.66E-05 
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Hmga2-R1 was not active in either orientation and was excluded from further analysis. Thus, we 
identified seven genomic sequences at six loci (NOTCH1, HMGA2, HES1, MYCN, ID4, and ID2) 
that display regulatory activity in Schwann cells.  To determine if the identified SOX10 
consensus sequences (Table 3) are important for the regulatory activity of the seven active 
regions described above (Fig. 2.9A) we deleted the SOX10 consensus sequence from each 
construct (termed ‘ΔSOX10’ in Fig. 2.9B) and compared the activity to the wild-type construct 
using the more active orientation. Notch1-R1, Notch1-R2, Hmga2-R2, Hes1-R1, and Id2-R1 
contain dimeric SOX10 consensus sequences, which were deleted along with the intervening 
sequence. Mycn-R1 contains a monomeric consensus sequence (ΔSOX10-1) and a dimeric 
consensus sequence (ΔSOX10-2), which were independently deleted. Id4-R1 contains a dimeric 
consensus sequence with a 20 base-pair intervening sequence. Since this intervening sequence is 
longer than those previously observed for validated dimeric SOX10 binding sites (Antonellis et 
al., 2008; Brewer et al., 2014; Gokey et al., 2012; Hodonsky et al., 2012; Jones et al., 2012; 
Peirano and Wegner, 2000) we studied each monomer independently. Specifically, we deleted 
the dimeric consensus sequence along with intervening sequence (ΔSOX10-1), the first 
monomer only (ΔSOX10-2), and the second monomer only (ΔSOX10-3). Deleting the SOX10 
consensus sequences in regions Notch1-R1, Hmga2-R2, Mycn-R1 (ΔSOX10-2), Id4-R1 
(ΔSOX10-1 and ΔSOX10-3), and Id2-R1 reduced luciferase activity in S16 cells by at least 50% 
(Fig. 2.9B), indicating that the SOX10 consensus sequences in these five regions are important 
for their regulatory activity. In contrast, deleting the SOX10 consensus sequences in Notch1-R2 
and Hes1-R1 did not reduce the enhancer activity associated with these genomic segments (Fig. 
2.9B). We have shown that SOX10 directly regulates SOX6 in Schwann cells (see above). 
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Figure 2.9 SOX10 activates the expression of inhibitors of glial cell differentiation.(A) Eight 
genomics segments at the rat Notch1, Hmga2, Hes1, Mycn, Id4, and Id2 loci were cloned 
upstream of a luciferase reporter gene in both the forward and reverse orientations and tested for 
luciferase activity in rat Schwann (S16) cells. Luciferase data are expressed relative to a control 
vector with no genomic insert (‘Empty’). Error bars represent standard deviations. (B) The 
conserved SOX10 consensus sequence(s) were deleted in each of the seven regions that were 
active in Fig. 6A (see text for details). Luciferase reporter gene constructs containing the wild-
type sequence (WT) or the sequence lacking the SOX10 consensus sequence(s) (ΔSOX10) were 
transfected into S16 cells and luciferase assays performed. Luciferase activities are expressed 
relative to the wild-type expression constructs and error bars represent standard deviations. 
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Table 2.3. Eight genomic segments within loci that inhibit glial cell differentiation 
1Coordinates refer to the March 2012 UCSC Genome Browser Rat assembly (rn5). 
2SOX10 consensus sequences are indicated in bold, underlined text. 
 
 
 
 
 
 
 
 
 
Element ID UCSC Coordinates1 SOX10 Consensus Sequence2 
Notch1-R1 chr3:9,307,836-9,308,296 ACAATGGGGCCTCTGT 
Notch1-R2 chr3:9,308,175-9,309,096 ACAATCGGCTTTGT 
Hmga2-R1 chr7:65,390,088-65,391,287 CTTAGACACAGCACTT 
Hmga2-R2 chr7:65,427,912-65,428,606 ACACAGGCCCCTCTTTGT 
Hes1-R1 chr11:77,415,315-
77,415,779 
TGTGTGAGCGCCATGTGT 
Mycn-R1 chr6:51,229,947-51,230,533 ACAATGGCCTCTTTCTACAGACAAT 
Id4-R1 chr17:18,701,460-
18,702,118 
ACAAAAACAGCAGTAAATGGAGGCCT
TTGT 
Id2-R1 chr6:53,090,794-53,091,254 ACAAGAAACACATTGT 
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To determine if SOX10 positively regulates the expression of Notch1, Hmga2, Hes1, Mycn, Id4, 
Id2, and Sox5 in cultured rat Schwann (S16) cells we again utilized the Sox10 siRNA that has 
been shown to efficiently down-regulate Sox10 expression(Gokey et al., 2012; Lopez-Anido et 
al., 2015). After isolation of mRNA at 24 hours post-transfection, qRT-PCR shows that Sox10 
depletion in S16 cells results in the reduced expression of all of the above genes except for 
Hmga2 (Fig. 2.10A). To directly test if NOTCH1, HMGA2, HES1, MYCN, ID4, ID2, SOX5, and 
SOX6 are developmentally regulated during myelination in vivo we examined mRNA levels at 
three timepoints in rat sciatic nerve (n=3 at each timepoint). P1 corresponds to the onset of  
myelination, P15 is a peak timepoint of myelination in the PNS, and adult sciatic nerve is a 
timepoint where active myelination has subsided. Interestingly, the expression of all seven genes 
tested (Notch1, Hmga2, Hes1, Mycn, Id4, Id2, Sox5, and Sox6) are highest at P1 and then 
repressed at P15 and adult, consistent with a role in repressing precocious myelination (Fig. 
2.10B). 
 
2.4 Discussion 
Previous efforts have identified SOX10 binding sites and target genes in Schwann cells (Lopez-
Anido et al., 2015; Srinivasan et al., 2012). These efforts, and others (Lee et al., 2008), have 
utilized a variety of experimental methodologies to identify putative SOX10 regulatory elements 
across diverse SOX10-positive tissues. While each approach uncovered novel SOX10 response 
elements, no single method has been successful in the identification of all SOX10 response 
elements. 
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Figure 2.10. Inhibitors of glial cell differentiation are developmentally regulated (A) Rat 
Schwann (S16) cells were treated with a control siRNA or a siRNA targeted against Sox10. 
Quantitative RT-PCR was used to measure expression levels of each indicated gene. Asterisks 
indicate a p-value smaller than 0.001 and error bars indicate standard deviations. (B) RNA was 
purified from three independent rat sciatic nerves at the P1, P15, and adult timepoints. 
Quantitative RT-PCR was used to measure expression levels of each indicated gene with values 
expressed relative to expression levels at P1. Asterisks indicate a p-value smaller than 0.005 and 
error bars indicate standard deviations. 
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While the strategies presented here also are unable to fully capture all SOX10 binding sites, the 
combination of multiple datasets and methodologies generally yields a stronger  
predictive power for identifying regulatory regions compared to any one individual method 
(Kwasnieski et al., 2014). Indeed, when we combined our DNase-seq data with previously 
generated SOX10 ChIP-seq data (Srinivasan et al., 2012), we were able to quickly prioritize and 
validate novel SOX10 response elements near genes with a known role in myelination. While 
previous efforts to identify SOX10 response elements focused on the required function of 
SOX10 in cultured cells or tissues at specific developmental stages, our computational approach 
utilizes sequence conservation to identify putative SOX10 regulatory regions throughout the 
genome in a tissue-independent manner. The combination of our less-biased (albeit less 
biologically relevant) computational approach with DNase-seq and ChIP-seq 
is likely the reason that we were able to identify specific repressors of myelination as putative 
SOX10 target genes (e.g., these would not have been identified in myelinating Schwann cells). 
As such, we feel that the datasets generated here will be useful to investigators studying 
comparative genomics, SOX protein function, and Schwann cell biology. First, the conserved 
sequences we identified could be used to similarly prioritize consensus sequences for other 
transcription factors important for vertebrate development. Second, the SOX10 consensus 
sequences we identified could be used to prioritize putative binding sites in other SOX10-
positive cells including oligodendrocytes, melanocytes, and developing enteric nervous system 
neurons (Kelsh, 2006). Finally, our DNase-seq data from rat Schwann (S16) cells will be useful 
for anyone studying transcriptional regulatory elements, highly expressed genes, or any other 
nuclear structure characterized by open chromatin in myelinating Schwann cells; S16 cells 
express many myelin-related genes (e.g., PMP22, MPZ, MBP, and MAG) and transcription 
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factors (e.g., SOX10 and EGR2) and are biochemically similar to myelinating Schwann cells 
(Hai et al., 2002). The analyses performed here may also provide insight into the nucleotide 
requirements for a SOX10 response element. We functionally evaluated a total of 62 conserved, 
genomic segments that harbor a predicted dimeric SOX10 binding site. Interestingly, simply 
cloning a highly conserved dimeric SOX10 consensus sequence upstream of a minimal promoter 
was not enough to enact regulatory activity in cultured Schwann cells as evidenced by the 50 
genomic segments with no (or very low) regulatory activity in Figure 2.1. While there are many 
possible explanations for this finding, one is that there are nucleotide-specific requirements for 
the intervening sequences (i.e., the nucleotides between the head-to-head monomeric sites). To 
assess this, we compared the length and GC content of all 62 dimeric sites to those dimeric sites 
that were both active and required for the observed regulatory activity (n=7). While there was no 
significant difference in the average intervening sequence length between the two groups, the 
seven active sites all had intervening sequence lengths between five and eight nucleotides 
consistent with previous reports that six basepairs provides the ideal spacing between monomers 
(Peirano and Wegner, 2000). Interestingly, there was a marked difference in the GC content 
when comparing the total population of intervening sequences (GC content = 35%) to the 
intervening sequences in the active dimeric sites (GC content = 61%). These data are consistent 
with the high GC content of the intervening sequences within previously validated dimeric 
SOX10 binding sites(Antonellis et al., 2008; Brewer et al., 2014; Gokey et al., 2012; Hodonsky 
et al., 2012; Peirano et al., 2000) and with a ‘G’ nucleotide being the most commonly observed 
nucleotide after the core motif (Srinivasan et al., 2012). Thus, future predictions of dimeric 
SOX10 binding sites should allow for high GC content and five to eight basepairs between the 
head-to-head consensus sequences. 
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Our efforts predicted eight putative SOX10 target loci with a known role in repressing glial cell 
differentiation: NOTCH1, HMGA2, HES1, MYCN, ID2, ID4, SOX5, and SOX6. These findings 
were unexpected due to the known role of SOX10 in regulating the expression of genes that 
encode myelin proteins (e.g., MBP, MPZ, and PMP22)(Jones et al., 2011; 2012; LeBlanc et al., 
2006; Li et al., 2007; Peirano et al., 2000; Wei and Miskimins, 2004). We showed that all eight 
loci are developmentally regulated during myelination in vivo in a manner consistent with a role 
in inhibiting glial cell differentiation. We were also able to functionally validate a SOX10 
binding site at seven of the eight loci. We identified a SOX10 ChIP-seq peak at HES1 and 
luciferase assays demonstrated that this genomic segment has strong enhancer activity (Fig. 
2.9A). However, deletion of the predicted SOX10 binding sites in Hes1-R1 (Table 3) did not 
reduce luciferase activity. Further mutagenesis of this genomic segment will be required to 
identify sequences necessary for the observed activity, which may reveal a degenerate SOX10 
consensus sequence. When we depleted SOX10 activity in Schwann cells in vitro and in vivo 
seven of the eight loci were down-regulated; while HMGA2 harbors a validated SOX10 response 
element (Fig. 2.10A), depletion of SOX10 activity did not reduce Hmga2 expression. Further 
analysis will be required to determine if the SOX10 response element at Hmga2 regulates an 
adjacent locus or if depletion of SOX10 at specific developmental timepoints results in reduced 
Hmga2 expression. Consistent with our findings, previous global analyses of SOX10 function 
revealed that two of the above eight loci are downstream of SOX10: Id2 and Notch1(Srinivasan 
et al., 2012); our analysis now localizes at least some of the SOX10-dependent enhancers 
responsible for the regulation of these two loci. 
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SOX5 and SOX6 are members of the SOXD family of transcription factors and act as negative 
regulators of myelination in the central nervous system (Stolt et al., 2006); these proteins, which 
do not have transactivation or transrepression domains (Lefebvre, 2010), inhibit the expression 
of SOX10 target genes (e.g., MBP) in oligodendrocytes by competing with SOX10 for DNA 
binding at sites within cis-acting regulatory elements. To allow oligodendrocyte differentiation 
and myelin production, SOX6 mRNA is targeted for degradation by two microRNAs (miR) in 
these cells: miR-219 and miR-338 (Zhao et al., 2010). It was recently reported that SOX13 (the 
third and final member of the SOXD subgroup) also has an antagonistic effect on the ability of 
SOX10 to activate the expression of myelin genes in the central nervous system (Baroti et al., 
2015). Indeed, SOX13 is among the group of 191 loci at which we identified a highly confident 
SOX10 binding site: a single, conserved genomic segment within SOX10 ChIP-seq and DNase-
seq peaks ~62 kb upstream of Sox13 (rn5 coordinates chr13:55425486-55425636) was identified. 
Interestingly, a relationship between SOXD and SOXE (SOX8, SOX9, and SOX10) transcription 
factors has been proposed since ablation of SOX8 or SOX9 (but not SOX10) reduces Sox6, but 
not Sox5, expression in the developing spinal cord (Stolt et al., 2006).  
 
In addition to genes encoding SOXD proteins, our studies predict that NOTCH1, HES1, MYCN, 
ID2, and ID4 are SOX10 target genes. NOTCH1 is a transmembrane receptor that regulates 
Schwann cell proliferation and inhibits Schwann cell differentiation in perinatal nerves, and 
facilitates dedifferentiation of Schwann cells after nerve injury (Woodhoo et al., 2009). HES1 is 
an effector of NOTCH signaling, acts as a transcriptional repressor (Jarriault et al., 1995; Sasai et 
al., 1992), and is highly expressed during early stages of Schwann cell development (Woodhoo 
et al., 2009). In cultured mouse oligodendrocytes, HES1 maintains cells in an immature state and 
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overexpression of HES1 results in reduced expression of myelin related genes (Mbp and Plp) 
(Ogata et al., 2011). MYCN is a proto-oncogene and is known to inhibit astrocyte differentiation 
from neural precursor cells (Sanosaka et al., 2008); however, the role of MYCN during Schwann 
cell myelination has not been studied. Inhibitors of differentiation 2 and 4 (ID2 and ID4) are 
known to inhibit oligodendrocyte differentiation and the lack of both proteins results in 
premature oligodendrocyte differentiation (Kondo and Raff, 2000; Marin-Husstege et al., 2006; 
Wang et al., 2001). Furthermore, Id2 and Id4 expression declines in Schwann cell development 
and ID2 limits induction of myelin protein zero expression in primary Schwann cells(Mager et 
al., 2008; Stewart et al., 1997). Consistent with our findings, RNA-seq of oligodendrocytes 
isolated at various stages of mouse brain development (Zhang et al., 2014) show that Sox5, Sox6, 
Notch1, Hes1, Mycn, Id2, and Id4 are developmentally regulated in the central nervous system—
Hmga2 does not appear to be expressed in the cells assessed in that study. Therefore, these genes 
likely play a role in preventing premature glial cell differentiation in both the central and 
peripheral nervous systems. 
 
Combined with previous findings, our data predict a model (Figure 2.11) where SOX10 activates 
the expression of genes that inhibit Schwann cell differentiation, possibly during early stages of 
Schwann cell development, thus preventing the precocious expression of myelin proteins. 
Subsequently, EGR2, NAB, and microRNAs are known to inhibit the expression of the negative 
regulators of myelination (e.g., SOXD proteins), which would allow the expression of myelin 
proteins. In addition to the data presented in this study, previous reports support specific aspects 
of this model. For example, EGR2 likely represses the expression of many of the eight loci 
reported here. EGR2 and NAB repress ID2 and ID4 before myelination via NAB binding to 
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CHD4 (Mager et al., 2008) [conditional ablation of CHD4 in Schwann cells causes increased 
expression of immature Schwann cell genes including ID2 and delayed myelination, radial 
sorting defects, hypomyelination, and the persistence of promyelinating Schwann cells in 
conditional knockout mice (Hung et al., 2012)]. Furthermore, a comparison of SOX10 and EGR2 
binding with expression profiles in Schwann cells treated with siRNA for SOX10 and EGR2-
deficent peripheral nerves (Srinivasan et al., 2012) revealed that NOTCH1 and ID2 are SOX10-
activated and EGR2-repressed, and ID2, HMGA2, SOX5, and ID4 remain high in peripheral 
nerves from Egr2- or Nab-deficient mice(Le et al., 2005; Mager et al., 2008). Finally, SOX10 
directly regulates the expression of EGR2 (Ghislain and Charnay, 2006) and miR-338 (Gokey et 
al., 2012). In sum, our findings suggest that SOX10 has a role in maintaining a premyelinating 
state during non-myelinating stages of Schwann cell development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
76	  	  
 
Figure 2.11. A model for the role of SOX10 in maintaining a pre-myelinating state. Previous to 
myelination (anti-myelination; left side), SOX10 activates the expression of negative regulators 
of myelination, which inhibit the expression of myelin genes such as MBP and MPZ. During 
activation of the myelination program (pro-myelination; right side), EGR2 and micro RNAs 
(miRs) inhibit the expression of negative regulators of myelination, which allows SOX10 (and 
EGR2) to positively regulate the expression of myelin genes. 
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Chapter 3 
Exploring the Role of SOX6 in Peripheral Nerve 
Myelination  
3.1 Introduction 
The myelin sheath accelerates the propagation of electric impulses along the nerves of both the 
peripheral and central nervous systems. In the peripheral nervous system (PNS), this function is 
mediated by Schwann cells, which wrap their membranes around axonal segments to form 
compact myelin. Schwann cells originate from the neural crest cells, which are a multipotent, 
transient cell population that differentiate into various cell types including melanocytes, sensory 
neurons, enteric nervous system ganglia. Migratory neural crest cells associate with individual 
axons and differentiate into Schwann cell precursors. Schwann cell precursors differentiate into 
an intermediate immature state before transitioning into myelinating and non-myelinating 
Schwann cells. Schwann cells are remarkably plastic and can demyelinate and dedifferentiate 
after nerve trauma (Jessen and Mirsky, 2005).  
 
Precise control of the transcriptional programs important for Schwann cell development ensures 
the correct timing of myelination in the peripheral nerve. Dysregulation of these pathways can 
78	  	  
lead to hypomyelination or hypermyelination and are known to be associated with pathology of 
demyelinating diseases (Noseda et al., 2013; Svaren and Meijer, 2008; Triolo et al., 2006). 
SOX10, a transcription factor critical for every stage of Schwann cell development, is known to 
direct the expression of positive regulators of myelination, including OCT6, EGR2/KROX20, 
MBP, MPZ (Britsch et al., 2001; Kuhlbrodt et al., 1998; Svaren and Meijer, 2008).  Conditional 
deletion of Sox10 in mice at any stage of Schwann cell development causes severe demyelination 
(Bremer et al., 2011; Britsch et al., 2001; Finzsch et al., 2010). Published data on SOX10’s role 
in Schwann cells present a paradoxical observation that SOX10 is expressed throughout the 
Schwann cell lineage but that pro-myelinating SOX10 target genes are not expressed during 
early periods of development. Negative regulators of myelination inhibit the expression of key 
myelin genes during the early stages of Schwann cell development and direct the 
dedifferentiation program following nerve injury. The transcriptional regulation of negative 
regulators of myelination is less understood and the mechanisms by which they suppress 
myelination are not well defined.  Interestingly, the data presented in chapter 2 provides evidence 
for a previously underappreciated role for SOX10 in activating the expression of myelin 
inhibitors such as SOX5, SOX6, NOTCH1, HMGA2, HES1, MYCN, ID4, and ID2 (Gopinath et 
al., 2016).  On further examining the SOX10 responsive enhancers at each of these loci we found 
that SOX10-CCS-13 within the SOX6 locus is directly upstream of a non-coding exon and we 
hypothesized that the SOX10-responsive intronic enhancer may be acting as an alternative 
promoter. To address this, I focused on characterizing the intronic SOX10 response element at 
SOX6 and on defining the role of SOX6 in Schwann cells.  In oligodendrocytes, SOX6 has been 
reported to compete with SOX10 for binding at MBP thereby inhibiting premature myelination 
in the central nervous system (Stolt et al., 2006). Specifically, in Sox6 null mice Mbp was 
79	  	  
prematurely expressed causing precocious myelination (Stolt et al., 2006). The function of SOX6 
has not yet been characterized in Schwann cells and, to date, MBP is the only known target of 
SOX6; however, only in vitro studies have been performed to show that SOX6 directly represses 
MBP expression. Identifying additional SOX6 target genes will give us novel insights into the 
regulatory pathways that control peripheral nerve myelination.  
 
In this chapter, I provide evidence that the intronic SOX10 response element at SOX6 (SOX10-
CCS-13) resides directly upstream of a previously unreported, promoter region. To understand 
the role of SOX6 in Schwann cells we performed RNA sequencing analysis after overexpressing 
GFP-tagged SOX6 in an in vitro cell culture model of myelinating Schwann cells. 
Comprehensive analysis of differentially expressed genes revealed a putative role for SOX6 in 
regulating Schwann cell proliferation during development and Schwann cell dedifferentiation 
after peripheral nerve injury. 
 
The author performed all the experiments presented in this chapter except the Svaren laboratory 
performed the quantitative RT-PCR. For the RNA-seq experiment, flow cytometry was 
performed at the University of Michigan Flow Cytometry core. cDNA library preparation and 
sequencing was performed by the University of Michigan Sequencing core.   
  
3.2 Methods 
3.2.1 Standard and quantitative RT-PCR 
1x105 cells were plated in a 6-well plate (USA Scientific cat # CC7682-7506) and incubated 
overnight at 37°C in 5% CO2. Transfections were performed using the following protocol for 
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each well: 1mL Opti-MEM (Thermo Fisher Scientific cat # 31985062) was mixed with 10μL 
Lipofectamine 2000 and this mixture was incubated for 10 minutes at room temperature (Mix 1). 
4μg of wild-type or E189X SOX10 (Inoue et al., 2004) 1mL of Opti-MEM (Mix 2). After the 10-
minute incubation 1mL of Mix 1 was added to Mix 2, mixed well, and incubated at room 
temperature for 20 minutes. The cells were washed with 2mL 1XPBS and 2mL of transfection 
mixture was added to each well. Mock transfections were performed in the absence of DNA. 
Cells were incubated at 37°C for 4 hours and then grown in 3mL standard growth media. After 
72 hours, total RNA was isolated from the transfected cells using the RNeasy kit (Qiagen cat # 
74104). Subsequently, cDNA was synthesized using 1μg of total RNA and the High Capacity 
cDNA Reverse Transcription Kit (Thermo Fisher Scientific 4368814). The following protocol 
was used for cDNA synthesis: 3.2μL ultrapure water, 2μL 10X random primers, 2μL 10X RT 
buffer, 0.8μL 25X dNTPs, 1μL RNase inhibitor, 1μL reverse transcriptase, and 1μg RNA in 
10μL ultrapure water. The cycler conditions are as follows: 25°C for 10 minutes, 37°C for two 
hours, and 85°C for five minutes. For standard RT-PCR was performed on isolated cDNA using 
gene specific primers. A PCR for β-actin served as a positive control. All PCR products were 
subjected to DNA sequencing to confirm specificity. The Svaren laboratory at the University of 
Wisconsin, Madison, performed the qRT-PCR assay.  
 
3.2.2 5’ Rapid amplification of cDNA ends (RACE) 
5’RACE (Thermo Fischer Scientific cat # 18374058) was performed using the manufacturer’s 
protocol.  First strand cDNA libraries were synthesized using total RNA isolated from S16 cells 
and a primer designed within exon 5 (GSP1) of Sox6. To generate gene-specific cDNA library 
the following protocol was used: 1.25μL rnSOX6 GSP1 (2 μM), 6.3μL (~5 μg) S16 RNA, and 
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7.95μL ultrapure water were added and the reaction was incubated at 70°C for 10 minutes, 
chilled on ice for one minute, briefly centrifuged, and the following components were added (in 
order): 2.5μL 10X PCR buffer, 2.5μL 25mM MgCl2, 1μL 10mM dNTP mix, and 2.5μL 0.1 M 
DTT. The reaction was gently mixed, centrifuged, incubated for one minute at 42°C, and 1μL of 
SuperScript II RT was added. The reaction was then incubated for 50 minutes at 42°C, and 
terminated by incubating at 70°C for 15 minutes. The mixture was briefly centrifuged and placed 
at 37°C for 30 minutes. The cDNA was then purified using S.N.A.P. column purification. First, 
120μL of binding solution (6M NaI) was added to the cDNA mixture (see above). Next, the 
entire mixture was transferred to a S.N.A.P. column, centrifuged at 13,000g for 20 seconds, and 
the flow through was saved until the recovery of the cDNA was ensured. The cDNA was washed 
by adding 0.4 mL of 1X wash buffer to the column, centrifuged at 13,000g for 20 seconds, and 
the flow through was discarded. The wash step was repeated three additional times. After 
washing, 400μL of 70% ethanol was added, centrifuged at 13,000g for 20 seconds, and the flow 
through was discarded. The ethanol wash step was repeated one additional time (two ethanol 
washes in total). Finally, the column was transferred to a clean recovery tube, 50μL of 65°C 
ultrapure water was added, and the column was centrifuged at 13,000g for 20 seconds. The 
cDNA was TdT-tailed by adding 6.5μL ultrapure water, 5μL 5X tailing buffer, 2.5μL 2mM 
dCTP, and 10μL S.N.A.P.-purified cDNA. No additional quantification was performed on the 
S.N.A.P.-purified cDNA prior to the TdT-tailing reaction. The reaction was incubated for three 
minutes at 94°C, chilled on ice for one minute, and briefly centrifuged. Next, 1μL TDT was 
added, gently mixed, and incubated at 37°C for 10 minutes. The reaction was incubated at 65°C 
for 10 minutes. 
 
82	  	  
Two nested PCRs were performed using a reverse primer designed within exon 4 (GSP2) of 
Sox6: 31.5μL ultrapure water, 5μL 10X PCR buffer, 3μL 25mM MgCl2, 1μL 10mM dNTPmix, 
2μL 10μM rnSOX6 GSP2, 2μL Abridged anchor primer, 5μL dC-tailed cDNA, and 0.5μL Taq 
polymerase (NEB Cat no. M0273S). A second nested PCR was performed using a reverse primer 
designed within exon 3 (GSP3) of Sox6: 33.5μL ultrapure water, 5μL 10X PCR buffer, 3μL 
25mM MgCl2, 1μL 10mM dNTP mix, 1μL 10μM rnSOX6 GSP3, 1μL 10μM AUAP primer, 
5μL of PCR product from first nested reaction, and 0.5μL Taq polymerase (NEB cat # M0273S). 
The nested PCR products were separated on a 1% agarose gel, the bands of the right sizes were 
gel excised, and purified using the QIAquick gel extraction kit (Qiagen Cat no. 28704). Gel 
purified PCR products were TA cloned (Invitrogen Cat no. 450071): 1μL 5’ RACE PCR 
product, 1μL salt solution (1.2 M NaCl2 and 0.06 M MgCl2), 1μL (10ng) pCR4 TOPO vector, 
and 3μL ultrapure water. The resulting plasmids were transformed into E. coli, plated on 
kanamycin selective plates, colonies were picked and grown overnight at 37°C. Plasmid DNA 
was isolated using Qiagen miniprep kit. 48 clones were subjected to Sanger sequencing.  
 
3.2.3 Cloning SOX6 isoforms 
Primers containing attB1 and attB2 Gateway cloning (Thermo Fisher Scientific) sequences were 
designed to amplify the mouse SOX6 open reading frame (ORF) and were synthesized by IDT. 
The primers were resuspended using ultrapure water (Thermo Fisher Scientific cat # 10977023) 
to make 200μM stock solutions and diluted 1:10 prior to PCR. Adult mouse brain cDNA was 
used as template DNA. The PCR product was cloned into pDONR221 using BP clonase as 
previously described except the reaction was incubated at room temperature overnight, 1μL 
Proteinase K was added the next day and the reaction was incubated at 37°C for ten minutes and 
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transformed into Top10 One shot E.coli cells as described in chapter 2. Eight individual colonies 
were picked and grown in 7mL of kanamycin selective media. Plasmid DNA was isolated using 
the Qiagen miniprep kit and was subjected to BsrG1 digestion to ensure presence of the insert as 
described in chapter 2. All the eight plasmids were subjected to Sanger sequencing and the PCR 
product contained two isoforms of SOX6: SOX6-full length (SOX6-FL), which contains exon 9 
and SOX6-ΔE9 among the eight plasmids. SOX6-FL and SOX6-ΔE9 were independently cloned 
into pDEST53 (Thermo Fischer Scientific), which contains an N-terminal GFP tag using LR 
clonase. The following protocol was used: 1μL pDEST53 plasmid, 1μL pDONR221 construct 
(150ng/ul), 6μL TE buffer, and 1μL LR clonase. The reaction was incubated at room 
temperature for one hour.  To terminate the reaction, 1μL Proteinase K was added and the 
reaction was incubated at 37°C for ten minutes. 3μL of above reaction was mixed with 12.5μL 
Top10 One shot E.coli cells (Thermo Fisher Scientific cat # C404003) and incubated on ice for 
15 minutes. The bacteria were heat shocked at 42°C for 45 seconds and were recovered by 
adding 62.5μL SOC growth media (Thermo Fisher Scientific cat # C404003) and incubating at 
37°C with shaking. The transformation reaction was plated on 100mg/mL ampicillin selective 
plates. The plates were incubated overnight at 37°C.  Individual colonies were picked and grown 
in 7mL of ampicillin selective media. Plasmid DNA was isolated using the Qiagen miniprep kit 
and was subjected to BsrG1 digestion. Two independent plasmids for each isoform were 
submitted for Sanger sequencing to ensure that GFP tag was in-frame with SOX6 ORFs. Both 
the isoforms were cloned in a similar manner into a vector that contains an N-terminal FLAG 
tag, pEZY-FLAG.  
 
3.2.4 Cell culture and transfections  
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HeLa cells were maintained in Dulbecco’s modified Eagle’s medium (Thermo Fisher Scientific 
cat # ILT12430054) supplemented with 10% fetal bovine serum (Thermo Fisher Scientific cat # 
26140-079), 2mM L-glutamine (Thermo Fisher Scientific cat # ILT25030081), and 1X 
Penicillin-Streptomycin (Thermo Fisher Scientific cat # ILT15070063) at 37°C in 5% CO2. 
1x105 cells were plated in a 6-well plate (USA Scientific cat # CC7682-7506) and incubated 
overnight at 37°C in 5% CO2. To isolate total RNA and whole cell lysates, HeLa cells were 
transfected with molar equivalents of GFP-SOX6-FL (4.05μg) and GFP-SOX6-ΔE9 (4μg) using 
Lipofectamine 2000 as described above. 48 hours post transfection total RNA and whole cell 
lysates (WCL) were isolated independently. Total RNA was isolated as described above. After 
RNA isolation, the samples were treated with DNase to remove any residual plasmid DNA 
contamination. To DNase treat the RNA we used the Qiagen RNase-Free DNase set (Qiagen cat 
# 79254). The following protocol was used: 10μL RNA, 10μL RDD buffer, 2.5μL DNase, and 
77.5μL ultrapure water. The reaction was incubated at room temperature for 10 minutes. 
Following DNase treatment, the RNA samples were cleaned up using RNeasy kit. cDNA was 
prepared as described above with (RT +) and without (RT -) reverse transcriptase enzyme. Image 
J was used to quantify the relative transcript abundance (Schneider et al., 2012). Whole cell 
lysates were isolated 48 hours after HeLa cells were transfected with tagged SOX6-FL and 
SOX6-ΔE9 using Radioimmunoprecipitation assay (RIPA) buffer (Thermo Fischer Scientific cat 
# 89900). The following protocol was used to isolate whole cell lysates: 2μL of 100X Halt 
Protease Inhibitor (Thermo Fischer Scientific cat # 78437) was added to 198μL of RIPA buffer. 
HeLa cells were harvested and 200μL of the above mixture was added to the cells, incubated at 
4°C for 30 minutes on a shaker, and centrifuged at 15,000rpm for 30 minutes at 4°C. The 
85	  	  
supernatant was transferred to a new tube and the lysates were stored at -80°C.  The lysates were 
quantified using the BCA assay (Thermo Fischer Scientific cat # 23227).  
 
3.2.5 Western blot analysis 
20-40μg of whole cell lysates was combined with 25μL 2X Novex Tris-Glycine SDS sample 
buffer (Thermo Fischer Scientific cat # LC2676) and 2μL β-mercaptoethanol (MP Biomedicals 
cat #194834). The samples were heated at 99°C for five minutes. The samples were loaded on 4-
20% Novex Tris-Glycine gels (Thermo Fischer Scientific cat # XP04200BOX) and 
electrophoresis was performed using 1X Novex Tris-Glycine SDS Running buffer (Thermo 
Fischer Scientific ILTLC2675) at 150 volts for 1 hour and 15 minutes. PVDF membranes were 
prepared by incubating in methanol for one minute and then incubating in 1X Transfer buffer 
(Thermo Fischer Scientific cat # LC3675) which contains 20% Methanol (Thermo Fischer 
Scientific cat # A452-1) for 15 minutes. Protein samples were transferred onto the PVDF 
membrane at 25 volts for 1 hour and 30 minutes. 2% blocking solution was prepared using 
1XTBST and non-fat milk powder (Dot Scientific cat # DSM17200-500). Membranes were 
blocked in blocking solution overnight at 4°C. Primary antibodies were prepared in the blocking 
solution and incubated at room temperature for one hour. The antibody concentrations used were 
as follows: rabbit anti-GFP (1:5000) (Sigma cat # G1544), rabbit anti-actin (1:5000) (Sigma cat 
#A5060), rabbit anti-KDM5C (1:250) (a kind gift from the Iwase lab) and mouse anti-flag 
(1:5000) (Sigma, F3165) Membranes were washed three times in 1XTBST. HRP-conjugated 
anti-rabbit antibody (1:10,000) and anti-mouse antibody (1:10,000) (Millipore cat #AP182P, 
AP192P) was added to blocking solution and incubated in secondary antibody solution for one 
hour at room temperature. Membranes were washed three times with 1X TBST, incubated with 
86	  	  
SuperSignal West Dura substrate (Thermo Fischer Scientific cat # 34075). Western blot analyses 
on whole cell lysates isolated from HeLa cells transfected with FLAG- SOX6-FL and FLAG-
SOX6-ΔE9 was performed using the same protocol except the lysates were run on a 6% tris-
glycine SDS gel (Thermo Fischer Scientific cat # XP00060BOX) and were transferred overnight 
at 4°C. 
 
3.2.6 Epoxomicin treatment of HeLa cells   
HeLa cells were transfected with molar equivalents of GFP-SOX6-FL (4.05μg) and GFP-SOX6-
ΔE9 (4μg) as previously described. 48 hours later, transfected HeLa cells were either treated 
with DMSO (Sigma cat #D2650) or 20μM epoxomicin (Millipore Corporation cat #324801) for 
2 hours. Whole cell lysates were isolated and western blot analysis was performed as described 
above. 
 
3.2.7 SOX6 protein localization studies  
For localization studies, ~25,000 S16 cells were plated in each well of a 4-well slide (Thermo 
Fischer Scientific cat # 08-774-25). The cells were grown overnight prior transfections. 1.5μg 
GFP-SOX6-ΔE9 was transfected using the protocol described above. 72 hours post transfections, 
the cells were washed with 500μL 1X PBS (Thermo Fischer Scientific cat # 70011044) for five 
minutes and fixed using 4% paraformaldehyde in 1XPBS for 10 minutes. The cells were then 
washed three times with 1X PBS and permeabilized with 0.1% Triton X-100 (MP Biomedical 
cat # 807426) in 1X PBS for 10 minutes. All cells were stained with DAPI (Molecular Probes cat 
# 21490) to visualize the nuclei and were washed with 1X PBS for three times. ProLong Gold 
anti-fade was applied to each well and the slides were covered with glass coverslips (Fischer 
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brand cat # 12-545-F). Cells were imaged using Olympus 1X71 inverted microscope using the 
40X objective and the Olympus cellSens image software.  
 
3.2.8 RNA-sequencing of Schwann cells upon overexpressing SOX6  
30-40% confluent T-75 flask of S16 cells were transfected with 10μg GFP-SOX6-ΔE9 using the 
protocol described in chapter 2. 72 hours post transfections the cells were prepared for flow 
cytometry. The cells were harvested and spun at 2000rpm for two minutes. The media was 
discarded and the cells were resuspended in 1X PBS so the final concentration was 3-4 million 
cells per mL. The cells were mixed well and passed through a 40μm cell strainer (Fischer Brand 
cat # 22363547). The cells were pipetted into a new 5mL falcon tube (Falcon cat # 352063) and 
flow cytometry was performed to collect GFP positive and GFP negative S16 cell populations at 
the University of Michigan Flow Cytometry core. Untransfected S16 cells served as the mock 
control and were used to establish base line florescence. RNA was isolated from GFP positive 
and negative populations using RNeasy kit and was treated with the DNase using the protocol 
described above. Three independent transfections using independently prepared GFP-SOX6-ΔE9 
were preformed and served as biological replicates. The RNA samples were submitted to the 
University of Michigan sequencing core for library preparation. mRNA libraries were generated 
using the TruSeq kit (Illumina cat # 20020594) and the three biological replicates were pooled 
and subjected to 50 base pair single end sequencing on a single lane on the HiSeq 4000 platform.  
 
FastQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) was used to assess the 
quality of reads. Rat (Rn5) ensembl genome was downloaded from Illumina 
(https://support.illumina.com/sequencing/sequencing_software/igenome.html) and the reads were 
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mapped using STAR (Dobin et al., 2013). Subsequently, number of reads were counted using 
HT-Seq and default parameters were used (Anders et al., 2015). Differential expression analysis 
between GFP positive and GFP negative samples was performed using DESeq2 (Love et al., 
2014). All programs were run on the flux servers at the University of Michigan.  
 
3.3 Results 
3.3.1 SOX10-CCS-13 is a previously unreported, alternative Sox6 promoter 
The SOX10 consensus sequence within SOX10-CCS-13 is conserved between human and 
zebrafish (Fig. 3.1A), further suggesting an important role for this SOX10 response element in 
jawed vertebrates. Additionally, analysis of SOX10 ChIP-seq data generated from rat sciatic 
nerve (Srinivasan et al., 2012) and our DNase-seq data generated from S16 cells revealed 
evidence for SOX10 binding and open chromatin at SOX10-CCS-13 (Fig. 3.1B)  Examination of 
SOX10-CCS-13 on the UCSC Genome Browser (Kent et al., 2002) revealed seven unique SOX6 
mRNA isoforms in human, mouse, and rat, distinguished by alternative, non-coding first exons. 
Interestingly, SOX10-CCS-13 maps directly upstream of the 3’-most alternative first exon, 
which we named SOX6 exon 1G (Fig. 3.2). We therefore hypothesized that SOX10-CCS-13 acts 
as an alternative promoter at SOX6. To test this, we performed 5’-rapid amplification of cDNA 
ends (5’-RACE). Briefly, a cDNA library was generated using RNA isolated from cultured rat 
Schwann (S16) cells and a reverse primer in exon 5 of the rat Sox6 gene. Subsequently, nested 
PCR was performed using reverse primers in exon 4 and then exon 3 of Sox6. The PCR products 
were cloned, sequenced, and aligned to the rat Sox6 locus. These analyses revealed the presence 
of five unique Sox6 transcription start sites in cultured Schwann cells with 14 of the 44 Sox6-
specific sequences mapping directly downstream of SOX10-CCS-13 (Fig. 3.2). 
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Figure 3.1. SOX10 binding and chromatin accessibility at SOX10-CCS-13. (A) Conservation of 
SOX10 consensus sequence (red text) and surrounding genomic region in mammals (human, 
mouse, and rat) and vertebrates (chicken and zebrafish). Uppercase letters indicate conserved 
bases and lowercase letters indicate non- conserved nucleotides. (B) SOX10 ChIP-seq and 
DNase-seq peaks are shown at SOX10-CCS-13. The y-axes represent normalized read depth 
(SOX10-ChIP-seq) and F-seq score (DNase-seq). The black box indicates the position of the 
SOX10 consensus sequence. The length of the genomic region we tested in the luciferase assay 
in indicated at the bottom and the arrows indicate the direction of transcription. 
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Analysis of RNA-seq data generated in S16 cells (Law et al., in review) also revealed 
reads that map to Sox6 exon 1G (Fig. 3.2), with split reads into downstream exons, but no split 
reads into upstream exons (data not shown). Additionally, we were able to amplify and 
sequence-verify a full length Sox6 mRNA that originates at exon 1G in S16 cells (Fig. 3.2). To 
assess the in vivo relevance of SOX10-CCS-13 we analyzed recently published SOX10 ChIP-seq 
data performed on nuclei isolated from rat spinal cord and sciatic nerve (Lopez-Anido et al., 
2015; Srinivasan et al., 2012). Furthermore, to establish that this genomic segment resides in 
open chromatin we performed DNase-seq analysis on nuclei isolated from cultured rat Schwann 
(S16) cells. The SOX10 ChIP-seq analyses revealed that SOX10 binds to SOX10-CCS-13 in 
relevant tissues in vivo and the DNase-seq experiment revealed that this genomic segment 
resides in open chromatin in cultured Schwann cells (Fig. 3.2, green box). Combined, these data 
support our conclusion that SOX10-CCS-13 is a SOX10 response element in Schwann cells.  
Interestingly, these genome-wide functional studies revealed additional SOX10 binding sites at 
Sox6 in vivo further supporting the notion that Sox6 is a SOX10 target gene (e.g., brown 
highlighted region in Fig. 3.2). Combined, our data indicate that SOX10-CCS-13 represents an 
alternative, SOX10-responsive promoter at Sox6. 
 
3.3.2 SOX10 is necessary and sufficient for the expression of Sox6 transcripts harboring 
exon 1G 
To determine if SOX10 is sufficient to direct the expression of Sox6 transcript containing exon 
1G, we performed RT-PCR using primers designed in Sox6 exon 1G and exon 2 in regions  
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Figure 3.2. SOX10-CCS-13 is an alternative promoter at the Sox6 locus. The ~579 kb rat Sox6 
locus is shown on the UCSC Rat Genome Browser. SOX10-CCS-13 is indicated in red along 
with the seven human, mouse, and rat SOX6 RefSeq mRNAs (blue). Sox6-specific 5’ RACE 
was performed on RNA from S16 cells and the five distinct Sox6 sequences were mapped to the 
rat genome. Please note that SOX10-CCS-13 maps to both the 5’ end of the seventh Sox6 
mRNA and the fifth unique 5’ RACE-generated sequence. RNA-Seq data from S16 cells were 
mapped to Sox6 (the y-axis indicates   sequence read depth) as was a PCR-amplified, full-length 
mRNA that contains Sox6 exon 1G. Genome-wide regulatory marks were also mapped to Sox6 
with the Y-axes indicating normalized sequence read depths (both SOX10 ChIP-seq data sets) 
and F-Seq scores (DNase-seq). The green highlighted region marks the general position of 
SOX10-CCS-13 across all data sets and the brown highlighted region marks another potential 
SOX10 response element at Sox6. 
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conserved between rat and mouse. While these primers amplify Sox6 transcripts containing exon 
1G from a cDNA library generated from RNA isolated from immortalized rat (S16) Schwann 
cells we were not able to amplify these transcripts from a cDNA library generated from cultured 
mouse motor neurons (MN1 cells), which do not express endogenous SOX10 (Fig. 3.3A). 
However, when MN1 cells were transfected with a construct to express wild-type SOX10, Sox6 
transcripts containing exon 1G were detected and verified by DNA sequence analysis. Mock 
transfection or transfection with a construct to express a non-functional mutant version of 
SOX10 (E189X) (Inoue et al., 2004) did not allow amplification of Sox6 transcripts containing 
exon 1G (Fig. 3.3A). Thus, SOX10 is sufficient to activate the expression of Sox6 transcripts 
harboring exon 1G in MN1 cells, which do not express endogenous SOX10 (Hodonsky et al., 
2012). To determine if SOX10 is necessary for the expression of Sox6 transcripts containing 
exon 1G in Schwann cells, we treated S16 cells with a previously validated siRNA against Sox10 
(Gokey et al., 2012; Lopez-Anido et al., 2015) and tested for an effect on total Sox6 mRNA 
levels and for an effect on the level of transcripts containing exon 1G. This analysis revealed a 
~70% decrease in both total Sox6 expression and in the expression of transcripts containing exon 
1G (Fig. 3.3B), consistent with SOX10 regulating the promoter activity of SOX10-CCS-13 
which is responsible for regulating exon 1G containing SOX6 transcript in Schwann cells. 
Combined, our data indicate that SOX10 is both necessary and sufficient for the expression of 
Sox6 mRNA isoform 7 (Fig. 3.3) in our in vitro cell culture model systems. 
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Figure 3.3. SOX10 is necessary and sufficient for SOX6 expression. (A) RT-PCR was  
performed to detect the expression of Sox6 transcripts harboring exon 1G using cDNA       
isolated from S16 cells, MN1 cells, or MN1 cells transfected with no expression construct 
(mock) or a construct to express wild-type or dominant-negative (E189X) SOX10. Base pair (bp) 
ladders are indicated on the left. RT-PCR for β-actin and samples including no cDNA (‘Blank’) 
were employed as positive and negative controls, respectively. Please note that while the same 
primers were used for each reaction, the rat (S16) PCR product was 402 base pairs and the 
mouse (MN1) PCR product was 349 bp; the rat genome   harbors a 53 base pair rat-specific 
insertion, which we confirmed via DNA sequence analysis. (B) Rat Schwann (S16) cells were 
treated with a control siRNA (left side) or a siRNA targeted against Sox10 (right side). 
Quantitative RT-PCR was used to measure expression levels of total Sox6 (green bars) or Sox6 
exon 1G-containing (purple bars) transcripts. Error bars indicate standard deviations. 
 
94	  	  
3.3.3 SOX6 mRNA undergoes alternative splicing and exon 9 is conserved among mammals 
SOX6 belongs to the SOXD family of transcription factors along with SOX5 and SOX13 
(Lefebvre, 2010).  The SOXD transcription factors inhibit myelination in oligodendrocytes 
(Baroti et al., 2015; Stolt et al., 2006) and the role of SOX6 in Schwann cells is not yet known. 
SOX6 mRNA undergoes alternative splicing to produce isoforms that either include (SOX6-FL) 
or exclude (SOX6-ΔE9) exon 9 (indicated by red arrow in Fig. 3.4A). I performed multiple 
species conservation analysis and interestingly, exon 9 is conserved only in mammals (red box in 
Fig. 3.4A). To test for the presence of exon 9 in mammals and lower vertebrates, we performed 
RT-PCR analysis using cDNA libraries prepared from mouse and zebrafish tissues. Forward and 
reverse primers were designed in mouse/zebrafish exon 8 and exon 10 respectively. cDNA 
libraries were generated from RNA isolated from brains of embryonic (E) 16.5 embryos, post-
natal day (P) 3 and adult mice. We were able to amplify transcripts with (293bp indicated by an 
arrow in Fig. 3.4B) and without exon 9 (170bp Fig. 3.4B) in mice. cDNA libraries were prepared 
from RNA was isolated from zebrafish embryos at 24 hours post fertilization (hpf), 48 hpf, 5 
days post fertilization (dpf) and from brain of adult zebrafish. RT-PCR analysis revealed the 
presence of transcript without exon 9 at all developmental time points (148bp, Fig. 3.4C). Taken 
together, these data indicate exon 9 is conserved only in mammals.  
 
3.3.4 Overexpressing both isoforms of SOX6 indicates lower expression of SOX6-FL  
SOX6 contains two coiled-coil (CC) domains, which is specific to the SOXD group and 
facilitates homo- and hetero-dimerization (Lefebvre, 2010). The HMG-domain is present 
towards the C-terminal of the protein. Interestingly, SOXD proteins do not contain 
transactivation or transrepression domain so their regulatory activity is dictated by the co-factors  
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Figure 3.4. SOX6 mRNA undergoes alternative splicing. (A) ~334kb mouse Sox6 locus showing 
two annotated RefSeq mRNA isoforms. The black arrow indicates the translational start site and 
the red arrow indicates exon 9. The region from exon 8 to exon 10 is highlighted in grey and a 
zoomed in view displaying the conservation of the region in shown. Exon 9 region is depicted in 
the red box. (B) RT-PCR analysis was performed to detect Sox6 transcripts with and without 
exon 9 using cDNA isolated from embryonic (E) day 16.5, post-natal (P) 3, and Adult brains 
from mice. RT-PCR for β-actin and samples including no cDNA (‘Blank’) were used as positive 
and negative controls, respectively. The arrow indicates the presence of exon 9 containing 
transcripts. (C) RT-PCR assay was performed to detect Sox6 transcripts with and without exon 9 
using cDNA isolated from 24 hours post fertilization (hpf), 48hpf, 5 days post fertilization (dpf) 
zebrafish embryos and adult zebrafish brain. RT-PCR for zfGars and samples including no 
cDNA (‘Blank’) were used as positive and negative controls, respectively. The arrow indicates 
the absence of exon 9 containing transcripts. Base pair (bp) ladder for both the gels are indicated 
on the left. 
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they interact with (Lefebvre, 2010) (Fig 3.5A). The two protein isoforms contain all the known 
functional domains both isoforms are known to display similar transcriptional activities 
(Lefebvre et al., 1998). The functional differences between the two isoforms are currently 
unknown and exon 9 does not code for any known functional domains (Cohen-Barak et al., 
2001). Amino acid sequence for exon 9 is highly conserved among mammals (Fig. 3.5B). We 
unable to identify any putative protein domain encoded by exon 9 using Pfam analysis (Finn et 
al., 2016). Lysine residues are targets for posttranslational modification and are often 
ubiquitinated (Zencheck et al., 2012).  Exon 9 contains three highly conserve lysine resides and 
we used UbPred software to identify potential ubiquitination sites (Radivojac et al., 2010). 
Interestingly, the last lysine within exon 9 (lysine residue shown in red in Fig. 3.5B) was 
predicted as an ubiquitination site suggesting that SOX6-FL may be targeted for proteosomal 
degradation.  
 
To investigate the functional differences between the two isoforms we cloned them into a 
plasmid, which contains an N-terminal GFP tag. To detect the expression levels of our fusion 
proteins, we transiently transfected HeLa cells, which were chosen because of their high 
transfection efficiency. HeLa cells were transfected with GFP-SOX6-FL, GFP-SOX6-ΔE9, 
MTMR2-1 (Fogarty et al., 2016), or a plasmid to express GFP, we isolated whole cell lysates and 
performed western blot analyses using anti-GFP antibody. MTMR2-1 is one of the isoforms of 
myotubularin-related protein 2 (MTMR2), which has been cloned into the same N-terminal GFP-
plasmid as the two SOX6 isoforms and serves as a positive control. 
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Figure 3.5. Schematic representing the two SOX6 protein isoforms. (A) SOX6- full length 
(SOX6-FL) and SOX6-ΔE9. The two coiled-coil domain (1st CC in orange and 2nd CC in grey) 
and HMG (green) domain are indicated. Exon 9 in SOX6-FL is shown in red. (B) Amino acid 
residues that exon 9 codes for is shown for different species.   Residues that are different among 
the species are depicted as green amino acids. Conserved lysine (K) residue shown in red is the 
predicted site for ubiquitination. 
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Figure 3.6. SOX6-ΔE9 is detected at higher levels upon overexpression in vitro. Western blot 
analyses using whole cell lysates isolated from HeLa cells transfected (A) with no expression 
construct (mock) or GFP-tagged SOX6-FL, SOX6-ΔE9, MTMR2-1 or plasmid expressing EGFP 
protein was performed using anti-GFP and anti-actin antibodies. (B) with no expression 
construct (mock) or FLAG-tagged SOX6-FL, SOX6-ΔE9, and CABIN1-2 was performed using 
anti-FLAG and ant-KDM5C antibodies. A protein ladder in kilodalton is shown on the left. The 
arrow indicates expected products for both SOX6 isoforms. 
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We detected appropriately sized bands for SOX6-ΔE9 (~114kDa), MTMR2-1(~100kDa), and 
GFP (~27kDa), and we did not detect fusion protein expression in mock-transfected cells (Fig 
3.6A). Interestingly, we were unable to detect the GFP-SOX6-FL product (~119kDa, indicated 
by the arrow in Fig 3.5B). To rule out the possibility of the GFP tag having an effect on protein 
expression, we performed similar analysis using SOX6-FL and SOX6-ΔE9 cloned into an 
expression construct with an N-terminal FLAG-tag. Here, we observed an appropriately sized 
product for SOX6-FL (~92kDa), SOX6-ΔE9 (~88kDa), CABIN1-2 (~70kDa) (Fig 3.6B). 
CABIN1-2 is an isoform of CABIN1 that has been cloned into the same N-terminal FLAG-
plasmid as the SOX6 isoforms and serves as a positive control (Fogarty et al., in preparation). 
Consistent with our expression studies using a GFP tag, we observed significantly lower levels 
of FLAG-SOX6-FL expression compared to FLAG-SOX6-ΔE9.  There are multiple 
explanations for reduced expression of SOX6-FL in our transient transfection assays, including: 
(i) variation in transfection efficiency between the two plasmids; (ii) specific degradation of the 
SOX6-FL transcript produced from the expression plasmid; and/or (iii) specific degradation of 
the SOX6-FL protein produced from the expression plasmid. 
  
To test the mRNA expression levels from the plasmid we performed RT-PCR using cDNA 
library prepared from RNA isolated from HeLa cells that were either mock transfected, or 
transfected with constructs to express either GFP-SOX6-FL or GFP-SOX6-ΔE9. RT-PCR 
primers were designed within the coding sequence of GFP and within exon one of SOX6. We 
were indeed able to amplify the right size product (136bp) from cells transfected with GFP-
SOX6-FL and GFP-SOX6-ΔE9 and unable to amplify a product from mock transfected HeLa 
cDNA (Fig 3.7). 
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Figure 3.7. GFP-SOX6-FL mRNA is expressed at lower levels in vitro.  RT-PCR was performed 
using cDNA library prepared from HeLa cells that were either mock (M) transfected or 
transfected with GFP-tagged SOX6-FL (FL) or GFP-tagged SOX6-ΔE9 (ΔE9) with (+) or 
without (-) reverse transcriptase (RT) enzyme and Φ does not contain a template. The 
experiment has been performed using cDNA libraries prepared from three independent 
transfections. Molecular weight ladder is shown on the left. A cartoon of pDEST53 plasmid, 
which was used to clone the SOX6 isoforms, is shown on the right.  This plasmid contains an N-
terminal GFP tag and a CMV promoter drives the expression of the fusion protein. Forward 
primer was designed towards the C-terminal of GFP open reading frame and reverse primer was 
designed within exon 1 of SOX6. β-actin served as a positive control. Base pair (bp) ladder is 
indicated on the left. 
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We were unable to amplify a product from cDNA libraries prepared without a reverse 
transcriptase (RT- in Fig. 3.7), ensuring that we were not amplifying products from plasmid 
DNA. To test the reproducibility of our data, we performed this experiment three times using 
cDNA libraries prepared from independent transfections. Amplification of endogenous β-actin 
served as a control to ensure the integrity of cDNA libraries. These data suggest that GFP-SOX6-
FL transcript is expressed at lower levels compared to GFP-SOX6-ΔE9 (Fig 3.7).  
 
To test the relative expression of GFP-SOX6-FL and GFP-SOX6-ΔE9 transcript to another 
plasmid encoded transcript we performed RT-PCR analysis to amplify a transcript encoded by a 
selection marker in the expression plasmid (Fig 3.8). The pDEST53 plasmid contains a  
neomycin selection cassette and primers were designed within this cassette and primers were 
designed within exon 13 and 14 of SOX6. We performed RT-PCR analysis using cDNA samples 
generated from HeLa cells that were either mock transfected, or transfected with GFP-SOX6-FL 
or GFP-SOX6-ΔE9 and using three different PCR amplification cycles: 26, 28, and 30. 
Following RT-PCR, the products were separated on agarose gels and the intensities of the bands 
were quantified using ImageJ software (Schneider et al., 2012). We were able to amplify the 
right size products for GFP-SOX6-FL, GFP-SOX6-ΔE9 (182bp) and neomycin (134bp) (Fig. 
3.8) for all the three PCR cycles. The relative abundance of FL and ΔE9 transcripts was 
calculated by normalizing the intensity of the SOX6 bands to the neomycin bands. The 
expression of SOX6-FL and SOX6-ΔE9 is comparable to their respective expression of 
neomycin (Fig. 3.8). However, GFP-SOX6-FL transcript is expressed at lower levels compared 
to GFP-SOX6-ΔE9. The difference we observe may be due to reduced transfection efficiency of 
GFP-SOX6-FL or due to post-translational modifications.  
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Figure 3.8. GFP-SOX6-ΔE9 transcript is expressed at higher levels in vitro. RT-PCR was       
performed using cDNA libraries prepared from mock (M), GFP-tagged SOX6-FL or GFP-tagged 
SOX6-ΔE9 (ΔE9) transfected HeLa cells and Φ does not contain a DNA template. The assay 
was performed at three different PCR cycles (26, 28, and 30). The position of the forward (F) 
and reverse (R) primers is indicated on the left.  The ImageJ quantification is shown on the right 
for the three cycle numbers. The x-axis on the graph indicates the two Sox6 mRNA (FL and 
ΔE9) isoforms and the y-axis indicates relative abundance of the two transcripts. Base pair (bp) 
ladder is indicated on the left. β-actin served as a positive control. 
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3.3.5 SOX6-FL protein expressed from the plasmid is not stabilized upon epoxomicin 
treatment 
Protein degradation in eukaryotes is mediated by the proteasome through the ubiquitin pathway. 
Once proteins have been ubiquitinated, they are targeted by the 26S proteasome for degradation 
(Varshavsky, 2017). Lysine residues within proteins are known to be ubiquitinated (Zencheck et 
al., 2012) and exon 9 contains a lysine residue predicted to undergo  
ubiquitination (Fig. 3.5B). To test if GFP-SOX6-FL is targeted by the proteasome, we treated 
HeLa cells with epoxomicin which inhibits in vivo proteasome function (Meng et al., 1999). 
Briefly, HeLa cells were mock transfected or transfected with GFP-SOX6-FL or GFP-SOX6-
ΔE9. 48 hours post transfections, HeLa cells were treated with DMSO or 20μM epoxomicin for 
2 hours and whole cell lysates were extracted as previously described and western blot analysis 
was performed using anti-GFP, anti-p53, and anti-Rab5 antibodies (Fig. 3.9). Epoxomicin 
treatment is known to stabilize p53 in HeLa cells and serves as our positive control to ensure 
inhibition of the proteasome (Meng et al., 1999). Treating the cells with DMSO did not affect the 
expression of GFP-SOX6-FL or GFP-SOX6-ΔE9 and these data are consistent with our earlier 
findings and we observe lower p53 levels in the DMSO treated cells. Indeed, we observe 
accumulation of p53 (53kDa) upon epoxomicin treatment however; we do not observe the right 
size band for GFP-SOX6-FL (indicated by the arrow in Fig. 3.9) and the level of GFP-SOX6-
ΔE9 (114kDa) is unchanged upon epoxomicin treatment. Rab-5 (24kDa) serves as our loading 
control. These data indicate that GFP-SOX6-FL is not targeted by the proteasome and 
transfection efficiency of the two plasmids accounts for the observed expression difference. 
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Figure 3.9. SOX6-ΔFL expression is unaffected by epoximicin treatment. Western blot analyses 
using whole cell lysates isolated from HeLa cells transfected with no expression construct 
(mock) or GFP-tagged SOX6-FL, SOX6-ΔE9 and treated either with DMSO or epoximicin 
using anti-GFP, anti-p53 and anti-Rab5 antibodies. A protein ladder in kilodalton is shown on 
the left. The arrow indicates expected products for both SOX6-FL isoform. 
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3.3.6 The SOX6-GFP fusion protein localizes to the nucleus in cultured Schwann cells  
GFP-SOX6-ΔE9 transfects better that GFP-SOX6-FL so we used the former for functional 
studies. SOX6 is a transcription factor and it has been shown to localize to the nucleus (Ohe et 
al., 2002). To ensure that the GFP-tag does not affect localization of SOX6, we transfected S16 
cells with GFP-SOX6-ΔE9. Our fluorescence microscopy analysis revealed that SOX6 fusion 
protein overlaps with nuclear DAPI staining (indicated by white arrows in Fig 3.10) suggesting 
that our fusion protein is able to translocate to the nucleus. These images were not taken on a 
confocal microscope and need to be validated. GFP-SOX6-ΔE9 forms puncta in the nucleus and 
the data are consistent with published data that suggest that endogenous SOX6 forms nuclear 
speckles and co-localizes with splicing factors (Ohe et al., 2002).  
 
3.3.7 Global transcriptome analysis suggests a role for SOX6 in Schwann cell 
dedifferentiation 
SOX6 is a negative regulator of myelination in oligodendrocytes and may act in a similar fashion 
in Schwann cells. Specifically, ablating Sox6 in the mouse CNS resulted in premature 
myelination and in vitro studies suggested that SOX6 represses the expression of Mbp by 
outcompeting SOX10 for promoter occupancy (Stolt et al., 2006). We therefore tested the 
hypothesis that SOX6 globally represses loci important for myelination in Schwann cells by 
over-expressing GFP-SOX6-ΔE9 in immortalized rat Schwann (S16) cells and performing RNA-
seq analysis. 
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Figure 3.10 SOX6-ΔE9 fusion protein localizes to the nucleus. S16 cells were transfected with 
GFP-tagged SOX6-ΔE9. Cells were fixed and treated with DAPI (blue) to stain the nucleus. The 
images form the first two panels were merged (Merge) to show co-localization. The white arrow 
indicates cells that express the fusion protein, which is localized to the nucleus. Scale bars, 
20um. 
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S16 cells express high levels of key myelin genes including Sox10, Mbp, and Mpz and are a 
relevant model to test our hypothesis (Hodonsky et al., 2012; Toda et al., 1994) (Law et al., 
under review). After transfection, flow cytometry was performed to collect GFP-positive and 
GFP-negative cells, RNA was isolated from both these cell populations, and we performed RNA 
seq analysis.  RNA was isolated from three independent GFP-positive and GFP-negative S16 
cells. Stranded libraries were prepared using the Truseq Illumina kit and all samples were pooled 
and sequenced on a single lane of a HiSeq4000. About 45-80 million high quality reads (FastQC 
quality score >38) were obtained for each sample and, of these, ~80% of the reads mapped to the 
rat genome (Table 3.1). To assess the variability between our biological replicates we performed 
principal component analysis (PCA) (Fig. 3.11A). Majority of the variance (84%) is explained 
by the first principal component (PC1), which separates the GFP-positive and GFP-negative 
samples.  The second principal component (PC2) explains the variance among biological 
replicates of the two experimental conditions (GFP-positive and GFP-negative) (Fig. 3.11A). We 
used DeSeq2 to identify differentially expressed (DE) genes by comparing the transcriptomes of 
GFP-positive and GFP-negative cells (Fig. 3.11B).  A total of 1,117 genes were differentially 
expressed between the two experimental conditions (680 up- and 437 down-regulated; adj P-
value <0.01).  
 
To gain insights into the function of SOX6 in Schwann cells, we performed gene ontology (GO) 
enrichment analysis using the overrepresentation test for biological processes using the 1,117 DE 
genes. GO analysis of up- regulated and down-regulated genes, separately, resulted in an 
enrichment of 188 and 111 GO terms, respectively (Table 3.2 and 3.3).  
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  Total number of reads Mapped unique (%) 
S16 SOX6 ΔE9 GFP positive- 1 81,837,766 80.7 
S16 SOX6 ΔE9 GFP negative- 1 88,615,458 83 
S16 SOX6 ΔE9 GFP positive- 2 87,861,686 80.9 
S16 SOX6 ΔE9 GFP negative- 2 43,342,890 81.1 
S16 SOX6 ΔE9 GFP positive- 3 46,662,646 81.2 
S16 SOX6 ΔE9 GFP negative- 3 47,821,905 83.3 
Table 3.1 Summary of the RNA-seq data. Total number for reads for each of sample and 
percentage (%)of the reads that mapped to rat ensemble (RN5) genome is shown 
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Figure 3.11. Global transcriptomic changes upon SOX6 overexpression in Schwann cells. (A) 
Principal component analysis performed to calculate the variability between the biological 
replicates. PC1 (x-axis) displays the majority of variance (84%) and PC2 (y-axis) displays the 
residual variance (9%). Different colored dots are associated with different biological replicate as 
shown on the right (B) MA plot showing the mean expression change of every gene (x-axis) 
plotted against log2 fold change (y-axis). The red line at 0 indicates genes no change in 
expression upon SOX6 overexpression. The dots about and below the red line are up- and down-
regulated, respectively. The red dots indicate genes that are significantly differentially expressed  
(p-value<0.05). Mbp is indicated by the blue circle 
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Consistent with the role of SOX6 in regulating cell proliferation during erythroid development 
we indeed observe a GO term (p-value= 9.04x10-9) associated with this specific function of 
SOX6 in our data (Dumitriu et al., 2006). Some of the GO terms associated with up-regulated 
genes important for Schwann cell biology are glial cell development, glial cell differentiation, 
gliogenesis, and positive regulation cell migration. The glial cell development GO term is 
associated with genes that are up-regulated and the list contains genes such as SIRT2, MMP14, 
MXRA8, DAG1, GFAP, NDRG1, SOD1, GSN, CD9, and LRP1. These genes are either 
implicated in facilitating Schwann cell regeneration following repair or promoting Schwann cell 
proliferation and migration. We identified 111 GO terms associated with the down-regulated 
genes in our RNA-seq analysis. SOX6 is known to inhibit neuronal differentiation (Lee et al., 
2014) and indeed we observe a GO term associated with neuron development that is enriched in 
our data. Interestingly, we did not observe any decrease in Mbp expression (Fig. 3.9) upon GFP-
SOX6-ΔE9 overexpression in S16 cells, suggesting that SOX6 may not directly or indirectly 
inhibit Mbp expression; however, additional analyses are required to confirm our findings and 
we cannot rule out that Mbp repression is mediated by full-length (FL) SOX6. Taken together 
our GO analysis reveals putative role for SOX6 during Schwann cell development and after 
nerve injury.  
 
3.3.8 MBP promoter activity is unaffected by SOX6 overexpression  
Previous studies showed that SOX6 is important for repressing premature myelination in the 
CNS. Moreover, it was shown that this process may involve SOX6 outcompeting SOX10 at 
myelin loci, specifically the Mbp promoter (Stolt et al., 2006). Interestingly, our RNA-seq data in 
S16 cells revealed no significant change in Mbp upon overexpression of SOX6-ΔE9. To explain  
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Figure 3.12. SOX6 overexpression does not reduce MBP promoter activity in Schwann cells. 
MBP promoter was cloned upstream of a c-fos minimal promoter driving luciferase reporter 
gene and luciferase assays were performed in S16 cells. (A) The luciferase activity of the MBP 
promoter was compared to an empty vector containing no genomic insert and y-axis shows the 
fold increase in luciferase expression. (B) MBP promoter activity without (-), in presence of 
increasing concentrations of SOX6 expression (50,100,150, and 200 ng) and in the presence of 
dominant-negative (E189XSOX10). The y-axis shows fold change in luciferase activity 
compared to untreated MBP promoter activity set to 100%. Errors bars in both the panels 
indicate standard deviations. P-value was calculated using two-tailed student t-test. 
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these apparently discrepant findings, we performed luciferase assays to test the effect of GFP-
SOX6-ΔE9 overexpression on MBP promoter activity. We cloned the Mbp promoter (same 
region as previously published (Stolt et al., 2006)) upstream of a c-fos minimal promoter driving 
luciferase reporter gene expression, and performed luciferase assays in S16 cells. The Mbp 
promoter we cloned harbors a conserved SOX10 monomeric site. This region displayed ~25-fold 
increase in luciferase activity compared to the empty vector, which does not contain a genomic 
insert (Fig. 3.10A) suggesting this genomic segment possesses regulatory activity in S16 cells. 
To test if SOX6 is able to repress MBP promoter activity in vitro, we co-transfected a construct 
to express GFP-SOX6-ΔE9 or one to express a dominant-negative form of SOX10 (E189X 
SOX10), which is known to repress luciferase activity of SOX10 genes (Brewer et al., 2014; 
Fogarty et al., 2016; Gopinath et al., 2016). With increasing concentrations of GFP-SOX6-ΔE9 
we did not observe a significant decrease in luciferase activity of the MBP promoter. Indeed, 
overexpression of E189X SOX10 causes a (p-value<0.01) reduction of 26% in the luciferase 
activity of the Mbp promoter. Combined, our in vitro data do not support a role for SOX6 in 
repressing Mbp expression in Schwann cells. 
 
3.4 Discussion 
Schwann cells develop from the neural crest cells and after their specification go through several 
developmental stages to become myelinating Schwann cells that ensheath the axons of the 
peripheral nerves. Gene regulatory networks govern the transition between each stage of 
Schwann cell development. The transcription factor SOX10 plays a central role in Schwann cell 
development by regulating genes in a stage specific manner (Svaren and Meijer, 2008). To date, 
SOX10 has been known to regulate a myelination promoting transcriptional program; however, 
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to observation that SOX10 is expressed during all stages of Schwann cell development has raised 
questions on how the myelination program is repressed during non-myelinating stages of cell 
development. Interestingly, we identified SOX10-responsive elements at loci known to inhibit 
glial cell differentiation (Chapter 2). SOX10-CCS-13 resides within an intron of the SOX6 locus 
and is directly upstream of a non-coding exon (exon 1G) suggesting that this intronic enhancer 
may be acting as an alternative promoter. Using 5’RACE we were able to identify a TSS directly 
downstream of SOX10-CCS-13 and we were able to identify reads that mapped to this exon and 
split reads that go into the downstream exon. Combined, these data indicate that the intronic 
enhancer is a SOX10-responsive promoter at the SOX6 locus (Fig. 3.2). Indeed, SOX10 is known 
to regulate other loci including genes that are mutated in demyelinating peripheral neuropathy, 
via alternative promoters (Brewer et al., 2014; Fogarty et al., 2016; Hodonsky et al., 2012). 
These data suggest that SOX10 may regulate loci to produce alternative protein products 
important for Schwann cell function. SOX10 is selectively expressed in other neural crest 
derived cells such as melanocytes. Interestingly, Sox6 expression is reduced (> 6-fold) in 
melanocytes derived from Sox10 haploinsufficient mice suggesting that SOX10 may regulate 
SOX6 expression in melanocytes (Fufa et al., 2015). Currently, the role of SOX6 in melanocytes 
has not yet been characterized.  
 
Alternative spicing is a post-transcriptional process, which increases the transcript diversity in 
eukaryotic organisms and recent data suggest that transcription elongation and splicing are 
coupled (Dujardin et al., 2013). Alternative splicing of SOX6 mRNA produces isoforms with and 
without exon 9 and our in vitro data indicate that SOX6 is regulated via an SOX10-reponsive 
alternative promoter. Interestingly, alternative promoters tend to influence alternative splicing 
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(Xin et al., 2008). SOX10 interacts with positive transcription elongation factor b (pTEFb) in 
Schwann cells and could play a role in regulating alternative promoters and alternative splicing.  
Among chordates, exon 9 is highly conserved among mammals (Fig. 3.4). This is not surprising 
as there are over 7,000 genes that contain mammalian specific exons (Merkin et al., 2015). 
Interestingly, MBP undergoes alternative splicing to produce at least seven different isoforms 
and exon 2 is conserved in mammals and absent in non-mammals (Gould et al., 2008; 
Schweigreiter et al., 2006). MBP isoforms with and without exon 2 display different functional 
properties. Exon 2 containing protein localized to the cytoplasm whereas the isoform without 
exon 2 localized primarily to the plasma membrane (Allinquant et al., 1991). Function of exon 9 
of SOX6 is currently unknown. To test the importance of exon 9, transgenes expressing the 
isoforms can be generated separately and the phenotype of the Sox6 mice (Smits et al., 2001) can 
be rescued by introducing isoform-specific transgene separately. 
 
We independently cloned both isoforms of mouse SOX6 (SOX6-FL and SOX6-ΔE9) into 
plasmids, which contain an N-terminal GFP or FLAG-tags. Human and mouse SOX6 proteins 
display 94.3% sequence identity and the functional domains are 100% conserved (Cohen-Barak 
et al., 2001). Both SOX6 isoforms display similar DNA-binding and transactivation activities 
and an N-terminal FLAG tag did not affect the activity of SOX6 (Lefebvre et al., 1998). We 
transfected HeLa cells with GFP-SOX6-FL and GFP-SOX6-ΔE9 and performed western blot 
analyses to confirm the presence of the fusion protein product. Our data revealed that SOX6-FL 
is expressed at lower levels compared to SOX6-ΔE9 (Fig. 3.6A). To ensure that the GFP tag is 
not having an effect on the expression of SOX6-FL and SOX6-ΔE9, we transiently transfected 
HeLa cells with FLAG-SOX6-FL and FLAG-SOX6-ΔE9 and performed western blot analyses 
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(Fig. 3.6B). Consistent with previous observations FLAG-SOX6-FL is expressed at lower levels 
compared to FLAG-SOX6-ΔE9. There are multiple explanations for reduced expression of 
SOX6-FL in our transient transfection assays, including: (i) specific degradation of the SOX6-FL 
transcript produced from the expression plasmid; (ii) specific degradation of the SOX6-FL 
protein produced from the expression plasmid and/or (iii) variation in transfection efficiency 
between the two plasmids. 
 
To test the expression of GFP-SOX6-FL and GFP-SOX6-ΔE9 transcripts produced from the 
plasmids we performed RT-PCR using cDNA libraries prepared from HeLa cells transfected 
with GFP-SOX6-FL and GFP-SOX6-ΔE9. We were able to detect the presence of both GFP-
SOX6-FL and GFP-SOX6-ΔE9 however GFP-SOX6-FL was expressed at lower levels (Fig. 
3.7). We next wanted to test the transcript levels of GFP-SOX6-FL and GFP-SOX6-ΔE9 relative 
to another transcript produced from the expression plasmid. These data revealed lower 
expression levels of GFP-SOX6-FL suggesting the observed difference could be due to post-
translational modifications of GFP-SOX6-FL or variation in transfection efficiency (Fig. 3.8).  
 
SOX6-FL contains exon 9 and UbPred software predicted that the last lysine within exon 9 
(residue shown in red in Fig. 3.5B) could be ubiquitinated. Ubiquitination of lysine residues 
targets proteins for proteosomal degradation (Zencheck et al., 2012) and we hypothesized that 
GFP-SOX6-FL is targeted by the proteasome leading to degradation of the protein. To test this 
hypothesis we transiently transfected HeLa cells with GFP-SOX6-FL and GFP-SOX6-ΔE9 and 
two days after transfection we treated the cells with epoxomicin, a drug known to irresversibly 
inhibit the proteasome (Meng et al., 1999). We performed western blot analysis using lysates 
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collected from DMSO and epoxomicin treated cells. If GFP-SOX6-FL is targeted by the 
proteasome, then we would observe stabilization of GFP-SOX6-FL upon epoxomicin treatment. 
However, we did not observe stabilization of GFP-SOX6-FL and the levels of GFP-SOX6-ΔE9 
were unchanged (Fig. 3.9) indicating that the difference we observe is due to reduced 
transfection efficiency of GFP-SOX6-FL. 
 
Previous reports suggest SOX6 inhibits myelination in the central nervous system and 
specifically deleting Sox6 in developing oligodendrocytes in mice caused premature myelination 
(Stolt et al., 2006), we hypothesized that SOX6 may compete with SOX10 for binding at myelin 
loci and inhibit myelination in Schwann cells. To test this hypothesis, we overexpressed GFP-
SOX6-ΔE9 in S16 cells. These cells were chosen because they express high levels of myelin 
genes such as Mbp and Mpz, and are thus a relevant model to test our hypothesis (Toda et al., 
1994) (Law et al., in review). Upon overexpressing GFP-SOX6-ΔE9 we expect to observe a 
decrease in expression of SOX10 target genes such as MBP and MPZ. After transfecting S16 
cells with GFP- SOX6-ΔE9, flow cytometry was performed to collect GFP-positive and GFP-
negative cells. We performed RNA-seq on both populations and identified differentially 
expressed genes 1,117 genes that were differentially expressed. Surprisingly, we did not observe 
a significant change in expression of myelin genes; expression of SOX10, EGR2, MBP, MPZ, 
and PMP22. We explored the relevance of these findings by performing luciferase assays to test 
the effect of overexpressing SOX6 on MBP promoter activity. Consistent with our RNA-seq 
data, we did not observe a significant change on promoter activity with increasing concentration 
of SOX6.  There are several caveats to our RNA-seq experiment. First, S16 cells are an 
immortalized cell line and may not be amenable to changing their cellular identity upon SOX6 
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overexpression. Knocking down SOX6 in primary Schwann cells and performing RNA-seq will 
complement our data. Second, SOX6 is known to heterodimerize with other members of the 
SOXD family (Lefebvre, 2010) and the factors required for repressing SOX10 target genes are 
not be expressed at high levels in S16 cells (Law et al., in review).  
 
Our RNA-seq experiments identified several putative SOX6 candidate target genes. Gene 
ontology analysis revealed several interesting direct or indirect targets of SOX6. Several GO 
terms important for Schwann cell development were enriched in our data set. This list contains 
genes such as SIRT2, MXRA8, DAG1, GFAP, NDRG1, GSN, SOD1, CD9, and LRP1 (Table 3.2). 
Sir-two-homolog 2 (SIRT2) is a NAD(+)-dependent deacetylase involved in myelination and 
remyelination after injury (Beirowski et al., 2011). Dystroglycan (DAG1) expression is reduced 
after injury during the axonal degeneration, however, it is upregulated at the onset of the 
regeneration process and interestingly there is evidence of SOX10 occupancy in rat sciatic nerve 
at this locus (Srinivasan et al., 2012). Dystroglacan interacts with laminin-2 to aid Schwann cells 
in wrapping around axons and facilitating remyelination (Masaki et al., 2000). Glial fibrillary 
acidic protein (GFAP) is a constituent of the cytoskeleton, which is upregulated during nerve 
damage and regeneration of Schwann cells post injury is impaired in GFAP-null mice. Schwann 
cell regeneration is delayed in GFAP-null mice and is due to reduced Schwann cell proliferation 
(Triolo et al., 2006). N-myc downstream-regulated gene 1 (NDRG1) plays a role in terminal 
differentiation of Schwann cells during the nerve regeneration process post injury and SOX10 
ChIP-seq data from rat sciatic nerve reveals SOX10 occupancy at NDRG1 (Hirata et al., 2004; 
Srinivasan et al., 2012). Gelsolin (GSN) recruits macrophages to the injury site to facilitates 
Schwann cell remyelination following nerve damage (Gonçalves et al., 2010). CD9 is a cell 
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surface glycoprotein which interacts with integrins to promoter Schwann cell migration in vitro 
(Anton et al., 1995). LDL receptor-related protein (LRP1) is predominantly expressed after 
Schwann cell injury and promotes Schwann cell migration to allow for regeneration (Mantuano 
et al., 2010). Recent data identified changes in H3K27ac enhancer marks post nerve injury using 
nerve crush injury in rats. Interestingly, these data reveal H3K27ac peaks at the SOX6 locus 
indicating that its expression may be induced post nerve injury (Hung et al., 2015). Our GO 
analysis indicates up regulation of genes involved in nerve regeneration post injury suggesting a 
role for SOX6 in Schwann cell dedifferentiation. Based on these findings we propose a model for 
putative role of SOX6 in the non-myelinating stages of Schwann cell development (Fig. 3.13). 
Schwann cells are in a proliferative state during the early stages of development and SOX10 may 
activate the expression of SOX6 to up-regulate expression of genes important for proliferation 
and migration. Negative regulators of myelination inhibit the expression of myelin genes at this 
stage (chapter 2). Once immature Schwann cells exit the cell cycle and become promyelinating, 
then EGR2 and microRNAs (miRs) inhibit the expression of SOX6 and SOX10 activates 
expression of myelin genes. Following nerve injury, SOX10 may activate the expression of 
SOX6, which then activates expression of genes that are important for dedifferentiation of 
Schwann cells. These genes facilitate Schwann cell regeneration by down regulating the 
myelination program, recruiting macrophages to the injury site, and then remyelinating the axons 
(Fig. 3.13).  
 
Table 3.4 and 3.5 show the top 10 significantly down- and up-regulated genes. Among these 
genes some of them have a known role in myelination. COUP transcription factor 1 (NR2F1) is 
the most significantly down-regulated gene. NR2F1 is a nuclear hormone receptor and a 
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transcription factor. Interestingly eight out of the top 10 down regulated genes have evidence for 
SOX10 binding in rat sciatic nerve (Srinivasan et al., 2012) these data suggest that SOX6 may 
inhibit the expression of SOX10 targets. The roles of the top 10 up regulated genes in Schwann 
cells are currently unknown. 
 
In summary, we identified a previously unreported SOX10-responsive promoter at the SOX6 
locus. Following nerve injury, Schwann cells undergo dedifferentiation followed by proliferation 
to mediate axonal regrowth. Our RNA-seq data indicates a putative role for SOX6 during 
development and activating genes involved in Schwann cell regeneration. Better understanding 
the regulatory mechanisms of SOX6 in Schwann cells will assist efforts toward developing 
therapeutics for nerve injury and other myelin-related diseases. 
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Figure 3.13. A model for the role of SOX6 during non-myelinating stages of Schwann cell 
development. During early stages of Schwann cell development, SOX10 activates the expression 
of SOX6, which activates expression of genes important for proliferation and migration (left 
panel). During activation of the myelination program (pro-myelination; middle panel), EGR2 
and micro RNAs (miRs) inhibit the expression of SOX6, which allows SOX10 (and EGR2) to 
positively regulate the expression of myelin genes. Following nerve trauma, SOX10 activates 
expression of SOX6 to up-regulate expression of genes critical for demyelination and 
remyelination of axons of the peripheral nerves. Adapted from Jessen and Mirsky, 2005. 
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GO biological process  
Homo 
sapiens 
Our 
List Expected P-value 
Localization  5501 263 159.99 1.42E-15 
Negative regulation of biological 
process 4937 239 143.59 5.58E-14 
Negative regulation of cellular 
process 4448 220 129.37 2.63E-13 
Response to stimulus 8033 335 233.64 6.90E-13 
Positive regulation of biological 
process  5607 255 163.08 5.90E-12 
Transport 4411 214 128.29 8.19E-12 
Regulation of cell differentiation 1681 110 48.89 1.20E-11 
Establishment of localization 4520 217 131.46 1.42E-11 
Regulation of cell death 1627 107 47.32 2.31E-11 
Developmental process 5511 249 160.29 3.97E-11 
Positive regulation of cellular process 4984 231 144.96 5.13E-11 
System development 4202 204 122.21 5.59E-11 
Anatomical structure development 5146 235 149.67 1.36E-10 
Regulation of apoptotic process  1495 99 43.48 2.04E-10 
Regulation of developmental process  2375 135 69.08 2.05E-10 
Regulation of programmed cell death  1510 99 43.92 3.73E-10 
Regulation of response to stimulus  4038 195 117.44 5.37E-10 
Multicellular organism development 4791 220 139.34 1.00E-09 
Response to organic substance  2782 148 80.91 1.55E-09 
Regulation of molecular function  3386 170 98.48 1.86E-09 
Regulation of localization 2605 141 75.77 1.95E-09 
Regulation of signal transduction 3076 158 89.46 3.06E-09 
Regulation of multicellular 
organismal process  2796 147 81.32 4.80E-09 
Negative regulation of cell death  945 71 27.49 5.48E-09 
Regulation of cell migration  724 60 21.06 7.87E-09 
Regulation of cell communication  3363 167 97.81 8.46E-09 
Regulation of cell proliferation 1594 99 46.36 9.04E-09 
Regulation of signaling 3413 168 99.27 1.46E-08 
Tissue development 1659 101 48.25 1.64E-08 
Secretion  1067 75 31.03 2.77E-08 
Negative regulation of apoptotic 
process  851 65 24.75 2.82E-08 
Cellular response to stimulus  6360 266 184.98 2.84E-08 
Response to chemical  4100 191 119.25 3.17E-08 
Regulation of biological process 11402 415 331.62 3.98E-08 
Regulation of cell motility  778 61 22.63 4.84E-08 
Negative regulation of programmed 
cell death 865 65 25.16 5.63E-08 
Regulation of locomotion 848 64 24.66 6.93E-08 
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Secretion by cell  961 69 27.95 8.90E-08 
Cellular process 15042 509 437.49 9.81E-08 
Biological regulation  12019 430 349.57 1.24E-07 
Biological process 17481 565 508.43 1.52E-07 
Regulation of biological quality 3557 169 103.45 2.21E-07 
Anatomical structure morphogenesis  2015 112 58.61 2.28E-07 
Regulation of cellular component 
movement  852 63 24.78 2.35E-07 
Negative regulation of multicellular 
organismal process 1053 72 30.63 2.70E-07 
Response to external stimulus 1870 106 54.39 2.86E-07 
Regulation of cellular process  10750 392 312.66 5.79E-07 
Leukocyte activation 881 63 25.62 8.96E-07 
Neutrophil degranulation  483 43 14.05 1.84E-06 
Cell communication  5414 228 157.46 2.01E-06 
Leukocyte degranulation 504 44 14.66 2.05E-06 
Neutrophil activation involved in 
immune response  485 43 14.11 2.08E-06 
Regulated exocytosis 686 53 19.95 2.17E-06 
Response to endogenous stimulus 1294 80 37.64 2.30E-06 
Response to organic cyclic 
compound 882 62 25.65 2.48E-06 
Animal organ development  2991 145 86.99 2.58E-06 
Myeloid leukocyte activation 567 47 16.49 2.60E-06 
Response to organonitrogen 
compound  884 62 25.71 2.71E-06 
Cell activation involved in immune 
response  612 49 17.8 3.35E-06 
Cellular response to chemical 
stimulus 2590 130 75.33 3.36E-06 
Neutrophil activation  493 43 14.34 3.39E-06 
Multicellular organismal process  6703 268 194.95 3.69E-06 
Myeloid cell activation involved in 
immune response  514 44 14.95 3.72E-06 
Cell activation 1027 68 29.87 3.80E-06 
Granulocyte activation  496 43 14.43 4.06E-06 
Neutrophil mediated immunity  497 43 14.46 4.31E-06 
Positive regulation of multicellular 
organismal process 1507 88 43.83 4.33E-06 
Regulation of cell adhesion 679 52 19.75 4.35E-06 
Myeloid leukocyte mediated 
immunity  517 44 15.04 4.44E-06 
Neurogenesis  1512 88 43.98 5.09E-06 
Exocytosis 770 56 22.4 5.79E-06 
Regulation of multicellular 1822 100 52.99 6.45E-06 
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organismal development  
Response to oxygen-containing 
compound 1446 85 42.06 6.57E-06 
Signal transduction  4932 210 143.45 6.72E-06 
Leukocyte activation involved in 
immune response  608 48 17.68 7.98E-06 
Negative regulation of signal 
transduction  1165 73 33.88 8.67E-06 
Negative regulation of response to 
stimulus  1456 85 42.35 9.07E-06 
Vesicle-mediated transport 1787 98 51.97 1.03E-05 
Signaling 5323 222 154.82 1.04E-05 
Response to hormone  784 56 22.8 1.09E-05 
Cellular developmental process  3599 164 104.68 1.16E-05 
Cardiovascular system development 496 42 14.43 1.28E-05 
Cell differentiation 3525 161 102.52 1.50E-05 
Blood vessel development  462 40 13.44 1.73E-05 
Response to nitrogen compound  997 65 29 1.74E-05 
Response to stress  3336 154 97.03 1.90E-05 
Vasculature development  486 41 14.14 2.24E-05 
Negative regulation of cell 
communication  1265 76 36.79 2.33E-05 
Negative regulation of signaling  1269 76 36.91 2.66E-05 
Regulation of catalytic activity  2511 123 73.03 4.83E-05 
Regulation of intracellular signal 
transduction  1793 96 52.15 5.15E-05 
Positive regulation of developmental 
process  1232 73 35.83 8.71E-05 
Anatomical structure formation 
involved in morphogenesis  837 56 24.34 1.04E-04 
Cell development 1493 83 43.42 1.30E-04 
Blood vessel morphogenesis  380 34 11.05 1.31E-04 
Generation of neurons  1418 80 41.24 1.31E-04 
Circulatory system development  807 54 23.47 1.91E-04 
Negative regulation of metabolic 
process 2790 130 81.15 3.07E-04 
Regulation of cellular protein 
metabolic process  2522 120 73.35 3.91E-04 
Positive regulation of cell 
communication 1612 86 46.88 4.24E-04 
Nervous system development  2230 109 64.86 4.95E-04 
Positive regulation of signaling  1619 86 47.09 5.12E-04 
Negative regulation of protein 
metabolic process  1120 66 32.57 5.80E-04 
Positive regulation of cell migration  425 35 12.36 5.92E-04 
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Negative regulation of cellular 
metabolic process 2514 119 73.12 5.97E-04 
Movement of cell or subcellular 
component 1471 80 42.78 6.08E-04 
Regulation of protein metabolic 
process  2768 128 80.51 6.20E-04 
Cellular response to organic 
substance 2139 105 62.21 7.44E-04 
Small molecule metabolic process 1817 93 52.85 7.45E-04 
Angiogenesis  295 28 8.58 7.61E-04 
Positive regulation of signal 
transduction 1481 80 43.07 8.02E-04 
Lipid metabolic process  1229 70 35.75 8.10E-04 
Regulation of neurogenesis  710 48 20.65 8.90E-04 
Locomotion 1216 69 35.37 1.16E-03 
Immune effector process  1028 61 29.9 1.50E-03 
Positive regulation of cell motility  443 35 12.88 1.56E-03 
Positive regulation of metabolic 
process 3278 144 95.34 1.65E-03 
Immune system process  2566 119 74.63 1.76E-03 
Regeneration  153 19 4.45 1.88E-03 
Negative regulation of nitrogen 
compound metabolic process  2347 111 68.26 1.92E-03 
Positive regulation of cellular 
metabolic process  3056 136 88.88 1.97E-03 
Organonitrogen compound metabolic 
process 5533 218 160.93 2.04E-03 
Regulation of nervous system 
development  801 51 23.3 2.13E-03 
Regulation of cell development  827 52 24.05 2.36E-03 
Regulation of phosphorus metabolic 
process 1735 88 50.46 2.58E-03 
Positive regulation of locomotion 475 36 13.82 2.76E-03 
Positive regulation of cellular 
component movement 455 35 13.23 2.88E-03 
Response to peptide hormone  375 31 10.91 3.08E-03 
Positive regulation of response to 
stimulus 2153 103 62.62 3.41E-03 
Regulation of phosphate metabolic 
process  1721 87 50.05 3.49E-03 
Positive regulation of cell 
differentiation 886 54 25.77 3.57E-03 
Aging 266 25 7.74 4.43E-03 
Cellular component organization 5306 209 154.32 4.47E-03 
Response to peptide 444 34 12.91 4.69E-03 
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Response to abiotic stimulus 1115 63 32.43 4.90E-03 
Negative regulation of cell 
proliferation 665 44 19.34 5.42E-03 
Biological adhesion  875 53 25.45 5.52E-03 
Negative regulation of intracellular 
signal transduction  491 36 14.28 5.93E-03 
Leukocyte mediated immunity 738 47 21.46 6.38E-03 
Intracellular signal transduction  1616 82 47 6.81E-03 
Negative regulation of developmental 
process 864 52 25.13 8.51E-03 
Response to inorganic substance  478 35 13.9 8.73E-03 
Negative regulation of cellular 
protein metabolic process  1061 60 30.86 9.03E-03 
Negative regulation of 
macromolecule metabolic process  2538 115 73.82 9.32E-03 
Cell adhesion 870 52 25.3 1.04E-02 
Positive regulation of cell 
proliferation  876 52 25.48 1.26E-02 
Regulation of cellular metabolic 
process  6179 234 179.71 1.35E-02 
Gliogenesis 193 20 5.61 1.44E-02 
Regulation of response to stress 1436 74 41.77 1.45E-02 
Regulation of metabolic process 6667 249 193.91 1.45E-02 
Regulation of muscle cell 
differentiation  176 19 5.12 1.46E-02 
Response to oxidative stress  364 29 10.59 1.50E-02 
Animal organ morphogenesis  882 52 25.65 1.54E-02 
Neuron projection development  624 41 18.15 1.56E-02 
Regulation of cellular response to 
growth factor stimulus 249 23 7.24 1.67E-02 
Regulation of sodium ion transport 85 13 2.47 1.68E-02 
Cell surface receptor signaling 
pathway  2289 105 66.57 1.77E-02 
Cellular lipid metabolic process 985 56 28.65 1.80E-02 
Negative regulation of cell 
differentiation 652 42 18.96 1.90E-02 
Positive regulation of intracellular 
signal transduction  940 54 27.34 2.05E-02 
Regulation of transforming growth 
factor beta receptor signaling 
pathway  101 14 2.94 2.11E-02 
Cell morphogenesis  632 41 18.38 2.12E-02 
Formation of primary germ layer 116 15 3.37 2.15E-02 
Glial cell development  87 13 2.53 2.16E-02 
Glial cell differentiation 148 17 4.3 2.27E-02 
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Epithelial cell development  182 19 5.29 2.35E-02 
Cellular component organization or 
biogenesis 5528 212 160.78 2.54E-02 
Organic acid metabolic process  997 56 29 2.57E-02 
Regulation of cellular response to 
transforming growth factor beta 
stimulus  103 14 3 2.64E-02 
Chemotaxis 503 35 14.63 2.66E-02 
Taxis 503 35 14.63 2.66E-02 
Cell migration 875 51 25.45 2.66E-02 
Regulation of protein 
phosphorylation  1356 70 39.44 2.68E-02 
Positive regulation of nitrogen 
compound metabolic process 2945 127 85.65 2.82E-02 
Positive regulation of macromolecule 
metabolic process 3034 130 88.24 2.89E-02 
Regulation of transport  1870 89 54.39 2.96E-02 
Oxoacid metabolic process  980 55 28.5 3.24E-02 
Cell proliferation 691 43 20.1 3.38E-02 
Neuron development  763 46 22.19 3.51E-02 
Negative regulation of phosphate 
metabolic process  577 38 16.78 3.54E-02 
Negative regulation of phosphorus 
metabolic process  578 38 16.81 3.68E-02 
Regulation of leukocyte migration  171 18 4.97 3.82E-02 
Negative regulation of catalytic 
activity 892 51 25.94 4.50E-02 
Cellular localization  2282 103 66.37 4.54E-02 
Regulation of phosphorylation  1484 74 43.16 4.58E-02 
Regulation of anatomical structure 
morphogenesis  968 54 28.15 4.72E-02 
Gland development  408 30 11.87 4.76E-02 
Negative regulation of molecular 
function 1172 62 34.09 4.88E-02 
Table 3.2. Gene ontology analysis of up-regulated genes. Overrepresentation analysis of up-
regulated genes (adj p-value<0.01) for biological process is shown. The numbers in the column 
labeled Homo sapiens, Our list, and Expected are all the genes within the human genome 
associated with the GO term, up-regulated genes from our DeSeq analysis associated with that 
term, and genes from our list expected by chance for that GO term, respectively.  
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GO biological process  
Homo 
sapiens 
Our 
List Expected P-value 
Developmental process  5511 162 97.43 3.14E-09 
Anatomical structure 
morphogenesis 2015 82 35.62 6.71E-09 
Response to organic substance  2782 100 49.18 1.77E-08 
Response to chemical 4100 129 72.48 4.03E-08 
Anatomical structure 
development 5146 149 90.98 2.07E-07 
Response to endoplasmic 
reticulum stress  247 24 4.37 2.96E-07 
Cellular response to organic 
substance 2139 81 37.82 3.53E-07 
Cellular protein metabolic 
process 3747 117 66.24 1.13E-06 
Multicellular organism 
development  4791 138 84.7 2.89E-06 
Response to stimulus 8033 201 142.01 3.60E-06 
Circulatory system 
development 807 42 14.27 6.00E-06 
Cell morphogenesis involved 
in differentiation  500 32 8.84 6.01E-06 
Cellular amino acid metabolic 
process  314 25 5.55 6.75E-06 
System development  4202 124 74.29 9.07E-06 
Cell morphogenesis 632 36 11.17 1.08E-05 
Organonitrogen compound 
metabolic process 5533 151 97.82 1.25E-05 
Macromolecule modification 3440 107 60.82 1.29E-05 
Biological process  17481 348 309.05 1.40E-05 
Cellular response to chemical 
stimulus 2590 87 45.79 2.23E-05 
Enzyme linked receptor 
protein signaling pathway  716 38 12.66 2.46E-05 
Protein metabolic process  4464 128 78.92 2.62E-05 
Animal organ development 2991 96 52.88 2.64E-05 
Cellular component 
morphogenesis 726 38 12.83 3.56E-05 
Renal system development 271 22 4.79 5.07E-05 
Cellular component 
organization  5306 144 93.8 6.11E-05 
Axon guidance 227 20 4.01 6.66E-05 
Nervous system development 2230 77 39.42 7.46E-05 
Neuron projection guidance 229 20 4.05 7.68E-05 
Urogenital system 305 23 5.39 8.78E-05 
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development 
Cellular protein modification 
process 3158 98 55.83 9.60E-05 
Protein modification process  3158 98 55.83 9.60E-05 
Neuron development  763 38 13.49 1.31E-04 
Cellular response to stimulus 6360 163 112.44 1.89E-04 
Cell morphogenesis involved 
in neuron differentiation  403 26 7.12 2.15E-04 
Axonogenesis  348 24 6.15 2.22E-04 
Axon development  378 25 6.68 2.51E-04 
Cellular component 
organization or biogenesis  5528 146 97.73 2.82E-04 
Cellular process  15042 311 265.93 3.01E-04 
Neuron projection 
development  624 33 11.03 3.12E-04 
Cell development 1493 57 26.39 3.55E-04 
Response to topologically 
incorrect protein 181 17 3.2 3.64E-04 
Kidney development  254 20 4.49 4.10E-04 
Response to unfolded protein 161 16 2.85 4.27E-04 
Heart development 477 28 8.43 4.36E-04 
Nitrogen compound metabolic 
process 8629 204 152.55 4.55E-04 
Neuron projection 
morphogenesis  454 27 8.03 5.88E-04 
Plasma membrane bounded 
cell projection morphogenesis  458 27 8.1 6.99E-04 
Locomotion  1216 49 21.5 7.38E-04 
Blood vessel development  462 27 8.17 8.30E-04 
Cell projection morphogenesis  462 27 8.17 8.30E-04 
Cellular macromolecule 
metabolic process  7017 173 124.05 8.58E-04 
Cardiovascular system 
development  496 28 8.77 9.61E-04 
IRE1-mediated unfolded 
protein response 58 10 1.03 1.10E-03 
Neuron differentiation  949 41 16.78 1.57E-03 
Primary metabolic process 9151 211 161.78 1.74E-03 
Endoplasmic reticulum 
unfolded protein response 115 13 2.03 1.85E-03 
Cell part morphogenesis 483 27 8.54 1.97E-03 
Regulation of developmental 
process 2375 76 41.99 2.14E-03 
Vasculature development 486 27 8.59 2.22E-03 
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Transmembrane receptor 
protein tyrosine kinase 
signaling pathway  519 28 9.18 2.37E-03 
Cellular metabolic process 9022 208 159.5 2.53E-03 
Macromolecule metabolic 
process 7766 185 137.29 2.65E-03 
Cellular response to 
topologically incorrect protein 140 14 2.48 2.73E-03 
Regulation of cellular protein 
metabolic process  2522 79 44.59 2.75E-03 
Movement of cell or 
subcellular component  1471 54 26.01 2.91E-03 
Head development 726 34 12.83 3.18E-03 
Negative regulation of cellular 
process 4448 120 78.64 3.44E-03 
Cellular response to unfolded 
protein  122 13 2.16 3.57E-03 
Organic substance metabolic 
process  9511 216 168.14 3.74E-03 
Regulation of protein 
metabolic process  2768 84 48.94 3.95E-03 
Chemotaxis 503 27 8.89 4.28E-03 
Taxis 503 27 8.89 4.28E-03 
Plasma membrane bounded 
cell projection organization  1039 42 18.37 6.23E-03 
Localization  5501 140 97.25 6.68E-03 
Cellular response to stress  1602 56 28.32 7.96E-03 
Regulation of GTPase activity  722 33 12.76 8.07E-03 
Brain development  688 32 12.16 8.24E-03 
ER to Golgi vesicle-mediated 
transport  178 15 3.15 8.66E-03 
Negative regulation of 
biological process  4937 128 87.28 1.03E-02 
Regulation of hydrolase 
activity  1413 51 24.98 1.05E-02 
Response to endogenous 
stimulus  1294 48 22.88 1.07E-02 
Cell projection organization  1066 42 18.85 1.19E-02 
Cellular response to 
endogenous stimulus  1067 42 18.86 1.22E-02 
Response to growth factor  501 26 8.86 1.29E-02 
Regulation of cellular 
metabolic process  6179 152 109.24 1.29E-02 
Multicellular organismal 
process  6703 162 118.5 1.31E-02 
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Regulation of cell 
communication  3363 95 59.45 1.37E-02 
Protein localization 1927 63 34.07 1.42E-02 
Cellular response to growth 
factor stimulus  472 25 8.34 1.45E-02 
Cell-substrate adhesion  164 14 2.9 1.71E-02 
Response to stress  3336 94 58.98 1.78E-02 
Positive regulation of 
hydrolase activity 976 39 17.25 2.10E-02 
Nephron development  122 12 2.16 2.24E-02 
Glycoprotein metabolic 
process 391 22 6.91 2.38E-02 
Regulation of macromolecule 
metabolic process 6139 150 108.53 2.44E-02 
Metabolic process  9949 220 175.89 2.54E-02 
Regulation of metabolic 
process  6667 160 117.87 2.57E-02 
Regulation of signaling  3413 95 60.34 2.60E-02 
Cellular protein localization  1338 48 23.65 2.64E-02 
Vesicle coating 65 9 1.15 2.76E-02 
Nitrogen compound transport  1671 56 29.54 2.85E-02 
tRNA aminoacylation for 
protein translation  49 8 0.87 2.98E-02 
Tube development  560 27 9.9 3.13E-02 
cellular macromolecule 
localization (GO:0070727) 1348 48 23.83 3.23E-02 
Macromolecule localization  2239 69 39.58 3.24E-02 
Positive regulation of GTPase 
activity  666 30 11.77 3.41E-02 
Vesicle targeting, to, from or 
within Golgi  68 9 1.2 3.96E-02 
Regulation of biological 
process  11402 244 201.58 4.51E-02 
tRNA aminoacylation  52 8 0.92 4.58E-02 
Branched-chain amino acid 
metabolic process  24 6 0.42 4.71E-02 
Cardiac chamber development 155 13 2.74 4.78E-02 
Table 3.3. Gene ontology analysis of down-regulated genes. Overrepresentation analysis of 
down-regulated genes (adj p-value<0.01) for biological process with GO ids (in parenthesis) is 
shown. The numbers in the column labeled Homo sapiens, Our list, and Expected are all the 
genes within the human genome associated with the GO term, down-regulated genes from our 
DeSeq analysis associated with that term, and genes from our list expected by chance for that 
GO term, respectively.  
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Table 3.4 Top 10 genes significantly down-regulated upon SOX6 overexpression in S16 cells.  
log2fold change is calculated relative to GFP negative cells and a negative values correspond to 
lower expression in GFP positive cells. Adjusted (adj) P-value calculated by DeSeq using 
Benjamini-Hochberg method for multiple testing. The last column indicates the rn5 co-ordinates 
for SOX10 ChIP-seq peak in rat sciatic nerve (Srinivasan et al., 2012) 
 
 
 
 
 
 
Gene Name log2FoldChange adj P-value 
SOX10 ChIP-seq peak 
(-/+) 10Kb 
COUP transcription 
factor 1 (Nr2f1) -0.643495256 1.50E-17 
chr2:5,547,324-
5,547,758 
Transcription factor AP-
2-beta (Tfap2b) -0.59948108 2.06E-14 - 
Potassium voltage-gated 
channel subfamily D 
member 3 (Kcnd3) -0.677286517 1.53E-11 
chr2:227,554,246-
227,554,782 
WW domain-containing 
protein 2 (Wwc2) -0.402951757 3.36E-10 
chr16:47,091,452-
47,092,740 
ETS translocation variant 
6 (Etv6) -0.577489698 8.94E-10 
chr4:230,430,522-
230,431,508 
Chromodomain-helicase-
DNA-binding protein 6 
(Chd6) -0.549825307 9.41E-10 
chr3:163,324,522-
163,325,039 
Cysteine-rich angiogenic 
inducer 61 (Cyr61) -0.516195683 1.03E-09 
chr2:270,058,231-
270,058,627 
CUGBP Elav-like family 
member 2 (Celf2) -0.563180159 1.37E-09 
chr17:76,894,056-
76,894,589 
Regulatory factor X 5 
(Rfx5) -0.447530029 1.68E-09 - 
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Gene Name log2FoldChange adj P-value 
SOX10 ChIP-seq 
peak (-/+) 10Kb 
Lysyl Oxidase Like 4 
(Loxl4) 1.944365168 1.53E-56 - 
Glutathione S-transferase 
P(Gstp1) 1.437891421 1.50E-52 
chr1:226,164,673-
226,165,173 
Wnt7a 2.425242064 1.19E-51 - 
Interleukin-23 subunit 
alpha(Il23a) 1.814388837 3.07E-51 - 
Rearrange during 
transfection (Ret) 2.287918881 6.80E-43 
chr4:216,155,302-
216,155,832 
Cysteine-rich secretory 
protein LCCL domain-
containing 2 (Crispld2) 2.273841049 1.26E-40 - 
Slit homolog 1 protein 
(Slit1) 1.586861198 2.82E-40 - 
Rab-like protein 2A 
(Rabl2a) 1.426088347 1.18E-37 - 
Dual specificity protein 
phosphatase 1 (Dusp1) 1.139397765 8.11E-35 - 
Keratin, type II cytoskeletal 
7 (Krt7) 2.097125454 8.11E-35 - 
Table 3.5 Top 10 genes significantly up-regulated upon SOX6 overexpression in S16 cells.  
log2fold change is calculated relative to GFP negative cells and a positive values correspond to 
higher expression in GFP positive cells. Adjusted (adj) P-value calculated by DeSeq2 using 
Benjamini-Hochberg method for multiple testing. The last column indicates the rn5 co-ordinates 
for SOX10 ChIP-seq peak in rat sciatic nerve (Srinivasan et al., 2012) 
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Chapter 4 
Conclusions and Future Directions 
4.1 Summary 
Compact myelin is a lipid rich layer formed by wrapping of glial cells around the axons of all 
jawed vertebrates. Schwann cells and oligodendrocytes myelinate axonal segments in the 
peripheral and the central nervous systems, respectively. The presence of myelin was first 
observed in ancient gnathostomes (jawed vertebrates), the placoderms (Zalc et al., 2008).  
Interestingly, neural crest cells are unique to vertebrates and differentiate into diverse cell types 
including Schwann cells and craniofacial structures such as the jaws (Sauka-Spengler and 
Bronner-Fraser, 2008) and co-evolution of myelin and jaws has been speculated (Zalc et al., 
2008). Myelination results in faster responses to stimulus due to increased propagation of action 
potentials and has significantly contributed to the rapid predatory and escape behaviors in jawed 
vertebrates (Sauka-Spengler and Bronner-Fraser, 2008; Schweigreiter et al., 2006; Zalc, 2016). 
During early vertebrate evolution, the lamprey lineage (jawless vertebrates) split from the other 
vertebrates before the emergence of hinged jaws. Lampreys express migratory neural crest cells 
and Schwann cells wrap their axons but they do not form compact myelin (Gelman et al., 2009; 
Medeiros, 2013). Interestingly, sequencing data from the lamprey genome identified the presence 
of various myelin proteins (Smith et al., 2013). 
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The SOXE family of transcription factors comprising SOX8, SOX9, and SOX10 are important 
for neural crest development and specification and interestingly, lampreys express three paralogs 
of SoxE genes (SoxE1, SoxE2, and SoxE3) (McCauley and Bronner-Fraser, 2006). However, 
only SoxE3 shares sequence homology with vertebrate SOX9 and there is little sequence 
similarity between the other two SOXE paralogs and SOX8 and SOX10 (McCauley and Bronner-
Fraser, 2006). Neofunctionalization of the SOXE proteins and appearances of cis-acting 
regulatory sequences may have contributed to the expression of myelin genes important for 
formation of compact myelin in jawed vertebrates. In this thesis, I have explored the gene 
regulatory network that controls formation of compact myelin in vertebrates. 
 
Schwann cells arise from trunk neural crest cells and myelinate motor and sensory axons of the 
peripheral nervous system. The formation of myelin around axons is a multistep process in 
which the neural crest cells differentiate to form Schwann cell precursors. These cells transition 
into an immature Schwann cell stage before becoming either myelinating or non-myelinating 
Schwann cells. Schwann cells that are associated with single large axons form a layer of compact 
myelin (Jessen and Mirsky, 2005). The importance of Schwann cells is underscored by their 
involvement in demyelinating diseases and identifying regulatory pathways governing 
development and function of Schwann cells will aid in a better understanding of pathology of 
these diseases (Svaren and Meijer, 2008). Positive and negative transcriptional regulators 
complement each other to ensure that formation of compact myelin occurs in a timely manner. 
Misregulation of these pathways can lead to hypomyelination (Svaren and Meijer, 2008) or 
hypermyelination (Noseda et al., 2013; Triolo et al., 2012) and are associated with the pathology 
of demyelinating diseases.  
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The SRY-related HMG box 10 (SOX10) is a transcription factor critical for Schwann cell 
development, function, and maintenance. SOX10 expression starts as the neural crest cells start 
migrating and continues to be expressed through the entirety of the Schwann cell lineage 
(Bremer et al., 2011; Kuhlbrodt et al., 1998). So far, SOX10 is known to direct a promyelinating 
cascade in Schwann cells by activating expression of genes important for myelin formation 
(Svaren and Meijer, 2008). Importantly, human mutations in SOX10 and SOX10 target genes 
have been implicated in demyelinating peripheral neuropathies (Inoue et al., 2004; Kulshrestha et 
al., 2017; Roa et al., 1996; Warner et al., 1998; Weterman et al., 2010). The main focus of my 
dissertation is to expand our current knowledge about the role of SOX10 in peripheral nerve 
myelination by identifying novel SOX10 target genes, which will help dissect the regulatory 
network controlled by SOX10 in Schwann cells.  
 
Previously, a number of direct SOX10 response elements were identified on a gene-by-gene 
basis. However, genome-wide approaches were needed to discover additional SOX10 gene 
targets in a less-biased and a high-throughput manner. Moreover, these studies would also 
facilitate identification of novel genes with no known role in myelination and studying the 
function of these novel genes in myelination will vastly improve our understanding of gene 
regulatory networks important for Schwann cell biology.  
 
In chapter 2, I presented a computational pipeline using sequence conservation to identify 
putative SOX10 consensus sequences in the human genome. We used this approach for two 
reasons: (i) if non-coding regions are conserved among diverse species, then they could harbor 
important biological function. This technique has been successfully implemented to identify 
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functional regulatory elements (Antonellis et al., 2008; Hardison et al., 1997); and (ii) SOX10 
binding sites conserved in human, mouse, and chicken have been identified and functionally 
validated (Antonellis et al., 2008; Gokey et al., 2012; Hodonsky et al., 2012). SOX10 binds to 
well-characterized consensus sequences (‘ACACA’, ‘ACAAG’,‘ACAAA’, or ‘ACAAT’) as a 
monomer or as a dimer when two consensus sequences are oriented in a head-to-head manner 
(Peirano and Wegner, 2000; Srinivasan et al., 2012). To identify conserved SOX10 consensus 
sequences we generated two datasets: (i) we compared the genomes of human, mouse, and 
chicken, and identified over two million conserved regions that are five base pairs or longer; and 
(ii) we identified all SOX10 consensus sequences in the human genome (33 million monomeric 
and ~549,000 dimeric consensus sequences). To prioritize elements for functional validation and 
to identify candidate genes, we focused on conserved dimeric SOX10 consensus sequences that 
resided within the gene body (intronic) or proximal promoter elements, and this revealed 238 
elements within 160 genes. The full panel of genes regulated by SOX10 at every developmental 
stage of myelination is not completely understood so we further prioritized by selecting loci with 
a known or predicted role in myelination and we identified 57 genomic elements for functional 
studies. We cloned the genomic regions surrounding the SOX10 consensus sequence for each 
element upstream of a minimal promoter driving luciferase reporter gene expression (Antonellis 
et al., 2008) and performed luciferase assays using cultured rat Schwann (S16) cells, which 
express endogenous SOX10 (Hodonsky et al., 2012). Seven out of 57 regions displayed greater 
than 2.5-fold increase in luciferase activity compared to an empty vector, which does not contain 
a genomic insert. Surprisingly, only ~12% of the regions we tested were active in vitro in 
Schwann cells and there could be multiple possibilities for this result. There are inherent 
drawbacks to using luciferase assays to test enhancer activity, which could contribute to a limited 
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set of regions being active. Although the regions we amplified and cloned were chosen based on 
general conservation, we may need to clone longer fragments for some of the regions to show 
greater enhancer activity and some genomic elements we tested may harbor sequences, which 
allow binding of a repressor, that could neutralize the effect of SOX10 thus resulting in low 
luciferase activity. Alternatively, SOX10 could be repressing the luciferase activity of some of 
the regions (Cruz-Solis et al., 2009). Another possibility could be the GC content of the 
intervening sequence within a dimeric SOX10 site.  When we compared the GC content of the 
intervening sequence of an active and an inactive dimeric site, we found high GC content 
correlated with high luciferase activity and these data are consistent with previous active dimeric 
SOX10 response elements (Antonellis et al., 2008; Brewer et al., 2014; Gokey et al., 2012; 
Hodonsky et al., 2012; Peirano et al., 2000). Therefore, the GC content of the intervening 
sequence can be used as a criterion for future predictions of dimeric SOX10 sites.  
 
Our computational strategy combined with functional validation revealed SOX10-responsive 
intronic enhancers at SOX5, SOX6, and NFIB. To further utilize our computational predictions 
we compared our conserved SOX10 consensus sequences to (i) SOX10 ChIP-seq data generated 
from sciatic nerve (Srinivasan et al., 2012), which became available to us as we were developing 
our computational pipeline; and (ii) we generated genome-wide chromatin accessibility by 
identifying DNase hypersensitive sites using cultured rat Schwann cells (S16 cells). This analysis 
revealed 214 genomic segments that reside within 191 loci. We performed gene ontology on 
these loci and interestingly three out of the top 10 biological processes were related to negative 
regulation of glial cells. Upon further functional validation, our data indicate that SOX10 
regulates the expression of NOTCH1, HMGA2, HES1, MYCN, ID2, ID4, SOX5, and SOX6. 
	  138	  	  
These data revealed a surprising role for SOX10 where it activates negative regulators of 
myelination and based on our data we proposed a model for SOX10 in maintaining a 
premyelinating state (Gopinath et al., 2016).  
 
There are caveats to identifying SOX10 response elements based on sequence analysis alone and    
genome-wide approaches such as ChIP-seq have identified putative SOX10 targets in a 
developmental stage specific manner (Srinivasan et al., 2012).  The work I have presented 
indicates that the best way to identify functional SOX10 elements is by combining these diverse 
data sets. This increased robustness and has led us to identify bona fide SOX10 targets. The 
comparative genomic datasets we developed will be beneficial to the scientific community.  The 
genomic segments conserved in human, mouse, and chicken can be used to identify putative 
consensus sequences for other transcription factors important for other cell types. Investigators 
can also use these data to identify SOX10 target genes in other SOX10-positive cells types such 
as oligodendrocytes, melanocytes, and enteric nervous system neurons.  
 
In chapter 3, we validated that the SOX10-responsive intronic enhancer at the SOX6 locus 
resides at an alternative promoter (Gopinath et al., 2016). SOX10 is known to regulate other loci 
via alternative promoters suggesting that the alternative protein products may be important for 
Schwann cell function (Brewer et al., 2014; Fogarty et al., 2016; Hodonsky et al., 2012). 
Interestingly, SOX6 mRNA undergoes alternative splicing and produces isoforms with (SOX6-
FL) and without exon 9 (SOX6-ΔE9), and this exon is conserved only in mammals. To 
understand the role of both these isoforms in Schwann cells, we cloned SOX6-FL and SOX6- 
ΔE9 into a plasmid that contains an N-terminal GFP tag. We overexpressed both these isoforms 
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in HeLa cells to detect the expression of the fusion protein. HeLa cells were chosen as they have 
high transfection efficiency.  Our in vitro data indicate that GFP-tagged SOX6-ΔE9 displays 
better transfection efficiency and we chose this isoform for follow-up functional studies and both 
isoforms are known to display similar transcriptional activities (Lefebvre et al., 1998). 
 
The function of SOX6 has not yet been studied in Schwann cells; however, SOX6 was reported 
to inhibit myelination in oligodendrocytes. The SOX family of transcription factors bind similar 
consensus motifs (Prior and Walter, 1996) and these data suggest a scenario where SOX6 may 
bind SOX motifs at the myelin loci prior myelination to inhibit their expression and at the onset 
of myelination SOX6 gets displaced from these motifs allowing SOX10 to bind and activate 
these genes. The counter acting SOX proteins would ensure timely activation of myelination.  
Our original hypothesis was that SOX6 inhibits expression of myelin genes by competing with 
SOX10 and to further explore its role in Schwann cells and identify a broader panel of genes 
regulated by SOX6 in Schwann cells we performed RNA sequencing.  
 
S16 cells express high levels of SOX10 and other myelin genes such as MBP and MPZ (Toda et 
al., 1994)(Law et al., in review). We overexpressed GFP-SOX6-ΔE9 in S16 cells to identify 
potential SOX6 target genes; we chose this isoform because it is more robustly expressed 
compared to SOX6-FL and both isoforms are known to display similar transcriptional activities 
(Lefebvre et al., 1998). After transfecting the S16 cells with GFP-SOX6-ΔE9, flow cytometry 
was performed to collect GFP-positive and GFP-negative cell populations, and RNA was 
isolated from three independent experiments. Libraries were prepared from these samples and 
sequenced to identify differentially regulated transcripts.  
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Interestingly, our RNA-seq data revealed no change in MBP expression upon SOX6 
overexpression and we performed luciferase assays to test if overexpressing SOX6 would cause 
reduced regulatory activity of the MBP promoter. We also did not observe significant changes in 
expression of other SOX10-target genes known to be important for myelination such as SOX10, 
EGR2, OCT6, MPZ, GJB1. These data suggest that SOX6 does not directly or indirectly inhibit 
the expression of myelin genes in S16 cells. Some potential pitfalls of our approach are that, 
while S16 cells express high levels of Sox10, Egr2, Mpz, Mbp (Law et al., in review), it is an 
immortalized cell line and may not accurately represent Schwann cells in vivo. Additionally, S16 
cells do not have axonal contact and may have lost their ability to revert to an immature stage. 
Interestingly, our gene ontology enrichment analysis provided insights into putative roles for 
SOX6 in Schwann cells. Specifically, our data indicate that SOX6 may up-regulate the 
expression of genes known to play critical role in Schwann cell proliferation, migration and 
regeneration such as SIRT2, MXRA8, DAG1, GFAP, NDRG1, SOD1, CD9, and LRP1.  
 
4.2 Future Directions 
While my dissertation has greatly improved our understanding of Schwann cell biology by 
revealing a novel role for SOX10 in maintaining Schwann cells in a premyelinating state and 
identifying SOX6 as a putative regulator during the non-myelinating stages of Schwann cell 
development, there are many questions that need to be addressed. 
 
4.2.1 Better defining the SOX10 consensus sequences 
During my thesis research, we developed a computational approach to identity conserved SOX10 
consensus sequences and we tested the regulatory activity of a subset of prioritized elements 
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using luciferase reporter assays. Although each element harbored a highly conserved dimeric 
SOX10 site, only ~12% of the regions were active in cultured Schwann cells. A lot of factors 
could be contributing to this result and one possibility could be the intervening sequence within 
the dimeric site. We observed that the GC content of the intervening sequence of an active 
dimeric SOX10 site was high (~60%) compared to the inactive sites. This is consistent with an 
analysis that was performed on ~400 ChIP-seq data generated for 119 transcription factors, 
which revealed that the majority transcription factors bind GC-rich sequences (Wang et al., 
2012). To test the necessity of high GC content of the intervening sequence, it would be worth 
introducing the intervening sequence from an active site to an inactive site and vice versa and 
performing luciferase reporter assays. If high GC content indeed plays a role in determining the 
activity of the SOX10 site then we would observe an increase in the luciferase activity when we 
increase the GC content of a previously inactive site. This will improve our understanding of the 
requirements of a dimeric SOX10 site.  
 
4.2.2 The role of SOX10 in peripheral nerve injury  
Schwann cells display remarkable plasticity and following nerve injury they dedifferentiate into 
a state that closely resembles the immature Schwann cell state (Quintes and Brinkmann, 2017). 
Schwann cells promote repair by: (i) downregulating the myelination program; (ii) upregulating 
negative inhibitors of myelination; (iii) recruiting macrophages to the injury site; and (iv) 
clearing myelin debris and regenerating tracks for axonal regrowth followed by remyelination 
(Jessen and Mirsky, 2016). The transcription factors c-jun and SOX2 are known to reprogram 
Schwann cells and facilitate repair post injury (Arthur-Farraj et al., 2012; Roberts et al., 2017b). 
SOX10 expression is unchanged following nerve injury (Arthur-Farraj et al., 2012). The 
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transcriptional program driving the dedifferentiation process is not fully characterized and the 
role of SOX10 in regulating genes post nerve injury has not yet been explored. Interestingly, 
NOTCH1, one of the genes we identified as SOX10 target, is important for Schwann cell 
demyelination after injury (Gopinath et al., 2016; Jessen and Mirsky, 2016).  In the data set 
generated in chapter 2, we found evidence for SOX10 binding and the presence of conserved 
SOX10 consensus sequences at additional loci known to be important for Schwann cell 
regeneration following injury: Ets1, Megf10, Ataxin10 (Atxn10), and SOX2-OT. ETS1 is a 
transcription factor induced following Schwann cell injury and is important for Schwann cell 
survival (Hung et al., 2015; Parkinson et al., 2002). Megf10 is up regulated during injury and is 
involved in phagocytosis of myelin debris to facilitate repair (Brosius Lutz et al., 2017). Atxn1 is 
up regulated in rat sciatic nerve after injury and may be involved in Schwann cell proliferation 
(Cheng et al., 2013). SOX2-OT is a multi-exon long non-coding (lnc) RNA which contains the 
SOX2 gene within one intron and SOX2-OT expression is up regulated in response to Schwann 
cell injury (Arthur-Farraj et al., 2017). These data suggest a role for SOX10 in activating the 
expression of these genes post nerve injury. Knockout Sox10 in vitro in S16 cells and test for 
reduced expression of Ets1, Megf10, Ataxin10 (Atxn10), and SOX2-OT. Luciferase assays can be 
performed by cloning the genomic segments containing the conserved SOX10 consensus 
sequence upstream of a luciferase reporter gene and test for their regulatory activity in Schwann 
cells. Delete each SOX10 binding site and test for a decrease in enhancer activity in cultured 
Schwann cells using luciferase assays. These studies will lead to the identification of a novel role 
for SOX10 in nerve regeneration following injury. 
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4.2.3 Identifying target genes of transcription factors that inhibit myelination  
In addition to SOX6 we identified other transcription factors such as SOX5, SOX6, NOTCH1, 
HMGA2, HES1, MYCN, ID4, and ID2 and identifying their gene targets will provide a 
comprehensive list of factors that control each stage of Schwann cell development. Interestingly 
SOX5 competes with SOX10 to inhibit melanocyte differentiation and melanocytes are neural 
crest derived cells (Stolt et al., 2008). SOX5 is expressed in migratory neural crest cells (Perez-
Alcala et al., 2004) and continues to be expressed during the early stages of melanocyte 
development (Stolt et al., 2008). SOX5 binds to SOX10 response elements at the MITF and DCT 
promoters and recruits co-repressor CtBP2 to inhibit their activity. MITF and DCT are both 
important for differentiation of melanocytes (Stolt et al., 2008). SOX5 is also known inhibit 
myelination in the central nervous system (Stolt et al., 2006) and SOX5 may act in a similar 
manner in Schwann cells. Our qRT-PCR data indicates that SOX5 is developmentally regulated 
in Schwann cells. To identify SOX5 target loci, SOX5 can be knocked out in primary Schwann 
cells and RNA-seq can be performed. Performing SOX5 ChIP-seq using a developing sciatic 
nerve will complement these studies. We expect SOX5 to inhibit myelination by inhibiting 
expression of SOX10 target genes such as EGR2, MBP and MPZ. 
  
4.2.4 The role of SOX6 in Schwann cells  
Negative regulators of myelination are up regulated post nerve injury and facilitate 
dedifferentiation of Schwann cells (Jessen and Mirsky, 2016). Based on our RNA-seq data 
SOX6 could be involved in the dedifferentiation process. A recent study identified global 
changes in H3K27ac enhancer marks post nerve injury and there are two H3K27ac peaks in 
intron 9 of Sox6 suggesting that expression may be induced post injury (Hung et al., 2015). To 
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directly test if SOX6 is up regulated following nerve injury, we could perform qRT-PCR using a 
cDNA library prepared from RNA isolated from sham and injured rodent sciatic nerve. We 
would expect increased Sox6 expression upon injury. Additionally, we could specifically test if 
SOX10-regulated SOX6 transcript containing exon 1G is up regulated post injury. These data 
may suggest that SOX10 activates the expression of SOX6 following never damage.  
 
If indeed we observe up regulation of SOX6 expression post nerve injury then we can identify 
genome-wide occupancy of SOX6, performing SOX6 ChIP-seq using injured sciatic nerve from 
a rodent model. These data would complement our RNA-seq data and will allow identification of 
direct SOX6 target genes.  
 
Homozygous Sox6 null mice are born alive but die within hours after birth and heterozygous 
mice were identical to their wild-type littermates (Smits et al., 2001). Deleting Sox6 specifically 
in oligodendrocytes causes premature expression of Mbp (Stolt et al., 2006). Terminal 
differentiation of oligodendrocyte precursor cells starts at the end of embryogenesis in mice 
(E18.5), however Sox6-/- mice undergo premature differentiation of OLs (E15.5) (Stolt et al., 
2006). Our data suggest that SOX10 regulates SOX6 transcript containing exon 1G and the 
alternative promoter contains a highly conserved SOX10 binding site (chapter 3). To further 
characterize the role of SOX6 in Schwann cells and to test the importance of the SOX10-
regulated SOX6 transcript, it would be interesting to knock out the Sox6 transcript containing 
exon 1G in mice using CRISPR-Cas9 approaches. Guide RNAs can be designed to target the 
conserved SOX10 binding site. Based on our in vitro data deleting SOX10-regulated Sox6 
transcript may cause defects in Schwann cells and other SOX10-positive cells such as 
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melanocytes and oligodendrocytes. If we don't observe any defects, it could be due to SOX5 
compensating for the loss of SOX6. SOX5 can effectively compensate for the loss of SOX6 in 
chondrocytes (Liu and Lefebvre, 2015; Smits et al., 2001). 
 
A conditional Sox6 mouse model can be generated which harbors lox P sites flanking exon 1G 
(Sox6 exon1Gfl/fl). This mouse model can be crossed to various Cre lines to specifically delete 
Sox6 in a temporal manner during Schwann cells development. Crossing Sox6 exon1Gfl/fl with 
Dhh::Cre, will specifically delete Sox6 exon1G transcript in the Schwann cell precursor stage. 
Cre recombinase under the control of Dhh regulatory element will express around E12.5 in mice 
(Jaegle et al., 2003). If SOX6 is a negative regulator of Schwann cell myelination then 
specifically deleting its expression in Schwann cell precursors would result in precocious 
myelination and we would observe ectopic expression of Mbp. If these mutant mice develop 
normally and we do not observe any phenotype during development then these mutant mice can 
also be used to test the importance of SOX6 post nerve injury. Nerve crush injuries can be 
performed in wild type and mutant mice and regeneration defects might be observed in Sox6 
mutant mice.  
 
To study the role of SOX6 during neural crest development Sox6 exon1Gfl/fl can be crossed with 
SOX10-MCS4 Cre (S4F Cre) (Stine et al., 2009). SOX10-MCS4 is a distal enhancer ~28kb 
upstream of SOX10 and is known to direct reporter gene expression in neural crest cells in 
zebrafish and mice (Antonellis et al., 2008). Using these mutant mice we can ask several exciting 
questions such as: is SOX6 important for neural crest specification, does it play a role in 
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migration of neural crest cells, how does loss of SOX6 in neural crest cells affect Schwann cell 
development? 
SOX10 expression starts in the premigratory neural crest cells and persists throughout the life of 
Schwann cells, which would suggest expression of SOX6 in all stages of Schwann cell 
development. Our data indicate that SOX6 expression reduces as myelination occurs (Gopinath et 
al., 2016). Therefore, it is necessary to identify the mechanism by which SOX6 is repressed to 
allow myelination to occur. In the CNS, SOX6 mRNA is targeted for degradation by microRNAs 
(including miR-338-3p) to allow oligodendrocyte differentiation.  Interestingly SOX10 in known 
to regulate the expression of miR-338-3p in Schwann cells (Gokey et al., 2012). miR-338-3p 
plays an important role in Schwann cells (Dugas and Notterpek, 2011; Yun et al., 2010) and 
could be repressing SOX6 expression for Schwann cell myelination. Clone the 3’UTR of SOX6 
downstream of a luciferase reporter mRNA, into S16 cells and test for reduced luciferase 
activity. Delete the miR-338-3p site from the 3’UTR of SOX6 and perform luciferase assays to 
test for increased activity.  
 
4.2.5 ZEB2 regulation by SOX10 
Recently, the transcription factor zinc finger E-box-binding homeo-box 2 (ZEB2) has been 
implicated in inhibiting the expression of myelin inhibitors during Schwann cell development 
and remyelination post injury. It has been called the ‘inhibitor of inhibitors’ and could be the 
switch that controls the transition from premyelination to myelination. ZEB2 is highly expressed 
prior to myelination and is re-expressed following nerve injury (Quintes et al., 2016; Wu et al., 
2016). However, the transcriptional regulation of ZEB2 expression in Schwann cells had not 
been studied. In chapter 2 we tested the regulatory activity of five regions within the ZEB2 locus 
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(SOX10-CCS-2,3,4,5,6, and 7) and none of the regions displayed greater than 2.5-fold activity 
and none of these regions showed evidence of SOX10 occupancy in sciatic nerve (Srinivasan et 
al., 2012). However, the regions we identified by comparing our computational predictions with 
SOX10 ChIP-seq (Srinivasan et al., 2012) and our DNase-seq revealed evidence for SOX10 
binding and conserved SOX10 site at the ZEB2 locus, suggesting that SOX10 may control the 
expression of ZEB2 during Schwann cell myelination. The genomic fragment harboring the 
conserved SOX10 site can be cloned upstream of a luciferase reporter gene and tested for 
enhancer activity in Schwann cells and the importance of the SOX10 site for the activity can be 
assessed by deleting the SOX10 site and performing luciferase assays. We would expect the 
region to be active in Schwann cells and the activity to be primarily driven by SOX10. qRT-PCR 
can be performed to test for decreased ZEB2 expression upon SOX10 knockdown in Schwann 
cells. RNA-seq data generated from oligodendrocytes at various developmental stages (Zhang et 
al., 2014) indicates that Zeb2 is highly expressed in newly forming oligodendrocytes and these 
consistent with observations made during Schwann cell development (Quintes et al., 2016). To 
identify target loci RNA-seq can be performed using sciatic nerve from mice with specific 
deletion of Zeb2 in Schwann cells. We would expect increased expression of myelin inhibitors. 
To identify genome-wide occupancy of ZEB2, ChIP-seq can be performed using primary 
Schwann cells. We would expect ZEB2 binding at inhibitors of myelination.  
 
4.3 Concluding Remarks 
Previously, SOX10 response elements were identified on a gene-by gene basis. Interestingly, our 
in-depth computational and functional analysis—in addition to recent ChIP-seq data sets 
published by our collaborator Dr. John Svaren—has revealed a novel role for SOX10 in 
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Schwann cells. We hope that the genome-wide data sets we have generated will be useful to the 
scientific community to uncover novel roles for SOX10 not only in Schwann cells but also in 
other cell types such as oligodendrocytes and melanocytes. We identified SOX6 as previously 
unreported target of SOX10 and our efforts revealed a putative role for SOX6 in Schwann cell 
repair and regeneration. Further understanding the role of SOX6 will provide key regulatory 
pathways that control Schwann cell dedifferentiation.  
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Appendix  
 
Element ID Locus Coordinates (hg18) Forward Primer Reverse Primer Size (bp) 
SOX10-CCS-01 PAX7 chr1:18,854,300-18,855,055 ATTCCAGTTTCCACGGTCAG GCTCAAGTCTGATGCTGCAA 756 
SOX10-CCS-02 ZEB2 chr2:144,875,965-144,876,906 AGCCCAGTTTTTCCTGAGGT GAGAACAGCTCATGTAAATTATTCCA 942 
SOX10-CCS-03 ZEB2 chr2:144,900,863-144,901,802 GCTCAATGTGTGAAAATGAAACA TGGCTATTTGGACCAAGAAACT 940 
SOX10-CCS-04 ZEB2 chr2:144,944,023-144,944,960 GAGTTGCAAGCAACCTGTGA TGAAGAACAACAGGCTTTGG 938 
SOX10-CCS-05 ZEB2 chr2:144,973,970-144,974,917 TATGGCAGCATTTGTTCAGC GAGCAATCCTTCCATTTCCA 948 
SOX10-CCS-06 ZEB2 chr2:144,988,817-144,989,623 AAGCAATGGACAGGCTTGAT TCCCCAAGATTCAGTTCAGG 807 
SOX10-CCS-07 PAX3 chr2:222,845,095-222,845,899 CGCCACTGTTTATCCCAG GAGAAACCTGGCAAGGG 805 
SOX10-CCS-08 SLIT2 chr4:20,088,937-20,089,889 TGCCCCTTCATATGAGTAACC CCTTGATGTCATGCAAATGG 953 
SOX10-CCS-09 PPARGC1A chr4:23,484,443-23,485,333 CAACAAGAAAGCTTGCCAGAG AGTGTGTGCCTGTGTATGTG 891 
SOX10-CCS-10 SOX6 chr11:16,099,680-16,100,466 CCAGTTTTCAGCTTACTTTGG CTGGAAATAAGACAGGGTGG 787 
SOX10-CCS-11 SOX6 chr11:16,268,203-16,269,201 CGGTTACTACCCTCAGAATGGA TTATTGGTGGCCAAAGCACT 999 
SOX10-CCS-12 SOX6 chr11:16,272,728-16,273,714 TGAAGTTGCCAGTTTTAATGC GGGAGTTCTGTTTTGGGACA 987 
SOX10-CCS-13 SOX6 chr11:16,334,301-16,335,278 TGACACCTTCCCAAATCACA TTCGTGCCAATGATGACCT 978 
SOX10-CCS-14 SOX6 chr11:16,382,713-16,383,658 CAACCAGGTTTCACCATCAA CTGGCTGAGAGTGTTCTGGA 946 
SOX10-CCS-15 SOX6 chr11:16,419,585-16,420,519 GGTCAGCACCTCTCCAACAT TTCCAGAGGCAGGTTTCATT 935 
SOX10-CCS-16 HTATIP2 chr11:20,350,779-20,351,724 TGTCTGTCCACATGGTTAGG AGCAAGATTGATTGGAAGG 946 
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SOX10-CCS-17 NTM chr11:130,816,285-130,817,036 ACAGCTCTTTTTGGTCATGCAG TTTTCTCCAGGCCTCCAGTG 752 
SOX10-CCS-18 SOX5 chr12:24,058,988-24,059,872 GACTCCTTAAATTCACAATCTGG GGCCCTGCTACTTTATCAGC 885 
SOX10-CCS-19 SOX5 chr12:24,059,397-24,060,164 AAGCGAGTGTCGCCTAGGTA TCCTCCCTCTGTGCTGTCTT 768 
SOX10-CCS-20 SOX5 chr12:24,064,421-24,065,373 CATTAACCAACCCCTGATGC TCCATGCACTTCCTTTGTGT 953 
SOX10-CCS-21 IGF1R chr15:97,238,558-97,239,353 TTCCTGGTAAACAGTTCTGCTG CCCCAGTACTGTGAGCAACA 796 
SOX10-CCS-22 TCF4 chr18:51,243,509-51,244,258 TCTTAGCATGGGCCCTATC GGGTTGTATCCATCTCAGAGC 750 
SOX10-CCS-23 AKT3 chr1:241,943,244-241,944,344 ACATGAATAAGGGAGAGAAGAGGA TGTGCCTTAACTTAGAAACACTCC 1101 
SOX10-CCS-24 FOXP1 chr3:71,181,977-71,183,215 GCCACTCCCTTCCCAAACTC CCTGGAGTCCTGTTGAGCAG 1239 
SOX10-CCS-25 FOXP1 chr3:71,373,215-71,374,005 GTCTGACTTAGGGGCGAGTG TGCTTGTTCGAGACAGGTCA 791 
SOX10-CCS-26 FOXP1 chr3:71,441,201-71,441,519 ACACACTGTTGACTTCACAAGT ACTGCATTGTGTAAATTTGCTGTG 319 
SOX10-CCS-27 FOXP2 chr7:113,841,332-113,842,324 AGTCAGTTCTTGCAATAGGAGG CTTTGGTGTGCAACGTGAGG 993 
SOX10-CCS-28 FOXP2 chr7:113,852,613-113,853,735 CACAGCCAGGTTGTTTCTGC CAAGATGTCCCTCTCTGCCA 1123 
SOX10-CCS-29 FOXP2 chr7:113,859,912-113,860,503 AGAAATGGGAAAATGTGGCATCT ATGGACTAGGACACAAATGCTCA 592 
SOX10-CCS-30 FOXP2 chr7:113,929,584-113,930,458 AGAAACTGACAGTGTTTTGGAAGT TGCTTGAGGAGAAAGGGGATC 875 
SOX10-CCS-31 FOXP2 chr7:114,082,350-114,083,553 AGACATGTATCTTTTTGAATCTGACA TGGCACATTCAGAACCCAGA 1204 
SOX10-CCS-32 LRPPRC chr2:44,053,183-44,053,867 TGTGGTTCCAAAACACTGGGT TGGTCATTTTCTTTGTGGGCC 685 
SOX10-CCS-33 NFIA chr1:61,419,236-61,419,765 CGGGGCTGGCATATAAGAGC TCCATCTTACAGACTTTCACAATGA 530 
SOX10-CCS-34 NFIA chr1:61,482,314-61,482,776 TGGGGTGTATGTGTATGCTGG ACAGCTAAACCCCTAGCCCT 463 
SOX10-CCS-35 NFIA chr1:61,685,814-61,686,119 CACCCAGAAAATCCGGCAGT TTCTGGAGCCGCTTATGACG 306 
SOX10-CCS-36 ROBO2 chr3:77,703,835-77,704,225 CACTGAAGTGTGCAAGTGTGC TGAAATAAGGCAACCAAGAGGC 391 
SOX10-CCS-37 ST18 chr8:53,370,162-53,370,714 TACCTCTAAGGAGCCTGCCA AGGGGGAAGTCAGAGATATGTCA 553 
SOX10-CCS-38 TCF7L2 chr10:114,809,055-114,809,611 GCTTTCAAGGCTGGACCACT AGGAGAAAACAATCTGCTCTTTTCC 557 
SOX10-CCS-39 TCF7L2 chr10:114,894,980-114,895,808 TGAACATGAGCTTGTGACCCA GGGGTGTCTGAATCCTCCTG 829 
SOX10-CCS-40 ZFP536 chr19:35,553,294-35,554,399 ATCCAGGCAAAACAGAGGGG ATACAGCAGGGAGGCAGATG 1106 
SOX10-CCS-41 ZFP536 chr19:35,584,495-35,585,327 TTTGTGGGTGGTAGGTGTGT GCTGGGAGAGGTAGAACAGG 833 
SOX10-CCS-42 BCAS3 chr17:56,264,175-56,264,859 GTCATTTGTCAAACGAAGCAGC GCACACTTTAAGATCCAAATTCTCC 685 
SOX10-CCS-43 BCAS3 chr17:56,683,905-56,684,657 AGACTGCTAGGTTCCCAGCT CTCTGGAGCCCTGGGTTATG 753 
SOX10-CCS-44 CELF4 chr18:33,340,118-33,340,363 TGCCTTCGTGTCTTGAAGCC CCATGGGCTTGACCTACAGG 246 
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SOX10-CCS-45 CNTLN chr9:17,440,149-17,440,784 CAGATTGGCATTTTCAGACCCA TCTGAAAAATCCACTGAGTTACTGC 636 
SOX10-CCS-46 EHBP1 chr2:63,083,637-63,084,587 TCCTACAAGTTGCATTCTGAACT CAGCATCAAGATGGTATTGTCTCAC 951 
SOX10-CCS-47 EHBP1 chr2:63,114,958-63,115,973 ATGGCTTTCAATATTGTATGTCTTGAA AGGACACATTACTCATTGCTTCAC 1016 
SOX10-CCS-48 HAT1 chr2:172,528,652-172,529,540 TGTGAATGAGTTGCAAGGACTG GTGACACAATTCTTACAGACCTGG 889 
SOX10-CCS-49 LRBA chr4:151,496,516-151,497,064 CCATGTAATACGGCCTTCTTCC TGCTAAAGTAACTCAGATTCACTGC 549 
SOX10-CCS-50 NFIB chr9:14,293,449-14,293,925 CCCAAGAATCATTGGACGTCT ATGTCTCCCTGCACTTCACC 477 
SOX10-CCS-51 NFIB chr9:14,299,332-14,299,796 GGAAGGAGTACATGTCCCATCC GGAAGTGAGTTTCCAAAGCACA 465 
SOX10-CCS-52 NFIB chr9:14,301,911-14,302,364 CCAGCCGATGGGTAATATTAATGG AAGTGTCAGCCAGTCTTGGG 454 
SOX10-CCS-53 POLA1 chrX:24,774,505-24,775,184 CCCTGGTCCTTGTTGGTTCC TGTGGCTGCTTCTTGGATGG 680 
SOX10-CCS-54 SORBS2 chr4:186,930,490-186,930,820 TGCTTGCAATGTTCCCTTGG GTTTGTAGCCGTGGGATCGA 331 
SOX10-CCS-55 TLE4 chr9:81,473,416-81,473,843 TGACAGGCATGACGTTGAGG ACAATCCTAAGCCAGGGAGAC 428 
SOX10-CCS-56 ZFHX3 chr16:71,426,545-71,427,021 GGAGGGTGGGATGTTTGAGG TTTCCCACCTGCTTCAGTGG 477 
SOX10-CCS-57 MPP7 chr10:28,530,884-28,531,299 ATACAGAGCCAGCTCACCAC TTGGCATGTTCCAGCTGTCA 416 
Table A.1. Primers used to amplify the 57 regions from human genomic DNA. Primer sequences are shown in 5’ to3’ direction.  The 
following Gateway sequences 5’-GGGGACAAGTTTGTACAAAAAAGCAGGCT-3’and 5’-
GGGGACCACTTTGTACAAGAAAGCTGGGT-3’were added to forward and reverse primers respectively. Length of regions 
amplified is shown in bp and do not include the Gateway sequences. 
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Element ID Coordinates (rn5) Forward Primer Reverse Primer Size (bp) 
Notch1-R1 chr3:9,307,836-9,308,296 AGTCCAGACCTGTGCCTATC CTTAGCCCCACCAGAAAAGG 461 
Notch1-R2 chr3:9,308,175-9,309,096 ACACAGATACTAAGACACGAGC TTGGTACTGCTGTCTGGGTG 922 
Hmga2-R1 chr7:65,390,088-65,391,287 CGAGCCACCTTGATTCAGAG GTCATCATTCGGTCCTGAGG 1200 
Hmga2-R2 chr7:65,427,912-65,428,606 GAGGCCTACGATTGGTGATC AGCAGGACAAGGGAGATCTC 695 
Hes1-R1 chr11:77,415,315-77,415,779 CAACTTCTCGGGTTTTCTGC AGCTGCTGGGAGGTGAGC 465 
Mycn-R1 chr6:51,229,947-51,230,533 CAGCGAGCATTAGAGTCTGC AATTCTCGTCTGGCATGCAG 587 
Id4-R1 chr17:18,701,460-18,702,118 TCATTTGCCCCAGAGAAAGC AAAGCAAAGAATGGGCCCAG 659 
Id2-R1 chr6:53,090,794-53,091,254 Region synthesized by IDT   
Table A.2. Primers used to amplify genomic segment at loci with SOX10 occupancy and open chromatin. Primer sequences are shown 
in 5’ to3’ direction. The following Gateway sequences 5’-GGGGACAAGTTTGTACAAAAAAGCAGGCT-3’and 5’-
GGGGACCACTTTGTACAAGAAAGCTGGGT-3’were added to forward and reverse primers respectively. Length of regions 
amplified is shown in bp and do not include the Gateway sequences 
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Element ID Forward Primer Reverse Primer 
SOX10-CCS-01 GCCTAATGAGTGTTGTTTAAAGAAGGGAGGGGGAACC GGTTCCCCCTCCCTTCTTTAAACAACACTCATTAGGC 
SOX10-CCS-13 TGCTTTTCTTTCTTTCATTTCACAAAAATTCAGGTTCCATAGACAGGAG CTCCTGTCTATGGAACCTGAATTTTTGTGAAATGAAAGAAAGAAAAGCA 
SOX10-CCS-18 GATCTGAACTGAGCCAAGGAATCCTCGCAGATGG CCATCTGCGAGGATTCCTTGGCTCAGTTCAGATC 
SOX10-CCS-19 TGGTGGTGTATTATGTGTCGCCTCTTGTTCCCC GGGGAACAAGAGGCGACACATAATACACCACCA 
SOX10-CCS-39 GTGTTTCTTCCCTTTGATCCTTCCTGTTCTGATCAAATGAGAAT ATTCTCATTTGATCAGAACAGGAAGGATCAAAGGGAAGAAACAC 
SOX10-CCS-43 CCATCAGAAACTGAACTCTAATGTAATCTGCCCTCTATGTTG CAACATAGAGGGCAGATTACATTAGAGTTCAGTTTCTGATGG 
SOX10-CCS-51 GCAGGGCTGCCTTCCCGGTTTAACTCTTTCCATG CATGGAAAGAGTTAAACCGGGAAGGCAGCCCTGC 
Notch1-R1 CCACTGAGTTCTATCCGCTCACTCCGTAAGTC GACTTACGGAGTGAGCGGATAGAACTCAGTGG 
Notch1-R2 CTGTGAGCAGTTTATTGGGCCTCTGTCAGACACTAA TTAGTGTCTGACAGAGGCCCAATAAACTGCTCACAG 
Hmga2-R1 CTCCCGGCTACACTTAGGCACTTCATACTTCTCA TGAGAAGTATGAAGTGCCTAAGTGTAGCCGGGAG 
Hmga2-R2 GACAATTCCTGGGCTGGCAGCCTGGTGG CCACCAGGCTGCCAGCCCAGGAATTGTC 
Hes1-R1 GCCGCCGGCTGTGGAACACCGCCCC GGGGCGGTGTTCCACAGCCGGCGGC 
Mycn-R1 ATGGCCTCTTTCTACAGGGTCAGCATGAGGAATG CATTCCTCATGCTGACCCTGTAGAAAGAGGCCAT 
 CAGATATGTCAGCAGTGGACAGACAATGGTCAGCAT ATGCTGACCATTGTCTGTCCACTGCTGACATATCTG 
Id4-R1 TAAACCCTTTTAATCCATGTTTCCTCCGCTGCCCTAC GTAGGGCAGCGGAGGAAACATGGATTAAAAGGGTTTA 
 GTAGGGCAGCGGAGGAAAAACAGCAGTAAATGGAG CTCCATTTACTGCTGTTTTTCCTCCGCTGCCCTAC 
 CAGCAGTAAATGGAGGCCCATGGATTAAAAGGGTTT AAACCCTTTTAATCCATGGGCCTCCATTTACTGCTG 
Id2-R1 GGCAGCGCACTAGGGACTCCCAAGCCGG CCGGCTTGGGAGTCCCTAGTGCGCTGCC 
Table A.3. Mutagenic Primers used to delete the SOX10 consensus sequences. Primer sequences are shown in 5’ to3’ direction.   
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rn_SOX6_GSP1 GATTTCTCCAAGAAGTTCACTCG 
rn_SOX6_GSP2 TCTCCTCCAGCTTCTTCTGC 
rn_SOX6_GSP3 TGGGTCATTGTTTCCTCTCC 
rnSOX6_RTPCR_Fwd GTGCTGTATCTCCCCACAGG 
rnSOX6_RTPCR_Rev TGGGTCATTGTTTCCTCTCC 
rnmmB-Actin RTPCR_F CGCGGGCGACGATGCTCC 
rnmmB-Actin RTPCR_R GTAGCCACGCTCGGTCAGG 
rnSox6_RTPCR_F3 GCCAGGAGTCTTCACTGCTCC 
rnSox6_3'UTR_R2 GGGAGCGAAATGTCAGAGTG 
Table A.4.5’RACE and RT-PCR primers. Primer sequences are shown in 5’ to3’ direction.   
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Element ID Primer 
mSox6 ORF F GGGGACAAGTTTGTACAAAAAAGCAGGCTTC ATGTCTTCCAAGCAAGCCACC 
mSox6 ORF R GGGGACCACTTTGTACAAGAAAGCTGGGTT TCAGTTGGCACTGACAGGC 
SOX6_Seq_F1 CCAACAGCAAGAACAGATCG 
SOX6_Seq_R1 ACAGGGCAGGAGAGTTGAGA 
SOX6_Seq_F2 GTGAAGTCCCCAACATCTCC 
SOX6_Seq_R2 TCCTCCTTTCGTCCTTTGC 
SOX6_Seq_F3 CGAAGATGATCCCAAATCAGA 
SOX6_Seq_F4 CATCACCACAGGAACAGGTG 
SOX6_Seq_R3 GACAGAACGCTGTCCCAGTC 
SOX6_Seq_F5 CTGGAAATCCATGTCCAACC 
SOX6_Seq_F6 TTGGGGAGTACAAGCAACTG 
Sox6 qRT-PCR F3 CTCGGAAGATGCGAGAACAG 
Sox6 qRT-PCR R3 GCCCAGTTTTCCATCTTCAC 
Neomycin pDEST53 F GGCTATTCGGCTATGACTGG 
Neomycin pDEST53 R CGTCCTGCAGTTCATTCAGG 
hs b-actin qRTPCR F GTACATGGCTGGGGTGTTG 
pDEST53 GFP F TACACATGGCATGGATGAGC 
Sox6 Ex1 qRT-PCR R TCATTGCTTCCTCTCCATCC 
Table A.5. Primers used to amplify the SOX6 open reading frame and primers used for sequencing the construct. RT-PCR primers 
used for HeLa cell transfections. Primer sequences are shown in 5’ to3’ direction.   
